US20140212444A1 - Compositions and methods for inducing an immune response - Google Patents
Compositions and methods for inducing an immune response Download PDFInfo
- Publication number
- US20140212444A1 US20140212444A1 US14/164,732 US201414164732A US2014212444A1 US 20140212444 A1 US20140212444 A1 US 20140212444A1 US 201414164732 A US201414164732 A US 201414164732A US 2014212444 A1 US2014212444 A1 US 2014212444A1
- Authority
- US
- United States
- Prior art keywords
- isl
- peptide
- protein
- cells
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 206
- 238000000034 method Methods 0.000 title claims abstract description 77
- 230000028993 immune response Effects 0.000 title abstract description 99
- 230000001939 inductive effect Effects 0.000 title abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 231
- 108090000623 proteins and genes Proteins 0.000 claims description 178
- 102000004169 proteins and genes Human genes 0.000 claims description 177
- 206010028980 Neoplasm Diseases 0.000 claims description 71
- 230000002163 immunogen Effects 0.000 claims description 55
- 201000011510 cancer Diseases 0.000 claims description 45
- 239000002671 adjuvant Substances 0.000 claims description 42
- 239000000427 antigen Substances 0.000 claims description 42
- 108091007433 antigens Proteins 0.000 claims description 41
- 102000036639 antigens Human genes 0.000 claims description 41
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 40
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 9
- 150000001408 amides Chemical group 0.000 claims description 4
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 43
- 239000003814 drug Substances 0.000 abstract description 20
- 230000003308 immunostimulating effect Effects 0.000 abstract description 17
- 238000011160 research Methods 0.000 abstract description 13
- 238000002255 vaccination Methods 0.000 abstract description 13
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 217
- 210000004027 cell Anatomy 0.000 description 86
- 230000000694 effects Effects 0.000 description 82
- 210000004443 dendritic cell Anatomy 0.000 description 78
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 71
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 71
- 102000004196 processed proteins & peptides Human genes 0.000 description 64
- 210000001744 T-lymphocyte Anatomy 0.000 description 55
- 102100022297 Integrin alpha-X Human genes 0.000 description 53
- 238000004519 manufacturing process Methods 0.000 description 43
- 102000004127 Cytokines Human genes 0.000 description 42
- 108090000695 Cytokines Proteins 0.000 description 42
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 42
- 201000010099 disease Diseases 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 239000003795 chemical substances by application Substances 0.000 description 32
- 230000004044 response Effects 0.000 description 30
- 208000015181 infectious disease Diseases 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 210000000068 Th17 cell Anatomy 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 24
- 244000052769 pathogen Species 0.000 description 23
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 22
- 244000005700 microbiome Species 0.000 description 22
- 230000004913 activation Effects 0.000 description 21
- 239000012634 fragment Substances 0.000 description 21
- 230000036039 immunity Effects 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 125000004122 cyclic group Chemical group 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 20
- 230000001717 pathogenic effect Effects 0.000 description 20
- -1 but not limited to Substances 0.000 description 19
- 102000000503 Collagen Type II Human genes 0.000 description 18
- 108010041390 Collagen Type II Proteins 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 102100037850 Interferon gamma Human genes 0.000 description 17
- 108010074328 Interferon-gamma Proteins 0.000 description 17
- 230000004069 differentiation Effects 0.000 description 17
- 210000000987 immune system Anatomy 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 210000002950 fibroblast Anatomy 0.000 description 16
- 230000001681 protective effect Effects 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 14
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 14
- 238000011161 development Methods 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 238000007363 ring formation reaction Methods 0.000 description 14
- 108050003558 Interleukin-17 Proteins 0.000 description 13
- 102000013691 Interleukin-17 Human genes 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 210000003289 regulatory T cell Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 206010003246 arthritis Diseases 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 241001529936 Murinae Species 0.000 description 11
- 210000001165 lymph node Anatomy 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 230000010534 mechanism of action Effects 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 230000003393 splenic effect Effects 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 108010058597 HLA-DR Antigens Proteins 0.000 description 10
- 102000006354 HLA-DR Antigens Human genes 0.000 description 10
- 108090000978 Interleukin-4 Proteins 0.000 description 10
- 102000004388 Interleukin-4 Human genes 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108090000631 Trypsin Proteins 0.000 description 10
- 102000004142 Trypsin Human genes 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 239000012588 trypsin Substances 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 9
- 108010065637 Interleukin-23 Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 108090000317 Chymotrypsin Proteins 0.000 description 8
- 241000233866 Fungi Species 0.000 description 8
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 8
- 102100033461 Interleukin-17A Human genes 0.000 description 8
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 229960002376 chymotrypsin Drugs 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 208000035473 Communicable disease Diseases 0.000 description 7
- 102000013264 Interleukin-23 Human genes 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000003232 mucoadhesive effect Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- PTSUYDXEEKDBQU-UHFFFAOYSA-N (6'-acetyloxy-5,6-diamino-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC(N)=C(N)C=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 PTSUYDXEEKDBQU-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 241000204031 Mycoplasma Species 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- 241000219061 Rheum Species 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000001142 circular dichroism spectrum Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000002840 nitric oxide donor Substances 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000001960 triggered effect Effects 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
- 241000186359 Mycobacterium Species 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000002983 circular dichroism Methods 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000016396 cytokine production Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000024949 interleukin-17 production Effects 0.000 description 5
- 230000017306 interleukin-6 production Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000010287 polarization Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000037452 priming Effects 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000007781 signaling event Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101100301068 Homo sapiens RBM45 gene Proteins 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 230000033289 adaptive immune response Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000009134 cell regulation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 150000002960 penicillins Chemical class 0.000 description 4
- 230000008823 permeabilization Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000003244 pro-oxidative effect Effects 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
- 241000282324 Felis Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 3
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 3
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000003614 tolerogenic effect Effects 0.000 description 3
- 230000005951 type IV hypersensitivity Effects 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- KHJYKJGDCZJYGX-ZOHMYHBWSA-N CII259-273 Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC[C@H](CN)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C1=CC=CC=C1 KHJYKJGDCZJYGX-ZOHMYHBWSA-N 0.000 description 2
- MIGZTFDJLOXCEJ-KZJCOHJUSA-N CN1CCCCNC(=O)NCN(C(=O)[C@@H](N)CC2=CNC3=C2C=CC=C3)CC(=O)NC(CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(CCCNC(=N)N)C1=O Chemical compound CN1CCCCNC(=O)NCN(C(=O)[C@@H](N)CC2=CNC3=C2C=CC=C3)CC(=O)NC(CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(CCCNC(=N)N)C1=O MIGZTFDJLOXCEJ-KZJCOHJUSA-N 0.000 description 2
- 102100029968 Calreticulin Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 102400001295 Class-II-associated invariant chain peptide Human genes 0.000 description 2
- 101800001887 Class-II-associated invariant chain peptide Proteins 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100020743 Dipeptidase 1 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010053491 HLA-DR beta-Chains Proteins 0.000 description 2
- 108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 description 2
- 108010055098 HLA-DRB1*04:02 antigen Proteins 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000228402 Histoplasma Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000283953 Lagomorpha Species 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000013967 Monokines Human genes 0.000 description 2
- 108010050619 Monokines Proteins 0.000 description 2
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 159000000013 aluminium salts Chemical class 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000003704 interleukin-23 production Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 1
- UPVAECPHCFMGML-IYQSZBERSA-N CC(NC(=O)CN1CCCCNC(=O)NCCCCCCC(=O)NC(CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(CCCNC(=N)N)C1=O)C(N)=O Chemical compound CC(NC(=O)CN1CCCCNC(=O)NCCCCCCC(=O)NC(CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(CCCNC(=N)N)C1=O)C(N)=O UPVAECPHCFMGML-IYQSZBERSA-N 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004082 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 101710177917 Fimbrial protein Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- GOWLTLODGKPXMN-MEKRSRHXSA-N OM-174 Chemical compound O1[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1CO[C@H]1[C@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 GOWLTLODGKPXMN-MEKRSRHXSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000006424 autoimmune oophoritis Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000004988 autoimmune vasculitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940108538 colistimethate Drugs 0.000 description 1
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000017214 establishment of T cell polarity Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940041006 first-generation cephalosporins Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000011580 granulomatous orchitis Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003571 opsonizing effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008255 pharmaceutical foam Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091006091 regulatory enzymes Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940041008 second-generation cephalosporins Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002226 simultaneous effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940048098 sodium sarcosinate Drugs 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- WWGXHTXOZKVJDN-UHFFFAOYSA-M sodium;n,n-diethylcarbamodithioate;trihydrate Chemical compound O.O.O.[Na+].CCN(CC)C([S-])=S WWGXHTXOZKVJDN-UHFFFAOYSA-M 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- MDDUHVRJJAFRAU-YZNNVMRBSA-N tert-butyl-[(1r,3s,5z)-3-[tert-butyl(dimethyl)silyl]oxy-5-(2-diphenylphosphorylethylidene)-4-methylidenecyclohexyl]oxy-dimethylsilane Chemical compound C1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)C(=C)\C1=C/CP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 MDDUHVRJJAFRAU-YZNNVMRBSA-N 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000000522 vaginal cream Substances 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Definitions
- compositions and methods for inducing an immune response in a subject provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith.
- ISL immunostimulatory ligands
- Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
- Treg cells act as suppressors of the immune response against tumors and infectious pathogens (Wilczynski et al. Front Biosci. 2008 Jan. 1; 13:2275-89.; Rouse & Suvas. J. Immunol. 2004 Aug. 15; 173(4):2211-5.; herein incorporated by reference in their entireties).
- IDO indoleamine 2,3 dioxygenase
- Th17 cells This key enzyme has been shown to be involved in both tumor- and pathogen associated tolerance (Munn & Mellor. J Clin Invest. 2007 May; 117(5):1147-54.; Popov & Schultze. J Mol Med. 2008 February; 86(2):145-60).; herein incorporated by reference in their entireties).
- the role of Th17 cells in cancer has been less well characterized, however cytokine, IL-17, has been shown to increase recruitment of macrophages to tumor sites and stimulate generation of cytotoxic T cells, indicating that Th17 cells play an anti-tumor role (Kolls & Lindén. Immunity. 2004 October; 21(4):467-76.; herein incorporated by reference in its entirety).
- Th17 cells The evidence for the involvement of Th17 cells in anti-infection immune responses is abundant. There are strong indications that Th17 cells, their key cytokine, IL-17, as well as the Th17-expanding cytokine, IL-23, all play important roles in protection against pathogens (Jin et al. Autoimmunity. 2008 March; 41(2):154-62.; herein incorporated by reference in its entirety).
- Treg cells express high affinity IL-2 receptors (CD25)
- experiments using anti-CD25 antibodies, or IL-2 conjugated with toxins have been carried out in various experimental tumor models and in human trials with mixed results (Schabowsky et al. Curr Opin Investig Drugs. 2007 December; 8(12):1002-8.; herein incorporated by reference in its entirety).
- depleting Treg cells by anti-CD25 antibodies failed to improve protective immunity against BCG in mice (Quinn et al. Eur J. Immunol. 2008 March; 38(3):695-705.; herein incorporated by reference in its entirety).
- Immunotherapy is an appealing anti-cancer treatment strategy.
- tumor cells express many immunogenic antigens
- the immune system often fails to recognize or respond to them. This occurs because cancer cells utilize mechanisms that render the immune system tolerant, thereby evading immune recognition and/or eradication (Zou. Nat. Rev Cancer. 2005 April; 5(4):263-74; herein incorporated by reference in its entirety).
- pathogens have evolved sophisticated strategies to manipulate and evade their host immune system (Rouse. J Immunol. 2004 Aug. 15; 173(4):2211-5; herein incorporated by reference in its entirety). Consequently, attempts to establish preventive or therapeutic immunity using conventional immunization protocols have often met with disappointing results (Orme. J Leukoc Biol. 2001 July; 70(1):1-10.; Guinn et al. Mol. Ther. 2007 June; 15(6):1065-71; herein incorporated by reference in their entireties).
- compositions and methods for inducing an immune response in a subject provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith.
- ISL immunostimulatory ligands
- Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
- the invention provides a composition (e.g., immunogenic composition) comprising one or more immunostimulatory ligands (ISLs) alone or in the context of another molecule (e.g., a peptide, protein, polysaccharide, oligosaccharide, carbohydrate, and/or carbohydrate-containing molecule).
- a composition e.g., immunogenic composition
- ISLs immunostimulatory ligands
- an ISL comprises the motif Q/K-K/R-R-A-A (SEQ ID NO.: 1) (e.g., QKRAA (SEQ ID NO.:2), QRRAA (SEQ ID NO.:3), KKRAA (SEQ ID NO.:4) or KRRAA (SEQ ID NO.:5)) or Q/R-K/R-R-A-A (SEQ ID NO.:6) (e.g., RKRAA (SEQ ID NO.: 13) and RRRAA (SEQ ID NO.: 14)).
- the present invention is not limited by a particular formulation of a composition (e.g., immunogenic composition) comprising an ISL or by a specific type of ISL.
- ISL and/or protein or peptide comprising an ISL is a soluble ISL and/or soluble protein or peptide comprising an ISL.
- ISL and/or protein or peptide comprising an ISL is in the form of a human leukocyte antigen (HLA) tetramer.
- ISL and/or protein or peptide comprising an ISL is in the form of a cell bound surface protein and/or peptide (e.g., a cell surface marker protein and/or peptide).
- ISL and/or protein or peptide comprising an ISL is in the form of a cell surface antigen.
- the ISL is a recombinant peptide and/or protein.
- the ISL is a cyclic peptide or protein comprising a sequence selected from SEQ ID NOS.
- the invention is not limited by the method or procedure utilized to generate a cyclic ISL peptide and/or protein. Indeed, a variety of methods may be utilized including, but not limited to, a urea backbone cyclic protocol (See, e.g., Hurevich et al., Journal of Peptide Science 2010, 16, 178), an amide backbone-to-side chain cyclic peptides synthesis scheme (e.g., using microwave heating synthesis (See, e.g., Hayouka et al. 2011)), other known cyclization methods (e.g., disclosed in Gilon et al. Biopolymers 1991, 31: 745-50), or a combination thereof.
- a urea backbone cyclic protocol See, e.g., Hurevich et al., Journal of Peptide Science 2010, 16, 178
- an amide backbone-to-side chain cyclic peptides synthesis scheme e.g., using microwave heating synthesis (See,
- the ISL is present in a biologically active protein or peptide (e.g., a protein or peptide displaying antigenic or immunogenic properties (e.g., capable of inducing an immune response in a subject administered the peptide)).
- the peptide or protein may have antigenic or immunogenic characteristics in the absence of the ISL, or, may have no antigenic or immunogenic properties in the absence of the ISL but when the ISL is introduced into the protein or peptide the protein or peptide displays antigenic or immunogenic properties.
- the invention is not limited by the type of peptide. Indeed, a peptide containing an ISL of the invention may be any peptide described herein.
- the peptide or protein is derived from a tumor or cancer protein.
- a peptide or protein (e.g., recombinantly produced peptide or protein) containing an ISL of the invention is generated using a backbone cyclization (BC) strategy and/or method (See, Example 5).
- BC backbone cyclization
- the cyclic peptide is a conformationally intact peptidomimetic ISL.
- the invention is not limited by the length of a peptide, protein, polysaccharide, oligosaccharide, carbohydrate, and/or carbohydrate-containing molecule sequence which harbours an ISL.
- a recombinant peptide and/or protein is engineered to contain an ISL.
- the peptide or protein may be from any microbe such as a bacterium, virus, fungi, yeast or the like.
- the protein or peptide is from Staphylococcus aureus; Staphylococcus epidermidis; Enterococcus faecalis; Mycobacterium tuberculsis; Streptococcus group B; Streptoccocus pneumoniae; Helicobacter pylori; Neisseria gonorrhea; Streptococcus group A; Borrelia burgdorferi; Coccidiodes immitis; Histoplasma sapsulatum; Neisseria meningitidis type B; Shigella flexneri; Escherichia coli; Haemophilus influenzae , bacteria of the strain or genus Klebsiella, Mycoplasma, E. coli , and/or
- the invention provides a method of inducing an immune response (e.g., innate and/or acquired immune response) in a subject comprising: administering to the subject a composition comprising an ISL (e.g., linear or cyclic peptide/ISL).
- the composition comprises a peptide, polypeptide, or protein comprising an immunostimulatory ligand.
- the immune response comprises expansion of Th17 cells.
- the Th17 cells are pathogen-specific.
- the immune response comprises inhibition of T regulatory cell differentiation or activity.
- the immune response comprises enhanced nitric oxide signalling and/or enhanced production of IL-6.
- the immune response is cancer and/or tumor specific (e.g., specific for a cancer epitope or a tumor epitope).
- the subject suffers from cancer, is suspected of having cancer, or is at risk of developing cancer.
- the subject suffers from an infectious disease, is suspected of having an infectious disease, or is at risk of contracting an infectious disease.
- an ISL of the invention comprising a linear or cyclic peptide and/or protein comprising a sequence selected from SEQ ID NOS. 1-6, 13 and 14 is used in the manufacture of a medicament (e.g., to act as an agonist or antagonist of share epitope-triggered signaling events (e.g., due to a particular conformation (e.g., ⁇ -helix conformation) of the peptide and/or protein) for the treatment and/or prevention of disease (e.g., autoimmune disease (e.g., rheumatoid arthritis)).
- autoimmune disease e.g., rheumatoid arthritis
- ISL is an effective adjuvant during vaccination and/or booster immunization against pathogens and/or tumors. In some embodiments, ISL shifts the immune balance from tolerance toward a Th17-polarized response. In some embodiments, ISL is provided as an immune adjuvant during anti-infection or anti-tumor chemotherapy. In some embodiments, ISL is administered to a subject to treat or prevent infection by bacteria, protozoa and/or viruses. In some embodiments, ISL is administered to a subject to treat or prevent infection by bacteria, protozoa and/or viruses capable of escaping immune eradication by Treg-mediated immune dysregulation. In some embodiments, the present invention provides a simultaneous effect on Treg and Th17. In some embodiments, ISL does not trigger neutralizing antibodies or allergic reactions.
- the invention also provides a method of inhibiting T cell tolerance in a subject comprising administering to the subject an effective dose of a composition comprising an isolated, recombinant immunostimulatory ligand (ISL), selected from the group consisting of SEQ ID NOS.: 1-6, 13 and 14 under conditions such that T cell tolerance is reduced in the subject.
- ISL immunostimulatory ligand
- the subject is selected from the group consisting of a subject suffering from cancer, suspected of having cancer, at risk of developing cancer, suffering from an infectious disease, suspected of having an infectious disease, or at risk of contracting an infectious disease.
- the invention provides a method of treating cancer in a subject comprising administering to the subject a composition comprising an ISL (e.g., to induce an innate or acquired (e.g., cancer specific) immune response in the subject).
- ISL is administered to a subject therapeutically to treat known cancer within a subject.
- ISL is administered to a subject prophylactically to prevent cancer developing in a subject (e.g. a subject at risk for cancer).
- the present invention finds use (e.g. therapeutically or prophylactically) with any type of cancer (e.g. bladder, melanoma, breast, non-Hodgkin lymphoma, colon, rectal, pancreatic, endometrial, prostate, kidney, skin (e.g. nonmelanoma), leukemia, thyroid, lung, etc.).
- the present invention provides a method of treating and/or preventing infection within a subject.
- a subject is known or suspected of having an infection (e.g. bacterial, viral, etc.).
- a subject is thought to be at risk for developing an infection (e.g. bacterial, viral, eukaryotic, etc.).
- ISL is administered to a subject to heighten immune response when a subject is expected to become at risk for infection (e.g. during chemotherapy, travel, when immunocompromised by another disease).
- the present invention provides methods of administering ISL to a subject to treat or prevent a disease (e.g. cancer), infection, condition, etc. followed by testing the subject for the presence of the disease (e.g. cancer), infection, condition, etc.
- the present invention provides methods of administering ISL to a subject to treat or prevent a disease (e.g. cancer), infection, condition, etc. followed by testing the subject for a change in the status of the disease (e.g. cancer), infection, condition, etc.
- the present invention provides methods comprising testing a subject for the presence of a disease (e.g. cancer), infection, condition, etc. followed by administering ISL to a subject to treat or prevent the disease (e.g.
- the present invention provides a method comprising testing a subject for the presence of a disease (e.g. cancer), infection, condition, etc. followed by administering ISL to a subject to treat or prevent the disease (e.g. cancer), infection, condition, etc. followed by testing the subject for the presence of, or a change in the status of, the disease (e.g. cancer), infection, condition, etc.
- FIG. 1 shows a plot demonstrating synergism between IPP and IFN- ⁇ .
- Human fibroblasts were preincubated overnight with various doses of IPP, followed by 48 h stimulation with various doses of rhIFN- ⁇ .
- IDO activity was determined by quantifying kynurenine production.
- FIG. 2 shows a plot demonstrating NO inhibits IFN- ⁇ -induced indoleamine 2,3-dioxygenase (IDO) activation.
- Human fibroblasts were preincubated overnight with or without 100 ⁇ M of the nitric oxide (NO) donor, S-nitroso-N-acetyl-1,1-penicillamine (SNAP), followed by stimulation with or without 1000 U/ml rhIFN- ⁇ , and IDO activity was measured by quantifying kynurenine production.
- NO nitric oxide
- SNAP S-nitroso-N-acetyl-1,1-penicillamine
- FIG. 3 shows that ISL activates nitric oxide (NO) signaling in dendritic cells (DCs).
- DCs dendritic cells
- CD11c+ DCs were purified using magnetic beads with >95% purity.
- DCs were then incubated with SE-positive (65-79*0401 or 65-79*0404), or with SE-negative (65-79*0402 or 65-79*0403) 15mer peptides and NO production was measured as described below. The results are expressed as mean ⁇ SEM fluorescence units (FU), or FU per minute. *p ⁇ 0.01 compared to all ligand controls.
- FIG. 4 shows Inhibition of IDO activity by ISL.
- A Human fibroblasts were incubated overnight with either medium, the NO donor, SNAP, or different 15mer peptides (100 U/ml). Cells were subsequently cultured for 48 h with or without rhIFN ⁇ (1000 U/ml) and cellular IDO activity was determined.
- B Murine L cells expressing either ISL-positive (L-0401, L-0404) or ISL-negative (L-0402, L-0402) DR ⁇ chains on their surface through cDNA transfection were incubated for 48 h with rmIFN ⁇ (1000 U/ml) and cellular IDO activity was determined.
- CD11+ CD8+ DC were purified from DBA/1 spleens and incubated for 24 h with LPS to induce maturation. Stimulation with IFN ⁇ and IDO activity determination were as above.
- Immature CD11+ CD8+ DC were purified from DBA/1 spleens and pre-incubated for 1 h with or without HBc particles engineered to express the 65-79 region of DR ⁇ chains, encoded by either ISL-positive (HBc*0401) or ISL-negative (HBc*0402) DRB1 alleles. DCs were subsequently stimulated with IFN ⁇ and IDO activity was determined.
- FIG. 5 shows ISL-stimulated cytokine production by DC.
- Splenic CD8+ and CD8 ⁇ DC were isolated from DBA/1 mice as above and cultured in 96-well plates over time in the presence or absence of ISL-positive (65-79*0401) or ISL-negative (65-79*0402) peptides (50 ⁇ g/ml). At various time points thereafter, supernatants were collected and assayed for cytokine content, using the Luminex platform.
- FIG. 6 shows inhibition of IDO activity by the ISL.
- A Murine L cells expressing either ISL-positive (L-565.5, or L-300.8) or ISL-negative (L-514.3, or L-259.3) functional HLA-DR molecules on their surface through cDNA transfection were incubated for 48 hrs with rhIFN ⁇ (1000 U/ml) and cellular IDO activity was determined.
- B M1 fibroblasts were incubated overnight with medium, NO donor SNAP, or 100 ⁇ g/ml of ISL ligands (65-79*0401, 65-79*0404), or with ISL-negative controls (65-79*0402, or 65-79*0403).
- CD11c+CD8+ and CD11c+ CD8 ⁇ DCs subsets were purified from DBA/1 spleens and their IDO activity in response to IFN ⁇ was determined.
- CD11c+CD8+ DCs were purified from DBA/1 spleens, maturated or not with LPS, and their IDO activity in response to IFN ⁇ was determined.
- DBA/1 splenic CD11c+CD8+ DCs were activated with or without IFN ⁇ , in the presence of absence of the NO donor SNAP. IDO activity was determined at 48 h as above.
- FIG. 7 shows The ISL activates IL-6 production in CD8-DCs.
- DBA/1 splenic unfractionated CD11c+ DCs (CD11c+), or their purified CD11c+CD8+ DCs (CD8+) or CD11c+CD8 ⁇ DCs (CD8 ⁇ ) subsets were cultured with the ISL 65-79*0401 or ISL-negative control 65-79*0402 or medium. Supernatants were collected at different time points and assayed for cytokine content using a Luminex platform.
- FIG. 8 shows the ISL augments IL-23 production in LPS-stimulated CD11c+DCs.
- DBA/1 bone marrow-derived CD11c+DCs were cultured with or without 100 ng/ml LPS in the presence or absence of ISL-positive or ISL-negative 15mer peptides (50 ⁇ g/ml). Supernatants were collected at different time points and assayed for IL-23 and IL-6 content by ELISA.
- FIG. 9 shows ISL inhibits Treg generation.
- DBA/1 bone marrow-derived CD11c+DCs were cultured overnight with 50 ⁇ g/ml SL ligand 65-79*0401 or ISL-negative control 65-79*0402, or medium.
- Syngeneic splenic CD4+ T cells were then added to the culture, and incubated with anti-CD3 and TGF- ⁇ for 5 days.
- flow cytometry dot plots showing percentages of CD25+Foxp3+ cells obtained from gated CD4+ T cells in each treatment. Each plot is representative of three experiments.
- bar graphs present results as mean percentage ⁇ SD of replicate samples.
- FIG. 10 shows ISL facilitates Th17 differentiation.
- DBA/1 bone marrow-derived CD11c+DCs were cultured overnight in the presence or absence of (A) ISL 65-79*0401 or ISL-negative control 65-79*0402, or (B) ISL-positive T-DRB1*0401 tetramers, versus ISL-negative T-DRB1*0301, or T-DRB1*1501 tetramers.
- Syngeneic splenic CD4+CD25 ⁇ CD62L+CD44 ⁇ na ⁇ ve T cells plus a Th17-differentiation cytokine/antibody cocktail were then added to the culture and incubated for 6 days.
- Intracellular IL17A was determined by flow cytometry. On the left: a representative experiment, one of three repetitions, showing percentages of CD4+IL17A+ cells as dot plots. On the right: bar graphs show results presented as mean percentage ⁇ SD of replicate samples.
- FIG. 11 shows activation of IL-17 production in CD4+ T cells by ISL.
- DBA/1 bone marrow-derived CD11c+ DCs were cultured overnight with different peptidic ligands as above.
- Syngeneic splenic CD4+ T cells plus a Th17-polarizing cocktail were added to the culture and incubated for 6 days.
- IL-17A-positive cells were quantified by flow cytometry.
- FIG. 12 shows ISL facilitates Th17 polarization in vivo.
- A DBA/1 mice were immunized with CII in CFA in the presence of PBS, 65-79*0401 or 65-79*0402. On day 7, cells from draining lymph nodes were isolated, cultured for 6 hours with PMA, Ionomycin and Brefeldin A and then stained with anti-mouse CD4, IL17A and IFN- ⁇ as above. On the left: Representative dot plots showing percentages of IL17A+ and IFN- ⁇ + cells obtained from gated CD4+ cells. On the right, bar graphs showing results as mean ⁇ SD of duplicate experiments.
- B DBA/1 and CII-TCR Tg mice were immunized as in (A). On day 7, splenic cells were isolated and cultured with the synthetic peptide CII 260-267 (5 ⁇ g/ml). Supernatants were collected every 24 hours and assayed for IL-17 levels by ELISA.
- FIG. 13 shows ISL function in autoimmunity; although the present invention is not limited to any particular mechanism of action and an understanding of the mechanism of action is not necessary to practice the present invention.
- FIG. 14 shows that ISL facilitates polarization of bacterial antigen-specific Th17 cells.
- FIG. 15 shows a synthesis scheme of c(HSn-4) compounds. Conditions: a) 20% piperidine, DMF; b) HBTU, DIPEA; c) HATU, DIPEA; d) Pd(PPh3)4 (0), PhSiH3; e) BTC, DIPEA; f) TFA, TIPS, TDW.
- FIG. 16 shows CD spectra of cyclic and 15-mer linear peptides. a) Random coil CD spectra were observed for the two linear 15-mer peptides. b) Type III ⁇ -turn CD spectra were observed for the three cyclic analogs.
- FIGS. 17A and 17B show dose-response experiments of NO production rate induced by cyclic analogs.
- Human M1 fibroblasts were incubated with different concentrations of the listed cyclic peptides, or with 50 ⁇ M of positive (65-79*0401) or negative (65 ⁇ 79*0402) control peptides.
- NO production rates were determined using the fluorescent probe 4,5-diaminofluorescein diacetate (DAF-2DA) (See Ling et al., Arthritis Res Ther 2007, 9, R5; Ling et al., J. J Immunol 2007, 179, 6359; Ling et al., Arthritis Rheum 2006, 54, 3423).
- DAF-2DA fluorescent probe 4,5-diaminofluorescein diacetate
- FIG. 18 shows a comparison of the degradation rates of c(HS4-4), 65-79*0401 and 65-79*0404 towards trypsin and chymotrypsin enzymatic cleavage.
- microorganism refers to any species or type of microorganism, including but not limited to, bacteria, viruses, archaea, fungi, protozoans, mycoplasma, prions, and parasitic organisms.
- the term microorganism encompasses both those organisms that are in and of themselves pathogenic to another organism (e.g., animals, including humans, and plants) and those organisms that produce agents that are pathogenic to another organism, while the organism itself is not directly pathogenic or infective to the other organism.
- pathogen refers to an organism (e.g., biological agent), including microorganisms, that causes a disease state (e.g., infection, pathologic condition, disease, etc.) in another organism (e.g., animals and plants) by directly infecting the other organism, or by producing agents that causes disease in another organism (e.g., bacteria that produce pathogenic toxins and the like).
- a disease state e.g., infection, pathologic condition, disease, etc.
- Pathogens include, but are not limited to, viruses, bacteria, archaea, fungi, protozoans, mycoplasma, prions, and parasitic organisms.
- bacteria and “bacterium” refer to all prokaryotic organisms, including those within all of the phyla in the Kingdom Procaryotae. It is intended that the term encompass all microorganisms considered to be bacteria including Mycoplasma, Chlamydia, Actinomyces, Streptomyces , and Rickettsia . All forms of bacteria are included within this definition including cocci, bacilli, spirochetes, spheroplasts, protoplasts, etc.
- fungi is used in reference to eukaryotic organisms such as molds and yeasts, including dimorphic fungi.
- disease and “pathologic condition” are used interchangeably, unless indicated otherwise herein, to describe a deviation from the condition regarded as normal or average for members of a species or group (e.g., humans), and which is detrimental to an affected individual under conditions that are not inimical to the majority of individuals of that species or group.
- a deviation can manifest as a state, signs, and/or symptoms (e.g., diarrhea, nausea, fever, pain, blisters, boils, rash, immune suppression, inflammation, etc.) that are associated with any impairment of the normal state of a subject or of any of its organs or tissues that interrupts or modifies the performance of normal functions.
- a disease or pathological condition may be caused by or result from contact with a microorganism (e.g., a pathogen or other infective agent (e.g., a virus or bacteria)), may be responsive to environmental factors (e.g., malnutrition, industrial hazards, and/or climate), may be responsive to an inherent defect of the organism (e.g., genetic anomalies) or to combinations of these and other factors.
- a microorganism e.g., a pathogen or other infective agent (e.g., a virus or bacteria)
- environmental factors e.g., malnutrition, industrial hazards, and/or climate
- an inherent defect of the organism e.g., genetic anomalies
- compositions and methods of the present invention refer to an individual to be treated by (e.g., administered) the compositions and methods of the present invention.
- Subjects include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and most preferably includes humans.
- the term “subject” generally refers to an individual who will be administered or who has been administered one or more compositions of the present invention (e.g., a composition for inducing an immune response (e.g., comprising ISL).
- a composition for inducing an immune response refers to a composition that, once administered to a subject (e.g., once, twice, three times or more (e.g., separated by weeks, months or years)), stimulates, generates and/or elicits an immune response in the subject (e.g., resulting in total or partial immunity to a microorganism (e.g., pathogen) capable of causing disease).
- a subject e.g., once, twice, three times or more (e.g., separated by weeks, months or years)
- stimulates generates and/or elicits an immune response in the subject (e.g., resulting in total or partial immunity to a microorganism (e.g., pathogen) capable of causing disease).
- a microorganism e.g., pathogen
- the composition comprises ISL (e.g., purified (e.g., synthetic, recombinant, or otherwise isolated)) or derivatives or analogues thereof (e.g., cyclic mimetic ISL fragments).
- the composition comprising ISL comprises one or more other compounds or agents including, but not limited to, therapeutic agents, physiologically tolerable liquids, gels, carriers, diluents, adjuvants, excipients, salicylates, steroids, immunosuppressants, immunostimulants, antibodies, cytokines, antibiotics, binders, fillers, preservatives, stabilizing agents, emulsifiers, and/or buffers.
- An immune response may be an innate (e.g., a non-specific) immune response or a learned (e.g., acquired (e.g., cellular or humoral) immune response (e.g. that decreases the infectivity, morbidity, or onset of mortality in a subject (e.g., caused by exposure to a pathogenic microorganism), that prevents infectivity, pathology, morbidity, or onset of mortality in a subject (e.g., caused by exposure to a pathogenic microorganism), or that decreases tolerance (e.g., to a tumor antigen) in a subject).
- innate e.g., a non-specific
- a learned e.g., acquired (e.g., cellular or humoral) immune response
- an immunogenic composition comprising ISL is administered to a subject to induce an immune response (e.g., as a vaccine (e.g., to prevent or attenuate a disease (e.g., by providing to the subject total or partial immunity against the disease or the total or partial attenuation (e.g., suppression) of a sign, symptom or condition of the disease))).
- an immune response e.g., as a vaccine (e.g., to prevent or attenuate a disease (e.g., by providing to the subject total or partial immunity against the disease or the total or partial attenuation (e.g., suppression) of a sign, symptom or condition of the disease)).
- adjuvant refers to any substance that can stimulate an immune response. Some adjuvants can cause activation of a cell of the immune system (e.g., an adjuvant can cause an immune cell to produce and secrete a cytokine).
- an amount effective to induce an immune response refers to the dosage level required (e.g., when administered to a subject) to stimulate, generate and/or elicit an immune response in the subject.
- An effective amount can be administered in one or more administrations (e.g., via the same or different route), applications or dosages and is not intended to be limited to a particular formulation or administration route.
- the term “under conditions such that said subject generates an immune response” refers to any condition that leads to a qualitative or quantitative induction, generation, and/or stimulation of an immune response (e.g., innate or acquired).
- immune response refers to any detectable response by the immune system of a subject.
- immune responses include, but are not limited to, an alteration (e.g., increase) in Toll receptor activation, lymphokine (e.g., cytokine (e.g., Th1, Th2 or Th17 type cytokines) or chemokine) expression and/or secretion, macrophage activation, dendritic cell activation, T cell (e.g., CD4+ or CD8+ T cell) activation, NK cell activation, and/or B cell activation (e.g., antibody generation and/or secretion).
- lymphokine e.g., cytokine (e.g., Th1, Th2 or Th17 type cytokines) or chemokine
- T cell e.g., CD4+ or CD8+ T cell
- NK cell activation e.g., NK cell activation
- B cell activation e.g., antibody generation and/or secretion
- immune responses include binding of an immunogen (e.g., antigen (e.g., immunogenic polypeptide)) to an MHC molecule and induction of a cytotoxic T lymphocyte (“CTL”) response, induction of a B cell response (e.g., antibody production), and/or T-helper lymphocyte response, and/or a delayed type hypersensitivity (DTH) response (e.g., against the antigen from which an immunogenic polypeptide is derived), expansion (e.g., growth of a population of cells) of cells of the immune system (e.g., T cells, B cells (e.g., of any stage of development (e.g., plasma cells), and increased processing and presentation of antigen by antigen presenting cells.
- an immunogen e.g., antigen (e.g., immunogenic polypeptide)
- CTL cytotoxic T lymphocyte
- B cell response e.g., antibody production
- T-helper lymphocyte response e.g., T-helper lymphocyte response
- an immune response may be to immunogens that the subject's immune system recognizes as foreign (e.g., non-self antigens from microorganisms (e.g., pathogens), or self-antigens recognized as foreign).
- immunogens that the subject's immune system recognizes as foreign
- immune response refers to any type of immune response, including, but not limited to, innate immune responses (e.g., activation of Toll receptor signaling cascade) cell-mediated immune responses (e.g., responses mediated by T cells (e.g., antigen-specific T cells) and non-specific cells of the immune system) and humoral immune responses (e.g., responses mediated by B cells (e.g., via generation and secretion of antibodies into the plasma, lymph, and/or tissue fluids).
- innate immune responses e.g., activation of Toll receptor signaling cascade
- T cells e.g., antigen-specific T cells
- B cells e.g., via generation and secretion of
- immune response is meant to encompass all aspects of the capability of a subject's immune system to respond to an antigen and/or immunogen (e.g., both the initial response to an immunogen (e.g., a pathogen) as well as acquired (e.g., memory) responses that are a result of an adaptive immune response).
- an antigen and/or immunogen e.g., both the initial response to an immunogen (e.g., a pathogen) as well as acquired (e.g., memory) responses that are a result of an adaptive immune response).
- the term “immunity” refers to protection from disease (e.g., preventing or attenuating (e.g., suppression of) a sign, symptom or condition of the disease) upon exposure to a microorganism (e.g., pathogen) capable of causing the disease.
- Immunity can be innate (e.g., non-adaptive (e.g., non-acquired) immune responses that exist in the absence of a previous exposure to an antigen) and/or acquired (e.g., immune responses that are mediated by B and T cells following a previous exposure to antigen (e.g., that exhibit increased specificity and reactivity to the antigen)).
- immunogen refers to an agent (e.g., a microorganism (e.g., bacterium, virus or fungus) or portion thereof)) that is capable of eliciting an immune response in a subject.
- immunogens elicit immunity against the immunogen (e.g., microorganism (e.g., pathogen) or portion thereof (e.g., an antigen)) when administered in combination with ISL of the present invention.
- pathogen product refers to any component or product derived from a pathogen including, but not limited to, polypeptides, peptides, proteins, nucleic acids, membrane fractions, and polysaccharides. Pathogen product include recombinant and synthetic agents.
- the term “enhanced immunity” refers to an increase in the level of adaptive and/or acquired immunity in a subject to a given immunogen and/or antigen (e.g., microorganism (e.g., pathogen)) following administration of a composition (e.g., composition for inducing an immune response of the present invention) relative to the level of adaptive and/or acquired immunity in a subject that has not been administered the composition (e.g., composition for inducing an immune response of the present invention).
- a composition e.g., composition for inducing an immune response of the present invention
- cytokine refers to immune system proteins that are biological response modifiers. They coordinate antibody and T-cell immune system interactions, and amplify immune reactivity. Cytokines include monokines synthesised by macrophages and lymphokines produced by activated T lymphocytes and natural killer cells. Monokines include interleukin (IL)-1, tumor necrosis factor (TNF), ⁇ - and ⁇ -interferon (IFN), and colony-stimulating factors. Lymphokines include IL's, ⁇ -IFN, granulocyte-macrophage colony-stimulating factor (GM-CSF), and lymphotoxin.
- IL interleukin
- TNF tumor necrosis factor
- IFN ⁇ - and ⁇ -interferon
- Lymphokines include IL's, ⁇ -IFN, granulocyte-macrophage colony-stimulating factor (GM-CSF), and lymphotoxin.
- Endothelial cells and fibroblasts and selected other cell types may also synthesise cytokines
- cytokines include IL-2, IL-4, IL-13, IL-17, GM-CSF, IFN- ⁇ , Flt-31, SCF, TNF- ⁇ .
- the terms “host,” “subject” and “patient” refer to any animal, including but not limited to, human and non-human animals (e.g. rodents, arthropods, insects (e.g., Diptera), fish (e.g., zebrafish), non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, ayes, etc.), that is studied, analyzed, tested, diagnosed or treated.
- human and non-human animals e.g. rodents, arthropods, insects (e.g., Diptera), fish (e.g., zebrafish), non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, ayes, etc.
- the terms “host,” “subject” and “patient” are used interchangeably.
- isolated when used in relation to a protein as in “isolated protein” refers to a protein or protein sequence (e.g., a polypeptide sequence) that is identified and separated from at least one contaminant protein with which it is ordinarily associated in its natural source. Isolated protein is present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated proteins and/or polypeptides are found in the state they exist in nature.
- recombinant when made in reference to a protein or a polypeptide refers to a protein molecule which is expressed using a recombinant nucleic acid molecule.
- a recombinant nucleic acid molecule refers to a nucleic acid molecule which is comprised of segments of nucleic acid joined together by means of molecular biological techniques.
- non-human animals refers to all non-human animals including, but are not limited to, vertebrates such as rodents, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, ayes, etc.
- the term “effective amount” refers to the amount of a composition (e.g., comprising ISL and/or peptide or protein comprising ISL) sufficient to effect beneficial or desired results.
- An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
- the term “a therapeutically effective amount” of a composition comprising ISL and/or peptide or protein comprising ISL is herein defined as the dosage level/amount required to achieve a therapeutically beneficial result in a subject (e.g., that induces an immune response in the subject).
- administering refers to the act of giving a drug, prodrug, or other agent, or therapeutic treatment (e.g., compositions of the present invention) to a subject (e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs).
- a subject e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs.
- routes of administration to the human body can be through the eyes (ophthalmic), mouth (oral), skin (transdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, rectal, by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.) and the like.
- autologous cells refers to cells that are a subject's own cells.
- allogeneic cells refers cells which are genetically different, but of the same species.
- compositions and methods for inducing an immune response in a subject provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith.
- ISL immunostimulatory ligands
- Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative) medicine.
- the invention provides a composition (e.g., immunogenic composition) comprising one or more immunostimulatory ligands (herein referred to as “ISLs”) alone or in the context of another molecule (e.g., a peptide, protein, polysaccharide, oligosaccharide, carbohydrate, and/or carbohydrate-containing molecule).
- ISLs immunostimulatory ligands
- the terms “immunostimulatory ligand,” “ISL,” “immunostimulatory ligands” or “ISLs”) refer to a peptide comprising an amino acid sequence comprising the motif Q/K-K/R-R-A-A (SEQ ID NO.: 1) (e.g., QKRAA (SEQ ID NO.:2), QRRAA (SEQ ID NO.:3), KKRAA (SEQ ID NO.:4) or KRRAA (SEQ ID NO.:5)) or Q/R-K/R-R-A-A (SEQ ID NO.:6) (e.g., RKRAA (SEQ ID NO.: 13) and RRRAA (SEQ ID NO.: 14)).
- QKRAA SEQ ID NO.:2
- QRRAA SEQ ID NO.:3
- KKRAA SEQ ID NO.:4
- KRRAA SEQ ID NO.:5
- Q/R-K/R-R-A-A SEQ ID NO.
- ISL and/or protein or peptide comprising an ISL is a soluble ISL and/or soluble protein or peptide comprising an ISL.
- ISL and/or protein or peptide comprising an ISL is in the form of a human leukocyte antigen (HLA) tetramer.
- HLA human leukocyte antigen
- ISL and/or protein or peptide comprising an ISL is in the form of a cell bound surface protein and/or peptide (e.g., a cell surface marker protein and/or peptide). In some embodiments, ISL and/or protein or peptide comprising an ISL is in the form of a cell surface antigen.
- the ISL is present in a biologically active protein or peptide (e.g., a protein or peptide displaying antigenic or immunogenic properties (e.g., capable of inducing an immune response in a subject administered the peptide)).
- the peptide or protein may have antigenic or immunogenic characteristics in the absence of the ISL, or, may have no antigenic or immunogenic properties in the absence of the ISL but when the ISL is introduced into the protein or peptide the protein or peptide displays antigenic or immunogenic properties.
- the invention is not limited by the type of peptide. Indeed, a peptide containing an ISL of the invention may be any peptide described herein.
- a peptide or protein (e.g., recombinantly produced peptide or protein) containing an ISL of the invention is generated using a backbone cyclization (BC) strategy (See, Example 5).
- BC backbone cyclization
- the invention is not limited by the method or procedure utilized to generate a cyclic ISL peptide and/or protein. Indeed, a variety of methods may be utilized including, but not limited to, a urea backbone cyclic protocol (See, e.g., Hurevich et al., Journal of Peptide Science 2010, 16, 178), an amide backbone-to-side chain cyclic peptides synthesis scheme (e.g., using microwave heating synthesis (See, e.g., Hayouka et al.
- the ISL is a recombinant peptide and/or protein.
- the ISL is a cyclic peptide or protein comprising a sequence selected from SEQ ID NOS. 1-6, 13 and 14.
- the invention provides multiple examples of cyclic peptides that are metabolically stable, selective (e.g., due to peptide conformation), and/or that are bioavailable.
- the cyclic peptides are in fast equilibrium among many conformations in solution with no single restricted conformation.
- the invention provides cyclic peptides, that retain the biological activity of their parent linear peptides, that also possess desirable pharmacological properties (See, e.g., Example 5).
- the invention provides cyclic peptides that activate nitric oxide (NO) production in the low nM range.
- NO nitric oxide
- a biologically active cyclic peptide of the invention possesses a stable ⁇ -helix conformation that contains the SE consensus motif.
- the activity of the cyclic peptide can be modified (e.g., the ability of the peptide to induce NO production and/or signaling events can be altered) based upon the conformation of the peptide generated (e.g., based upon the ring size generated using a cyclization method described herein).
- the invention provides methods of generating and characterizing cyclic peptides encompassing all types of peptides including linear peptides as well as peptides that possess secondary, tertiary and/or quaternary structures (e.g., that possess ⁇ -helix conformation and/or ⁇ -turn conformations).
- peptides and/or proteins of the invention are utilized as agonists (e.g., to induce NO production and/or signaling events (e.g., utilizing a peptide and/or protein of the invention that possesses a desired conformation (e.g., a secondary or higher structure conformation important for biologic activity (e.g. for dimerization or coupling to target protein).
- peptides and/or proteins of the invention are utilized as antagonists (e.g., to block immune system activity (e.g. NO production and/or signaling events (e.g., utilizing a peptide and/or protein of the invention that possesses a desired conformation (e.g., a conformation that impedes the activity of normal biologic activity (e.g. that blocks dimerization or coupling to target protein(s))))).
- immune system activity e.g. NO production and/or signaling events
- a peptide and/or protein of the invention that possesses a desired conformation (e.g., a conformation that impedes the activity of normal biologic activity (e.g. that blocks dimerization or coupling to target protein(s)))
- a desired conformation e.g., a conformation that impedes the activity of normal biologic activity (e.g. that blocks dimerization or coupling to target protein(s))
- the cyclic peptide is a conformationally intact peptidomimetic ISL.
- the invention is not limited by the length of a peptide, protein, polysaccharide, oligosaccharide, carbohydrate, and/or carbohydrate-containing molecule sequence which harbours an ISL.
- a recombinant peptide and/or protein is engineered to contain an ISL.
- the peptide or protein may be from any microbe such as a bacteria, virus, fungi, yeast or the like.
- the protein or peptide is from Staphylococcus aureus; Staphylococcus epidermidis; Enterococcus faecalis; Mycobacterium tuberculsis; Streptococcus group B; Streptoccocus pneumoniae; Helicobacter pylori; Neisseria gonorrhea; Streptococcus group A; Borrelia burgdorferi; Coccidiodes immitis; Histoplasma sapsulatum; Neisseria meningitidis type B; Shigella flexneri; Escherichia coli; Haemophilus influenzae , bacteria of the strain or genus Klebsiella, Mycoplasma, E. coli , and/or Mycobacterium.
- the protein or peptide containing an ISL is from a pathogen (e.g., bacteria or virus) to which a Th17 type immune response is beneficial in the clearance of the pathogen from a host.
- a pathogen e.g., bacteria or virus
- the protein or peptide is from a bacteria of the strain or genus Klebsiella, Mycoplasma, E. coli , and/or Mycobacterium .
- the protein or peptide containing an ISL is a tumor antigen or a cancer antigen. The invention is not limited to any particular tumor or cancer antigen.
- an ISL may be utilized with any tumor or cancer antigen known in the art (e.g., to make the tumor or cancer antigen antigenic and/or immunogenic (e.g., in order to overcome immune evasion characteristics of the tumor and/or cancer)).
- an immunogenic composition of the invention comprises an ISL in the context of a recombinant or isolated protein or peptide which comprises an amino acid sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of a sequence found in its native state in a host organism (e.g., a cancer or tumor antigen and/or a protein or polypeptide of a microorganism).
- Peptides or proteins may be native or recombinant, full-length protein or optionally a mature protein in which any signal sequence has been removed.
- the protein may be isolated directly from a sample (e.g., a microorganism or tumor) or produced by recombinant DNA techniques.
- Immunogenic fragments of a protein or peptide containing an ISL may be incorporated into an immunogenic composition of the invention.
- the invention is not limited by the length of polypeptide or protein containing an ISL.
- a protein or polypeptide containing ISL comprises at least 5 amino acids, 10 amino acids, preferably 20 amino acids, more preferably 30 amino acids, more preferably 40 amino acids or 50 amino acids, more preferably 100 or more amino acids, taken contiguously from the amino acid sequence of a protein.
- a protein or polypeptide containing ISL include proteins or polypeptides that when administered at an effective dose, (e.g., either alone or together with a pharmaceutically acceptable carrier and/or adjuvant), elicit a protective immune response against the host microorganism and/or tumor from which the protein and/or polypeptide is derived, and more preferably, such immune response is protective (e.g., prophylactically and/or therapeutically) against infection caused by the microorganism and/or disease caused by the tumor and/or cancer.
- a protein or polypeptide containing ISL is immunologically reactive with antibodies generated against the microorganism and/or tumor or cancer or with antibodies generated by infection of a mammalian host with the microorganism.
- a protein or polypeptide containing ISL contains one or more T cell epitopes.
- immunogenic compositions of the invention may contain fusion proteins of a protein or polypeptide containing ISL proteins.
- fusion proteins may be made recombinantly and may comprise one portion of at least 2, 3, 4, 5, 6 or more proteins or polypeptides (e.g., from a microorganism and/or tumor/cancer).
- a fusion protein may comprise multiple portions of at least 2, 3, 4, or 5 proteins/peptides. These may combine different proteins or fragments thereof in the same protein.
- the invention also includes individual fusion proteins of proteins or fragments thereof, as a fusion protein with heterologous sequences such as a provider of T-cell epitopes or purification tags, for example: ⁇ -galactosidase, glutathione-S-transferase, green fluorescent proteins (GFP), epitope tags such as FLAG, myc tag, poly histidine, or viral surface proteins such as influenza virus haemagglutinin, or bacterial proteins such as tetanus toxoid, diphtheria toxoid, and/or CRM197.
- heterologous sequences such as a provider of T-cell epitopes or purification tags, for example: ⁇ -galactosidase, glutathione-S-transferase, green fluorescent proteins (GFP), epitope tags such as FLAG, myc tag, poly histidine, or viral surface proteins such as influenza virus haemagglutinin, or bacterial proteins such as tetanus tox
- a protein or peptide comprises an amino acid sequence comprising the motif Q/K-K/R-R-A-A (SEQ ID NO.: 1).
- an ISL comprises the sequence QKRAA (SEQ ID NO.:2).
- an ISL comprises the sequence QRRAA (SEQ ID NO.:3).
- an ISL comprises the sequence KKRAA (SEQ ID NO.:4).
- an ISL comprises the sequence KRRAA (SEQ ID NO.:5).
- an ISL comprises the sequence Q/R-K/R-R-A-A (SEQ ID NO.:6) (e.g., RKRAA (SEQ ID NO.: 13) and RRRAA (SEQ ID NO.: 14)).
- a protein or peptide comprises a cyclic peptide (e.g., generated using a backbone cyclization (BC) strategy) comprising the sequence Q/K-K/R-R-A-A (SEQ ID NO.: 1) (e.g., QKRAA (SEQ ID NO.:2), QRRAA (SEQ ID NO.:3), KKRAA (SEQ ID NO.:4) or KRRAA (SEQ ID NO.:5)) or Q/R-K/R-R-A-A (SEQ ID NO.:6) (e.g., RKRAA (SEQ ID NO.: 13) and RRRAA (SEQ ID NO.: 14)).
- a cyclic peptide e.g., generated using a backbone cyclization (BC) strategy
- Q/K-K/R-R-A-A SEQ ID NO.: 1
- QKRAA SEQ ID NO.:2
- QRRAA SEQ ID NO.:3
- KKRAA
- the invention provides one or more ISLs and methods of inducing an immune response (e.g., innate and/or adaptive immune responses) in a subject therewith.
- administration of a composition comprising ISL and/or a peptide or protein containing an ISL of the invention generates an innate immune response (e.g., activates Toll-like receptor signaling and/or activation of NF-kB) in a subject.
- compositions e.g. comprising an ISL
- IDO indoleamine 2,3 dioxygenase
- IL-6 is a regulatory T cell (Treg)-inhibitory cytokine with Th17-polarizing activity.
- the invention provides compositions (e.g. comprising an ISL) and methods of using the same to inhibit Treg-inducing signals and/or to stimulate Th17-cell differentiation (e.g., ISL is utilized to potentiate Th17 differentiating (e.g.
- the invention also provides a composition comprising ISL and/or protein or peptide comprising an ISL and methods of using the same to inhibit T cell tolerance in a subject (e.g., to inhibit tolerance to a tumor and/or cancer present in a subject (e.g., via administering a composition comprising ISL and/or protein or peptide comprising an ISL to a subject with cancer and/or a tumor).
- administration of a composition comprising ISL and/or a peptide or protein containing an ISL of the invention to a subject inhibits T regulatory cell activity and/or differentiation in the subject.
- a preferred embodiment of the invention is a method of preventing or treating cancer and/or tumor growth or spread comprising the step of administering an immunogenic composition or vaccine of the invention to a patient in need thereof.
- the patient is awaiting elective surgery.
- Another embodiment of the invention is a use of the immunogenic composition of the invention in the manufacture of a vaccine for treatment or prevention of cancer and/or tumor metastasis (e.g., post-surgical treatment).
- a composition comprising one or more ISLs and/or a composition (e.g., immunogenic composition) comprising a protein or peptide comprising an ISL of the invention may comprise one or more different agents in addition to the one or more ISLs and/or protein or peptide comprising an ISL.
- agents or cofactors include, but are not limited to, adjuvants, surfactants, additives, buffers, solubilizers, chelators, oils, salts, therapeutic agents, drugs, bioactive agents, antibacterials, and antimicrobial agents (e.g., antibiotics, antivirals, etc.).
- a composition comprising one or more ISLs and/or protein or peptide comprising an ISL of the invention comprises an agent and/or co-factor that enhance the ability of the one or more ISLs and/or protein or peptide comprising an ISL to induce an immune response (e.g., an adjuvant).
- an agent and/or co-factor that enhance the ability of the one or more ISLs and/or protein or peptide comprising an ISL to induce an immune response e.g., an adjuvant.
- the presence of one or more co-factors or agents reduces the amount of ISL and/or protein or peptide comprising an ISL required for induction of an immune response (e.g., a protective immune respone (e.g., protective immunization)).
- the presence of one or more co-factors or agents can be used to skew the immune response towards a cellular (e.g., T cell mediated) or humoral (e.g., antibody mediated) immune response.
- the present invention is not limited by the type of co-factor or agent used in a therapeutic agent of the present invention.
- the co-factor or agent is a drug or therapeutic used for cancer treatment and/or therapy known in the art.
- a therapeutically effective amount of a composition comprising ISL and/or peptide or protein comprising an ISL is administered to a subject.
- Adjuvants are described in general in Vaccine Design—the Subunit and Adjuvant Approach, edited by Powell and Newman, Plenum Press, New York, 1995.
- the present invention is not limited by the type of adjuvant utilized (e.g., for use in a composition (e.g., pharmaceutical composition) comprising ISL and/or protein or peptide comprising an ISL).
- suitable adjuvants include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate.
- an adjuvant may be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.
- compositions comprising ISL and/or protein or peptide comprising an ISL of the present invention comprises one or more adjuvants that induce a Th1-type response.
- a composition comprising a NE and immunogen of the present invention comprises one or more adjuvants that induce a Th2-type response.
- a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention comprises one or more adjuvants that induce a Th17-type response
- an immune response is generated to an antigen through the interaction of the antigen with the cells of the immune system.
- Immune responses may be broadly categorized into two categories: humoral and cell mediated immune responses (e.g., traditionally characterized by antibody and cellular effector mechanisms of protection, respectively). These categories of response have been termed Th1-type responses (cell-mediated response), and Th2-type immune responses (humoral response).
- Stimulation of an immune response can result from a direct or indirect response of a cell or component of the immune system to an intervention (e.g., exposure to an immunogen).
- Immune responses can be measured in many ways including activation, proliferation or differentiation of cells of the immune system (e.g., B cells, T cells, dendritic cells, APCs, macrophages, NK cells, NKT cells etc.); up-regulated or down-regulated expression of markers and cytokines; stimulation of IgA, IgM, or IgG titer; splenomegaly (including increased spleen cellularity); hyperplasia and mixed cellular infiltrates in various organs.
- Other responses, cells, and components of the immune system that can be assessed with respect to immune stimulation are known in the art.
- compositions and methods of the present invention induce expression and secretion of cytokines (e.g., by macrophages, dendritic cells and/or CD4+ T cells). Modulation of expression of a particular cytokine can occur locally or systemically. It is known that cytokine profiles can determine T cell regulatory and effector functions in immune responses. In some embodiments, Th1-type cytokines can be induced, and thus, the immunostimulatory compositions of the present invention can promote a Th1 type antigen-specific immune response including cytotoxic T-cells.
- Th2-type cytokines can be induced thereby promoting a Th2 type antigen-specific immune response.
- Th17-type cytokines are induced, and thus, the immunostimulatory compositions of the present invention promotes a Th17 type antigen-specific immune response including inhibition of T regulatory cell activity.
- Cytokines play a role in directing the T cell response.
- Helper (CD4+) T cells orchestrate the immune response of mammals through production of soluble factors that act on other immune system cells, including B and other T cells. Most mature CD4+T helper cells express one of two cytokine profiles: Th1 or Th2.
- Th1-type CD4+ T cells secrete IL-2, IL-3, IFN- ⁇ , GM-CSF and high levels of TNF- ⁇ .
- Th2 cells express IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, GM-CSF and low levels of TNF- ⁇ .
- Th1 type cytokines promote both cell-mediated immunity, and humoral immunity that is characterized by immunoglobulin class switching to IgG2a in mice and IgG1 in humans. Th1 responses may also be associated with delayed-type hypersensitivity and autoimmune disease. Th2 type cytokines induce primarily humoral immunity and induce class switching to IgG1 and IgE.
- the antibody isotypes associated with Th1 responses generally have neutralizing and opsonizing capabilities whereas those associated with Th2 responses are associated more with allergic responses.
- cytokines IL-12 and IFN- ⁇ are positive Th1 and negative Th2 regulators.
- IL-12 promotes IFN- ⁇ production, and IFN- ⁇ provides positive feedback for IL-12.
- IL-4 and IL-10 appear important for the establishment of the Th2 cytokine profile and to down-regulate Th1 cytokine production.
- the present invention provides a method of stimulating a Th1-type immune response in a subject comprising administering to a subject a composition comprising ISL and/or protein or peptide comprising an ISL.
- the present invention provides a method of stimulating a Th2-type immune response in a subject comprising administering to a subject a composition comprising a ISL and/or protein or peptide comprising an ISL.
- adjuvants can be used (e.g., can be co-administered with a composition of the present invention) to skew an immune response toward either a Th1 or Th2 type immune response.
- adjuvants that induce Th2 or weak Th1 responses include, but are not limited to, alum, saponins, and SB-As4.
- adjuvants that induce Th1 responses include but are not limited to MPL, MDP, ISCOMS, IL-12, IFN- ⁇ , and SB-AS2.
- Th1-type immunogens can be used (e.g., as an adjuvant) in compositions and methods of the present invention. These include, but are not limited to, the following.
- monophosphoryl lipid A e.g., in particular 3-de-O-acylated monophosphoryl lipid A (3D-MPL)
- 3D-MPL is a well known adjuvant manufactured by Ribi Immunochem, Montana. Chemically it is often supplied as a mixture of 3-de-O-acylated monophosphoryl lipid A with either 4, 5, or 6 acylated chains.
- diphosphoryl lipid A, and 3-O-deacylated variants thereof are used.
- 3D-MPL is used in the form of a particulate formulation (e.g., having a small particle size less than 0.2 ⁇ m in diameter, described in EP 0 689 454, hereby incorporated by reference in its entirety).
- saponins are used as an immunogen (e.g., Th1-type adjuvant) in a composition of the present invention.
- Saponins are well known adjuvants (See, e.g., Lacaille-Dubois and Wagner (1996) Phytomedicine vol 2 pp 363-386).
- Examples of saponins include Quil A (derived from the bark of the South American tree Quillaja Saponaria Molina), and fractions thereof (See, e.g., U.S. Pat. No. 5,057,540; Kensil, Crit. Rev Ther Drug Carrier Syst, 1996, 12 (1-2):1-55; and EP 0 362 279, each of which is hereby incorporated by reference in its entirety).
- haemolytic saponins QS7, QS 17, and QS21 HPLC purified fractions of Quil A; See, e.g., Kensil et al. (1991). J. Immunology 146, 431-437, U.S. Pat. No. 5,057,540; WO 96/33739; WO 96/11711 and EP 0 362 279, each of which is hereby incorporated by reference in its entirety).
- QS21 and polysorbate or cyclodextrin See, e.g., WO 99/10008, hereby incorporated by reference in its entirety.
- an immunogenic oligonucleotide containing unmethylated CpG dinucleotides (“CpG”) is used as an adjuvant in the present invention.
- CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA.
- CpG is known in the art as being an adjuvant when administered by both systemic and mucosal routes (See, e.g., WO 96/02555, EP 468520, Davis et al., J. Immunol, 1998, 160(2):870-876; McCluskie and Davis, J. Immunol., 1998, 161(9):4463-6; and U.S. Pat. App. No.
- the immunostimulatory sequence is Purine-Purine-C-G-pyrimidine-pyrimidine; wherein the CG motif is not methylated.
- CpG oligonucleotides activate various immune subsets including natural killer cells (which produce IFN- ⁇ ) and macrophages.
- CpG oligonucleotides are formulated into a composition of the present invention for inducing an immune response.
- a free solution of CpG is co-administered together with an antigen (e.g., present within a NE solution (See, e.g., WO 96/02555; hereby incorporated by reference).
- a CpG oligonucleotide is covalently conjugated to an antigen (See, e.g., WO 98/16247, hereby incorporated by reference), or formulated with a carrier such as aluminium hydroxide (See, e.g., Brazolot-Millan et al., Proc. Natl. Acad Sci., USA, 1998, 95(26), 15553-8 (e.g., ISL and/or protein or peptide comprising an ISL).
- an antigen See, e.g., WO 98/16247, hereby incorporated by reference
- a carrier such as aluminium hydroxide
- adjuvants such as Complete Freunds Adjuvant and Incomplete Freunds Adjuvant, cytokines (e.g., interleukins (e.g., IL-2, IFN- ⁇ , IL-4, IL-6, IL-17, IL-23, etc.), macrophage colony stimulating factor, tumor necrosis factor, etc.), detoxified mutants of a bacterial ADP-ribosylating toxin such as a cholera toxin (CT), a pertussis toxin (PT), or an E.
- cytokines e.g., interleukins (e.g., IL-2, IFN- ⁇ , IL-4, IL-6, IL-17, IL-23, etc.
- macrophage colony stimulating factor e.g., tumor necrosis factor, etc.
- a bacterial ADP-ribosylating toxin such as a cholera toxin (CT), a pertussis toxin (PT), or
- Coli heat-labile toxin particularly LT-K63 (where lysine is substituted for the wild-type amino acid at position 63)
- LT-R72 where arginine is substituted for the wild-type amino acid at position 72
- CT-S 109 where serine is substituted for the wild-type amino acid at position 109
- PT-K9/G129 where lysine is substituted for the wild-type amino acid at position 9 and glycine substituted at position 129)
- adjuvants that find use in the present invention include poly(di(carboxylatophenoxy)phosphazene (PCPP polymer; Virus Research Institute, USA); derivatives of lipopolysaccharides such as monophosphoryl lipid A (MPL; Ribi ImmunoChem Research, Inc., Hamilton, Mont.), muramyl dipeptide (MDP; Ribi) and threonyl-muramyl dipeptide (t-MDP; Ribi); OM-174 (a glucosamine disaccharide related to lipid A; OM Pharma SA, Meyrin, Switzerland); and Leishmania elongation factor (a purified Leishmania protein; Corixa Corporation, Seattle, Wash.).
- PCPP polymer polymer
- Virus Research Institute, USA poly(di(carboxylatophenoxy)phosphazene
- MPL monophosphoryl lipid A
- MDP muramyl dipeptide
- t-MDP threonyl-muramyl
- Adjuvants may be added to a composition comprising ISL and/or protein or peptide comprising an ISL, or, the adjuvant may be formulated with carriers, for example liposomes, or metallic salts (e.g., aluminium salts (e.g., aluminium hydroxide)) prior to combining with or co-administration with a composition comprising ISL and/or protein or peptide comprising an ISL.
- carriers for example liposomes, or metallic salts (e.g., aluminium salts (e.g., aluminium hydroxide)) prior to combining with or co-administration with a composition comprising ISL and/or protein or peptide comprising an ISL.
- a composition comprising ISL and/or protein or peptide comprising an ISL comprises a single adjuvant. In other embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL comprises two or more adjuvants (See, e.g., WO 94/00153; WO 95/17210; WO 96/33739; WO 98/56414; WO 99/12565; WO 99/11241; and WO 94/00153, each of which is hereby incorporated by reference in its entirety).
- a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention comprises one or more mucoadhesives (See, e.g., U.S. Pat. App. No. 20050281843, hereby incorporated by reference in its entirety).
- the present invention is not limited by the type of mucoadhesive utilized.
- mucoadhesives are contemplated to be useful in the present invention including, but not limited to, cross-linked derivatives of poly(acrylic acid) (e.g., carbopol and polycarbophil), polyvinyl alcohol, polyvinyl pyrollidone, polysaccharides (e.g., alginate and chitosan), hydroxypropyl methylcellulose, lectins, fimbrial proteins, and carboxymethylcellulose.
- a mucoadhesive e.g., in a composition comprising ISL and/or protein or peptide comprising an ISL
- a mucoadhesive enhances induction of an immune response in a subject (e.g., administered a composition of the present invention) due to an increase in duration and/or amount of exposure to an immunogen that a subject experiences when a mucoadhesive is used compared to the duration and/or amount of exposure to an immunogen in the absence of using the mucoadhesive.
- a composition of the present invention may comprise sterile aqueous preparations.
- Acceptable vehicles and solvents include, but are not limited to, water, Ringer's solution, phosphate buffered saline and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed mineral or non-mineral oil may be employed including synthetic mono-ordi-glycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- Carrier formulations suitable for mucosal, subcutaneous, intramuscular, intraperitoneal, intravenous, or administration via other routes may be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa.
- compositions comprising ISL and/or protein or peptide comprising an ISL that possess a range of biologic activity (e.g., based upon the structure of the peptide and/or protein (e.g., linear, possessing secondary, tertiary and/or quaternary structure (e.g., ⁇ -helix and/or ⁇ -turn conformation that mimics a parent molecule or that blocks activity of a parent molecule))), as well as methods of generating and characterizing the same. Accordingly, in some embodiments, compositions and methods of the invention are utilized for the treatment and/or prevention of disease. The invention is not limited by the type of disease that may be treated and/or prevented utilizing a composition or method disclosed herein.
- the disease is an autoimmune disease.
- the invention is not limited by the type of autoimmune disease. Indeed, compositions and methods of the invention find use in a variety of autoimmune diseases including, but not limited to, rheumatoid arthritis, systemic lupus erythematosus (SLE), Cogan's syndrome, unclassified systemic autoimmune disease, Raynaud's syndrome, Wegener's granulomatosis, autoimmune uveoretinitis, autoimmune vasculitis, bullous pemphigus, myasthenia gravis, autoimmune thyroiditis or Hashimoto's disease, Sjogren's syndrome, granulomatous orchitis, autoimmune oophoritis, Crohn's disease, sarcoidosis, rheumatic carditis, ankylosing spondylitis, Grave's disease, or autoimmune thrombocytopenic purpura.
- a composition comprising ISL and/or protein or peptide comprising an ISL can be used therapeutically (e.g., to enhance an immune response (e.g., against a pathogen and/or a tumor or cancer) or to inhibit an immune response (e.g., using a non-biologically active peptide mimetic) or as a prophylactic (e.g., for immunization (e.g., to prevent signs or symptoms of disease)).
- a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention can be administered to a subject via a number of different delivery routes and methods.
- compositions of the present invention are administered mucosally (e.g., using standard techniques; See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Company, Easton, Pa., 19th edition, 1995 (e.g., for mucosal delivery techniques, including intranasal, pulmonary, vaginal and rectal techniques), as well as European Publication No. 517,565 and Illum et al., J. Controlled Rel., 1994, 29:133-141 (e.g., for techniques of intranasal administration), each of which is hereby incorporated by reference in its entirety).
- mucosally e.g., using standard techniques; See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Company, Easton, Pa., 19th edition, 1995 (e.g., for mucosal delivery techniques, including intranasal, pulmonary, vaginal and rectal techniques), as well as European Publication No. 517,565 and Illum et
- compositions of the present invention may be administered dermally or transdermally, using standard techniques (See, e.g., Remington: The Science arid Practice of Pharmacy, Mack Publishing Company, Easton, Pa., 19th edition, 1995).
- the present invention is not limited by the route of administration.
- compositions of the present invention can be administered to a subject (e.g., mucosally (e.g., nasal mucosa, vaginal mucosa, etc.)) by multiple methods, including, but not limited to: being suspended in a solution and applied to a surface; being suspended in a solution and sprayed onto a surface using a spray applicator; being mixed with a mucoadhesive and applied (e.g., sprayed or wiped) onto a surface (e.g., mucosal surface); being placed on or impregnated onto a nasal and/or vaginal applicator and applied; being applied by a controlled-release mechanism; being applied as a liposome; or being applied on a polymer.
- a subject e.g., mucosally (e.g., nasal mucosa, vaginal mucosa, etc.)
- multiple methods including, but not limited to: being suspended in a solution and applied to a surface; being suspended in
- a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention may be used to protect or treat a subject susceptible to, or suffering from, disease by means of administering a composition of the present invention via a mucosal route (e.g., an oral/alimentary or nasal route).
- a mucosal route e.g., an oral/alimentary or nasal route.
- Alternative mucosal routes include intravaginal and intra-rectal routes.
- Methods of intranasal vaccination are well known in the art, including the administration of a droplet or spray form of the vaccine into the nasopharynx of a subject to be immunized.
- a nebulized or aerosolized composition comprising ISL and/or protein or peptide comprising an ISL is provided.
- compositions of the present invention may also be administered via the oral route.
- a composition comprising ISL and/or protein or peptide comprising an ISL may comprise a pharmaceutically acceptable excipient and/or include alkaline buffers, or enteric capsules.
- Formulations for nasal delivery may include those with dextran or cyclodextran and saponin as an adjuvant.
- compositions of the present invention may also be administered via a vaginal route.
- a composition comprising ISL and/or protein or peptide comprising an ISL may comprise pharmaceutically acceptable excipients and/or emulsifiers, polymers (e.g., CARBOPOL), and other known stabilizers of vaginal creams and suppositories.
- compositions of the present invention are administered via a rectal route.
- a composition comprising ISL and/or protein or peptide comprising an ISL may comprise excipients and/or waxes and polymers known in the art for forming rectal suppositories.
- the same route of administration (e.g., mucosal administration) is chosen for both a priming and boosting vaccination.
- multiple routes of administration are utilized (e.g., at the same time, or, alternatively, sequentially) in order to stimulate an immune response (e.g., using a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention).
- a composition comprising ISL and/or protein or peptide comprising an ISL is administered to a mucosal surface of a subject in either a priming or boosting vaccination regime.
- a composition comprising ISL and/or protein or peptide comprising an ISL is administered systemically in either a priming or boosting vaccination regime.
- a composition comprising ISL and/or protein or peptide comprising an ISL is administered to a subject in a priming vaccination regimen via mucosal administration and a boosting regimen via systemic administration.
- a composition comprising ISL and/or protein or peptide comprising an ISL is administered to a subject in a priming vaccination regimen via systemic administration and a boosting regimen via mucosal administration.
- systemic routes of administration include, but are not limited to, a parenteral, intramuscular, intradermal, transdermal, subcutaneous, intraperitoneal or intravenous administration.
- a composition comprising ISL and/or protein or peptide comprising an ISL may be used for both prophylactic and therapeutic purposes.
- compositions of the present invention are administered by pulmonary delivery.
- a composition of the present invention can be delivered to the lungs of a subject (e.g., a human) via inhalation (e.g., thereby traversing across the lung epithelial lining to the blood stream (See, e.g., Adjei, et al. Pharmaceutical Research 1990; 7:565-569; Adjei, et al. Int. J. Pharmaceutics 1990; 63:135-144; Braquet, et al. J. Cardiovascular Pharmacology 1989 143-146; Hubbard, et al. (1989) Annals of Internal Medicine, Vol. III, pp. 206-212; Smith, et al.
- nebulizers metered dose inhalers
- powder inhalers all of which are familiar to those skilled in the art.
- Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer (Mallinckrodt Inc., St. Louis, Mo.); the Acorn II nebulizer (Marquest Medical Products, Englewood, Colo.); the Ventolin metered dose inhaler (Glaxo Inc., Research Triangle Park, N.C.); and the Spinhaler powder inhaler (Fisons Corp., Bedford, Mass.).
- each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvants, surfactants, carriers and/or other agents useful in therapy. Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.
- a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention may be used to protect and/or treat a subject susceptible to, or suffering from, a disease by means of administering a compositions comprising ISL and/or protein or peptide comprising an ISL by mucosal, intramuscular, intraperitoneal, intradermal, transdermal, pulmonary, intravenous, subcutaneous or other route of administration described herein.
- Methods of systemic administration of an immunogenic composition comprising ISL and/or protein or peptide comprising an ISL may include conventional syringes and needles, or devices designed for ballistic delivery of solid vaccines (See, e.g., WO 99/27961, hereby incorporated by reference), or needleless pressure liquid jet device (See, e.g., U.S. Pat. No. 4,596,556; U.S. Pat. No. 5,993,412, each of which are hereby incorporated by reference), or transdermal patches (See, e.g., WO 97/48440; WO 98/28037, each of which are hereby incorporated by reference).
- the present invention may also be used to enhance the immunogenicity of antigens applied to the skin (transdermal or transcutaneous delivery, See, e.g., WO 98/20734; WO 98/28037, each of which are hereby incorporated by reference).
- the present invention provides a delivery device for systemic administration, pre-filled with an immunogenic composition of the present invention.
- the present invention is not limited by the type of subject administered (e.g., in order to stimulate an immune response (e.g., in order to generate protective immunity (e.g., mucosal and/or systemic immunity))) a composition of the present invention.
- a wide variety of subjects are contemplated to be benefited from administration of a composition of the present invention.
- the subject is a human.
- the subject is a subject displaying signs, symptoms or other characteristics of cancer (e.g., a subject diagnosed as having cancer).
- human subjects are of any age (e.g., adults, children, infants, etc.) that have been or are likely to become exposed to a microorganism.
- compositions and methods of the present invention are utilized to vaccinate a group of people (e.g., a population of a region, city, state and/or country) for their own health (e.g., to prevent or treat disease) and/or to prevent or reduce the risk of disease spread from animals (e.g., birds, cattle, sheep, pigs, etc.) to humans.
- animals e.g., birds, cattle, sheep, pigs, etc.
- the subjects are non-human mammals (e.g., pigs, cattle, goats, horses, sheep, or other livestock; or mice, rats, rabbits or other animal).
- compositions and methods of the present invention are utilized in research settings (e.g., with research animals).
- composition of the present invention may be formulated for administration by any route, such as mucosal, oral, topical, parenteral or other route described herein.
- the compositions may be in any one or more different forms including, but not limited to, tablets, capsules, powders, granules, lozenges, foams, creams or liquid preparations.
- Topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, foams, and aerosols, and may contain appropriate conventional additives such as preservatives, solvents (e.g., to assist penetration), and emollients in ointments and creams.
- Topical formulations may also include agents that enhance penetration of the active ingredients through the skin.
- agents include a binary combination of N-(hydroxyethyl) pyrrolidone and a cell-envelope disordering compound, a sugar ester in combination with a sulfoxide or phosphine oxide, and sucrose monooleate, decyl methyl sulfoxide, and alcohol.
- surfactants or wetting agents including, but not limited to, polyoxyethylene sorbitan mono-oleoate (Polysorbate 80); sorbitan mono-oleate (Span 80); p-isooctyl polyoxyethylene-phenol polymer (Triton WR-1330); polyoxyethylene sorbitan tri-oleate (Tween 85); dioctyl sodium sulfosuccinate; and sodium sarcosinate (Sarcosyl NL-97); and other pharmaceutically acceptable surfactants.
- surfactants or wetting agents including, but not limited to, polyoxyethylene sorbitan mono-oleoate (Polysorbate 80); sorbitan mono-oleate (Span 80); p-isooctyl polyoxyethylene-phenol polymer (Triton WR-1330); polyoxyethylene sorbitan tri-oleate (Tween 85); dioctyl sodium sulfosuccinate; and sodium sarcosinate (Sar
- compositions may further comprise one or more alcohols, zinc-containing compounds, emollients, humectants, thickening and/or gelling agents, neutralizing agents, and surfactants.
- Water used in the formulations is preferably deionized water having a neutral pH.
- Additional additives in the topical formulations include, but are not limited to, silicone fluids, dyes, fragrances, pH adjusters, and vitamins.
- Topical formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation.
- the ointment base can comprise one or more of petrolatum, mineral oil, ceresin, lanolin alcohol, panthenol, glycerin, bisabolol, cocoa butter and the like.
- compositions of the present invention may be formulated and used as foams.
- Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product.
- compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions.
- the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers.
- additional materials useful in physically formulating various dosage forms of the compositions of the present invention such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers.
- such materials when added, preferably do not unduly interfere with the biological activities of the components of the compositions of the present invention.
- the formulations can be sterilized and, if desired, mixed with auxiliary agents (e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like) that do not deleteriously interact with the ISL and/or protein or peptide comprising an ISL of the formulation.
- auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like
- immunostimulatory compositions of the present invention are administered in the form of a pharmaceutically acceptable salt.
- the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof.
- Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic.
- such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.
- Suitable buffering agents include, but are not limited to, acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v).
- Suitable preservatives may include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).
- Vaccine preparation is generally described in Vaccine Design (“The subunit and adjuvant approach” (eds Powell M. F. & Newman M. J.) (1995) Plenum Press New York). Encapsulation within liposomes is described by Fullerton, U.S. Pat. No. 4,235,877.
- a composition comprising ISL and/or protein or peptide comprising an ISL is co-administered with one or more antibiotics.
- one or more antibiotics may be administered with, before and/or after administration of a composition comprising ISL and/or protein or peptide comprising an ISL.
- the present invention is not limited by the type of antibiotic co-administered.
- antibiotics may be co-administered including, but not limited to, ⁇ -lactam antibiotics, penicillins (such as natural penicillins, aminopenicillins, penicillinase-resistant penicillins, carboxy penicillins, ureido penicillins), cephalosporins (first generation, second generation, and third generation cephalosporins), and other ⁇ -lactams (such as imipenem, monobactams,), ⁇ -lactamase inhibitors, vancomycin, aminoglycosides and spectinomycin, tetracyclines, chloramphenicol, erythromycin, lincomycin, clindamycin, rifampin, metronidazole, polymyxins, doxycycline, quinolones (e.g., ciprofloxacin), sulfonamides, trimethoprim, and quinolines.
- penicillins such as natural penicillins, aminopenicillins, penicillina
- these agents include agents that inhibit cell wall synthesis (e.g., penicillins, cephalosporins, cycloserine, vancomycin, bacitracin); and the imidazole antifungal agents (e.g., miconazole, ketoconazole and clotrimazole); agents that act directly to disrupt the cell membrane of the microorganism (e.g., detergents such as polmyxin and colistimethate and the antifungals nystatin and amphotericin B); agents that affect the ribosomal subunits to inhibit protein synthesis (e.g., chloramphenicol, the tetracyclines, erthromycin and clindamycin); agents that alter protein synthesis and lead to cell death (e.g., aminoglycosides); agents that affect nucleic acid metabolism (e.g., the rifamycins and the quinolones); the antimetabolites (e.g., trimethoprim and sulf
- the present invention also includes methods involving co-administration of a composition comprising ISL and/or protein or peptide comprising an ISL with one or more additional active and/or immunostimulatory agents (e.g., a composition comprising ISL and/or protein or peptide comprising an ISL, an antibiotic, anti-oxidant, etc.).
- additional active and/or immunostimulatory agents e.g., a composition comprising ISL and/or protein or peptide comprising an ISL, an antibiotic, anti-oxidant, etc.
- additional active and/or immunostimulatory agents e.g., a composition comprising ISL and/or protein or peptide comprising an ISL, an antibiotic, anti-oxidant, etc.
- additional active and/or immunostimulatory agents e.g., a composition comprising ISL and/or protein or peptide comprising an ISL, an antibiotic, anti-oxidant, etc.
- the pharmaceutical formulations and modes of administration may be any of those described herein.
- the two or more co-administered agents may each be administered using different modes (e.g., routes) or different formulations.
- the additional agents to be co-administered e.g., antibiotics, adjuvants, etc.
- Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compositions, increasing convenience to the subject and a physician.
- Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer based systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Pat. No. 5,075,109, hereby incorporated by reference.
- Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like.
- lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di- and tri-glycerides
- hydrogel release systems such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di- and tri-glycerides
- sylastic systems such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di- and tri-glycerides
- peptide based systems such as fatty acids
- wax coatings such as those described in U.S. Pat. Nos.
- a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention comprises a suitable amount of ISL and/or protein or peptide comprising an ISL to induce an immune response in a subject when administered to the subject.
- the immune response is sufficient to provide the subject protection (e.g., immune protection) against a subsequent exposure to an immunogen (e.g., a pathogen) or the microorganism (e.g., bacteria or virus) from which the protein or peptide comprising an ISL was derived.
- an immunogen e.g., a pathogen
- the microorganism e.g., bacteria or virus
- the amount of ISL and/or protein or peptide comprising an ISL in a composition comprising a ISL and/or protein or peptide comprising an ISL is selected as that amount which induces an immunoprotective response without significant, adverse side effects.
- the amount will vary depending upon which specific ISL and/or protein or peptide comprising an ISL or combination thereof is/are employed, and can vary from subject to subject, depending on a number of factors including, but not limited to, the species, age and general condition (e.g., health) of the subject, and the mode of administration.
- Procedures for determining the appropriate amount of ISL and/or protein or peptide comprising an ISL administered to a subject to elicit an immune response (e.g., a protective immune response (e.g., protective immunity)) in a subject are well known to those skilled in the art.
- each dose (e.g., of a composition comprising ISL and/or protein or peptide comprising an ISL (e.g., administered to a subject to induce an immune response (e.g., a protective immune response (e.g., protective immunity))) comprises 0.05-5000 ⁇ g of each ISL and/or protein or peptide comprising an ISL (e.g., recombinant and/or purified peptide or protein), in some embodiments, each dose will comprise 1-500 ⁇ g, in some embodiments, each dose will comprise 350-750 ⁇ g, in some embodiments, each dose will comprise 50-200 ⁇ g, in some embodiments, each dose will comprise 25-75 ⁇ g of ISL and/or protein or peptide comprising an ISL (e.g., recombinant and/or purified peptide or protein).
- each dose comprises an amount of the ISL and/or protein or peptide comprising an ISL sufficient to generate an immune response.
- An effective amount of the immunogen in a dose need not be quantified, as long as the amount of ISL and/or protein or peptide comprising an ISL generates an immune response in a subject when administered to the subject.
- An optimal amount for a particular administration e.g., to induce an immune response (e.g., a protective immune response (e.g., protective immunity))
- an immune response e.g., a protective immune response (e.g., protective immunity)
- each dose e.g., of a composition comprising a ISL and/or protein or peptide comprising an ISL (e.g., administered to a subject to induce and immune response)
- each dose is from 0.001 to 15% or more (e.g., 0.001-10%, 0.5-5%, 1-3%, 2%, 6%, 10%, 15% or more) by weight ISL and/or protein or peptide comprising an ISL.
- an initial or prime administration dose contains more ISL and/or protein or peptide comprising an ISL than a subsequent boost dose
- a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention is formulated in a concentrated dose that can be diluted prior to administration to a subject.
- dilutions of a concentrated composition may be administered to a subject such that the subject receives any one or more of the specific dosages provided herein.
- dilution of a concentrated composition may be made such that a subject is administered (e.g., in a single dose) a composition comprising 0.5-50% of the ISL and/or protein or peptide comprising an ISL present in the concentrated composition.
- a subject is administered in a single dose a composition comprising 1% of the ISL and/or protein or peptide comprising an ISL present in the concentrated composition.
- Concentrated compositions are contemplated to be useful in a setting in which large numbers of subjects may be administered a composition of the present invention (e.g., an immunization clinic, hospital, school, etc.).
- a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention is stable at room temperature for more than 1 week, in some embodiments for more than 2 weeks, in some embodiments for more than 3 weeks, in some embodiments for more than 4 weeks, in some embodiments for more than 5 weeks, and in some embodiments for more than 6 weeks.
- a subject may receive one or more boost administrations (e.g., around 2 weeks, around 3 weeks, around 4 weeks, around 5 weeks, around 6 weeks, around 7 weeks, around 8 weeks, around 10 weeks, around 3 months, around 4 months, around 6 months, around 9 months, around 1 year, around 2 years, around 3 years, around 5 years, around 10 years) subsequent to a first, second, third, fourth, fifth, sixth, seventh, eights, ninth, tenth, and/or more than tenth administration.
- boost administrations e.g., around 2 weeks, around 3 weeks, around 4 weeks, around 5 weeks, around 6 weeks, around 7 weeks, around 8 weeks, around 10 weeks, around 3 months, around 4 months, around 6 months, around 9 months, around 1 year, around 2 years, around 3 years, around 5 years, around 10 years
- reintroduction of ISL and/or protein or peptide comprising an ISL in a boost dose enables vigorous systemic immunity in a subject.
- the boost can be with the same formulation given for the primary immune response, or can be with a different formulation that contains a different ISL and/or protein or peptide comprising an ISL.
- the dosage regimen will also, at least in part, be determined by the need of the subject and be dependent on the judgment of a practitioner.
- Dosage units may be proportionately increased or decreased based on several factors including, but not limited to, the weight, age, and health status of the subject. In addition, dosage units may be increased or decreased for subsequent administrations (e.g., boost administrations).
- a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention finds use where the nature of the infectious and/or disease causing agent (e.g., for which protective immunity is sought to be elicited) is known, as well as where the nature of the infectious and/or disease causing agent is unknown (e.g., in emerging disease (e.g., of pandemic proportion (e.g., influenza or other outbreaks of disease))).
- infectious and/or disease causing agent e.g., for which protective immunity is sought to be elicited
- pandemic proportion e.g., influenza or other outbreaks of disease
- compositions and methods of the present invention will find use in various settings, including research settings.
- compositions and methods of the present invention also find use in studies of the immune system (e.g., characterization of adaptive immune responses (e.g., protective immune responses (e.g., mucosal or systemic immunity))).
- Uses of the compositions and methods provided by the present invention encompass human and non-human subjects and samples from those subjects, and also encompass research applications using these subjects.
- Compositions and methods of the present invention are also useful in studying and optimizing ISL and/or protein or peptide comprising an ISL, and other components and for screening for new components.
- the present invention be limited to any particular subject and/or application setting.
- compositions of the present invention are useful for preventing and/or treating a wide variety of diseases and infections caused by viruses, bacteria, parasites, and fungi, as well as for eliciting an immune response against a variety of antigens.
- the compositions can also be used in order to prepare antibodies, both polyclonal and monoclonal (e.g., for diagnostic purposes), as well as for immunopurification of an antigen of interest. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) can be immunized with the compositions of the present invention.
- the animal is usually boosted 2-6 weeks later with one or more—administrations of the antigen.
- Polyclonal antisera can then be obtained from the immunized animal and used according to known procedures (See, e.g., Jurgens et al., J. Chrom. 1985, 348:363-370).
- the present invention provides a kit comprising a composition comprising ISL and/or protein or peptide comprising an ISL.
- the kit further provides a device for administering the composition.
- the present invention is not limited by the type of device included in the kit.
- all kit components are present within a single container (e.g., vial or tube).
- each kit component is located in a single container (e.g., vial or tube).
- one or more kit component are located in a single container (e.g., vial or tube) with other components of the same kit being located in a separate container (e.g., vial or tube).
- a kit comprises a buffer.
- the kit further comprises instructions for use.
- IPP Isopentenyl diphosphate
- IPP IPP had a very strong synergistic effect with IFN- ⁇ on IDO activation (ISLE FIG. 1 ). For example, at 10 ⁇ M, IPP more than doubled IDO activation in cells treated with 500 U/ml IFN- ⁇ and more than tripled IDO activation in cells treated with 100 U/ml IFN- ⁇ .
- NO has a pro-oxidative effect. NO has also been shown to inhibit IDO activation (Alberati-Giani et al. J. Immunol. 159, 419-426, 1997.; Hucke et al. Infect Immun. 72, 2723-2730, 2004.; herein incorporated by reference in their entireties). Consistent with published reports in other cell systems, the NO donor S-nitroso-Nacetylpenicillamine (SNAP) had an inhibitory effect on IFN- ⁇ -induced activation of IDO in fibroblasts (ISLE FIG. 2 ). Thus, IPP is not only a highly potent antioxidant, it also operate synergistically with IFN ⁇ to increase the activity of IDO, a key enzyme in immune tolerance.
- IDO plays an important role in T cell regulation, and NO has been previously found to inhibit IDO activity (Alberati-Giani et al. J. Immunol. 159, 419-426, 1997.; Hucke et al. Infect Immun. 72, 2723-2730, 2004.; herein incorporated by reference in their entireties).
- ISL affects IDO activity.
- ISL-positive peptides 65-79*0401 and 65-79*0404 effectively blocked conversion of tryptophan to kynurenine, while ISL-negative peptides 65-79*0402 and 65-79*0403 did not have such effect (ISLE FIG. 4A ).
- Murine L cells expressing ISL-positive DR ⁇ chains on their surface through cDNA transfection (lines L-0401 and L-0404, expressing the ISL-positive DR ⁇ 0401 and DR ⁇ 0404 molecules, respectively), produced significantly less kynurenine in response to IFN ⁇ , when compared to transfectants expressing ISL-negative DR ⁇ chains (lines L-0402 and L-0403, expressing ISL-negative molecules DR ⁇ 0402 and DR ⁇ 0403, respectively) (ISLE FIG. 4B ).
- IFN ⁇ -induced IDO activity was found in DCs expressing the CD8a surface marker (CD8+ DC), but not in CD8 ⁇ -negative DC(CD8 ⁇ DC).
- CD8+ DC CD8a surface marker
- CD8 ⁇ -negative DC CD8 ⁇ -negative DC
- immature CD11c+ CD8+ DC were purified from DBA/1 spleens and pre-exposed to ISL in the form of HBc particles engineered to express the 65-79 region of DR ⁇ chains, encoded by the ISL-positive allele DRB1*0401 (particle HBc*0401).
- ISL-negative particles (HBc*0402), expressing the DR ⁇ 65-79 region encoded by the ISL-negative DRB1*0402 allele were used as control (these 2 particles differ by only 2 amino acid residues in the 70-74 region of the insert).
- DCs were subsequently stimulated with IFN ⁇ and IDO activity was determined. ISL-positive, but not ISL-negative particles inhibited IDO activity in DC (ISLE FIG. 4D ).
- DC can also regulate immune responses by production of various cytokines that can activate or expand particular subsets of T cells, thereby polarizing the immune response.
- cytokines that can activate or expand particular subsets of T cells, thereby polarizing the immune response.
- ISL-mediated signaling in DC could induce particular cytokines
- Supernatants of ISL-stimulated DC were examined using the Luminex platform. While CD8+ DC showed no production of any cytokines, in the CD8 ⁇ subset, the ISL-positive peptide 65-79*0401 triggered a robust production of IL-6 (ISLE FIG. 5 ). The ISL-negative peptide 65-79*0402 did not trigger any increased production, similar to cultures incubated with PBS. Other cytokines (IL-4, IL-10 and IL-12) did not show any increased production, indicating the specificity of ISL effect.
- IL-4, IL-10 and IL-12 did not show any increased production, indicating the specificity of ISL effect.
- mice were from Jackson Laboratory. Experiments were carried out in 5-10 week-old male DBA/1, Balb/c, C57BL/6, or a DBA/1 mouse line carrying transgenic (Tg) collagen type II (CII)-specific TCR (D1Lac.Cg-Tg(TCRa,TCRb)24Efro/J); the latter mouse line is designated herein as “CII-TCR Tg mice.”
- Tg transgenic collagen type II
- CII-specific TCR D1Lac.Cg-Tg(TCRa,TCRb)24Efro/J
- Monoclonal antibodies against mouse CD3 (clone 2C11), IL-4 (clone 11B11), IFN ⁇ (clone R46A2), and IL-2 (clone S4B6) were purified from the supernatants of hybridomas obtained from the University of Michigan Hybridoma Core Facility.
- Purified anti-mouse CD28 (clone 37.51) and murine rIL-23 were purchased from e-Bioscience (San Diego, Calif.).
- Human rTGF ⁇ and rIFN ⁇ , as well as murine rIL-4, rIFN ⁇ , rGM-CSF and rIL-6 were purchased from Peprotech (Rocky Hill, N.J.).
- ISL-expressing 15mer peptides designated as 65-79*0401 (aa sequence 65-KDLLEQKRAAVDTYC-79 SEQ ID NO.: 7), or 65-79*0404 (aa sequence 65-KDLLEQRRAAVDTYC-79 SEQ ID NO.: 8), corresponded to the third allelic hypervariable region (HVR3) of the DR ⁇ chain encoded by of ISL-positive HLA-DRB1*0401 or HLA-DRB1*0404 alleles, respectively.
- HVR3 allelic hypervariable region
- Control 15mer peptides 65-79*0402 (65-KDILEDERAAVDTYC-79 SEQ ID NO.: 9) and 65-79*0403 (65-KDLLEQRRAEVDTYC-79 SEQ ID NO.: 10) corresponded to the HVR3 of the DR ⁇ chain encoded by of ISL-negative HLA-DRB1*0402 or HLA-DRB1*0403 alleles, respectively.
- the CII259-273 peptide which corresponds to residues 259-273 of chicken CII.
- HBc particles engineered to express the HVR3 of the HLA-DR ⁇ chain were prepared at the Lithuanian Biomedical Research and Study Center, (Riga, Lithuania)(Holoshitz & Ling. 2007 Ann N Y Acad Sci 1110:73-83.; herein incorporated by reference in its entirety).
- HBc particles expressing a ISL-positive HVR3, encoded by HLA-DRB1*0401 (designated here as HBc*0401) or a ISL-negative HVR3, encoded by HLA-DRB1*0402 (designated here as HBc*0402) were used in experiments conducted herein.
- ISL-positive HLA-DR tetramers DRB1*0401/DRA1*0101 (designated here as T-DRB1*0401), ISL-negative DRB1*1501/DRA1*0101 (T-DRB1*1501), and ISL-negative DRB1*0301/DRA1*0101 (T-DRB1*0301), all containing identical class II-associated invariant chain peptide (CLIP) in the peptide-binding groove, were generated by the National Institutes of Health Tetramer Core Facility as previously described (Day et al. 2003. J Clin Invest 112:831-842.; herein incorporated by reference in its entirety. Unless stated otherwise, all chemicals were from Sigma-Aldrich (St. Louis, Mo.).
- Murine L cell transfectants expressing human HLA-DR ⁇ / ⁇ heterodimers (Olson et al. Hum Immunol 41:193-200.; herein incorporated by reference in its entirety) and human fibroblast line M1 (Holoshitz & Ling. 2007 Ann N Y Acad Sci 1110:73-83.; herein incorporated by reference in its entirety) were maintained as we previously described.
- mouse bone barrow cells were plated in culture flasks (2 ⁇ 106 cells/ml per T150, Costar, Corning, N.Y.) in RPMI 1640 medium containing 2 mM L-glutamine, 10% FBS, 1% Penicillin-Streptomycin, 10 mM HEPES buffer solution, 10 mM Sodium Pyruvate, 50 mM 2-mercaptoethanol, GM-CSF (10 ng/ml) and IL-4 (10 ng/ml). On day 3, half of the medium was removed and fresh medium containing GM-CSF (10 ng/ml) and IL-4 (10 ng/ml) were added.
- DCs were purified using positive selection columns with CD11c microbeads (Miltenyi Biotec Inc, CA, USA) as previously described (Grohmann et al. 1998 Immunity 9:315-323.; herein incorporated by reference in its entirety).
- CD11c microbeads Miltenyi Biotec Inc, CA, USA
- freshly isolated splenic DCs were subjected to positive selection with CD11c and CD8 ⁇ microbeads.
- CD4+ T cells were isolated from the spleen, using a negative selection immunomagnetic isolation kit (EasySep®, Stem Cell technology, Vancouver, Canada) according to the manufacturer's instructions.
- CD4+T cells were incubated with FITC anti-mouse CD4 and a mixture of PE-labeled anti-CD25, APC-labeled anti-CD62L and Pe-Cy 7 -labeled anti-CD44 antibodies (all from Biolegend, San Diego, Calif.).
- CD4+CD25 ⁇ CD62L+CD44 ⁇ na ⁇ ve T cells were sorted using a FACSDivaTM instrument (Becton Dickinson, Franklin Lakes, N.J.) with a purity >98%.
- Splenic cells from DBA/1 mice were isolated followed by purification of DC subtypes using positive selection columns with CD11c and CD8 ⁇ microbeads. Purified cells were stained for flow cytometry analysis using PE anti-mouse CD8 (clone 53-6.7, BD Pharmigen, San Jose, Calif.), FITC anti-rabbit CRT (ABR—Affinity Bioreagents, Rockford, Ill.) and isotype controls (Biolegend, San Diego, Calif.).
- DBA/1 bone marrow-derived CD11c+DCs were placed in 24-well plates (BD Biosciences, San Jose, Calif.) at a density of 2.5 ⁇ 105 cells per well and cultured overnight with or without 50 ⁇ g/ml of peptidic (65-79*0401 or 65-79*0402), or 2 ⁇ g/ml of tetrameric (T-DR1*0401, T-DR1*0301, or T-DR1*1501) ligands at 37° C.
- cells were harvested and stained for flow cytometric analysis using FITC anti-mouse CD4 (clone XMG1.2), PE anti-mouse CD25 (clone PC61) and isotype controls (Biolegend, San Diego, Calif.).
- FITC anti-mouse CD4 clone XMG1.2
- PE anti-mouse CD25 clone PC61
- isotype controls Biolegend, San Diego, Calif.
- cells were permeabilized and fixed using a Cytofix/Cytoperm kit (BD Biosciences, San Jose, Calif.) as recommended by the manufacturer.
- Bone marrow-derived CD11c+DCs (2.5 ⁇ 10 5 cells per well) were cultured overnight in 24-well plates with or without ISL ligands or controls as above. Then, 5 ⁇ 105 CD4+ T cells or CD4+CD25 ⁇ CD62L+CD44 ⁇ na ⁇ ve T cells were added at the ratio of 2:1 in the presence of Th17-polarazing cytokine/antibodies cocktail containing: anti-IL4 (2 ⁇ g/ml), anti-IFN ⁇ (2 ⁇ g/ml), anti-IL2 (3 ⁇ g/ml), rhTGFI3 (5 ng/ml), rmIL-6 (20 ng/ml), rmIL-23 (10 ng/ml), anti-CD3 (5 ⁇ g/ml) and anti-CD28 (1 ⁇ g/ml) as previously described (32).
- CFISL Cells were labeled with 1 ⁇ M of CFISL (Molecular ProbesTM, Invitrogen Corporation, Carlsbad, Calif.), stained with CD4-PercP, CD25-Pe, and Foxp3-APC or IL-17A-APC antibodies (Biolegend, San Diego, Calif.) and proliferation was determined by measuring the percentages of CFISL-labeled cycling CD4+ T, CD4+CD25+Foxp3+ Treg or CD4+IL17A+Th17 cells, using a FACS analysis.
- mice were injected subcutaneously in the footpad with 100 ⁇ g of chicken collagen type II (CII) (Chondrex, Inc, Redmond, Wash.) emulsified in CFA (4 mg/ml).
- the inoculums contained 10 ⁇ g of either ISL-positive 65-79*0401 or ISL-negative 65-79*0402 ligands in PBS, or an equal volum of PBS alone.
- Animals were sacrificed 7 days after immunization.
- inguinal and popliteal lymph nodes were collected and single cell suspensions were prepared. Unfractionated lymph node cells were cultured with PMA, Ionomycin and Brefeldin A for 6 hours as above.
- IL-17 production splenocytes from mice immunized as above were stimulated in vitro with 5 ⁇ g of CII259-273 peptide. At different time points thereafter, supernatants were collected and assayed for IL-17 by ELISA as above.
- the ISL Inhibits IDO Activity
- the ISL activates NO signaling in different cell lineages from several species (Holoshitz & Ling. 2007 Ann N Y Acad Sci 1110:73-83.; Ling et al. 2006 Arthritis Rheum 54:3423-3432.; Ling et al. 2007 Arthritis Res Ther 9:R5.; Ling et al. 2007 J Immunol 179:6359-6367.; herein incorporated by reference in their entireties).
- the ISL activated robust NO production in CD11c+DCs from several mouse strains in a strictly allele-specific manner. Thus, similar to its effect in many other cell lineages, the ISL activates NO signaling in mouse DCs as well.
- Transfectants expressing ISL-positive HLA-DR molecules on their surface produced significantly less kynurenine in response to IFN ⁇ , compared to transfectants expressing ISL-negative HLA-DR molecules (lines L-514.3 and L-259.3 expressing ISL-negative DR ⁇ 0402 or DR ⁇ 0403 molecules, respectively) (ISLE FIG. 6 ).
- IFN ⁇ -induced IDO activity in DBA/1 mice was observed in CD11c+CD8+ DCs, but not in CD11c+CD8 ⁇ DCs (ISLE FIG. 6C ), similar to published reports in other strains (Fallarino et al. 2002. Int Immunol 14:65-68.; herein incorporated by reference in its entirety).
- CD11c+CD8+ DCs were incubated for 24 hrs with or without LPS (1 ⁇ g/ml) and IFN ⁇ -induced IDO activity was determined.
- Activation of IDO in immature DCs was significantly more potent than in mature cells (ISLE FIG. 6D ).
- IDO activation in DBA/1 mice was inhibited by NO by demonstrating that IFN ⁇ -induced IDO activity in DBA/1 immature CD11c+CD8+ DCs is potently inhibited by the NO-donor SNAP (ISLE FIG. 6E ).
- DBA/1 immature CD11c+CD8+ DCs were pre-incubated with HBc particles engineered to express the HVR3 (residues 65-79) encoded by the ISL-positive allele DRB1*0401 (designated HBc*0401), or the HVR3 encoded by the ISL-negative allele DRB1*0402 (HBc*0402).
- ISL ligand inhibits IDO activity in CD11c+CD8+ DCs.
- DCs can affect immune responses by producing cytokines capable of activating or expanding particular subsets of T cells, thereby polarizing the immune response.
- cytokines capable of activating or expanding particular subsets of T cells, thereby polarizing the immune response.
- TGF ⁇ facilitates differentiation of Th17 cells, while IL-23 is involved in the expansion of this subset.
- the ISL ligand 65-79*0401 activated a robust production of IL-6 in CD11c+CD8 ⁇ DCs, but not in the CD11c+CD8+ subset (ISLE FIG. 7 ).
- IL-6 levels peaked at a relatively early time point (24 h) and later declined. This pattern is likely a result of short half life of the peptidic ligand due to rapid degradation in tissue culture conditions.
- the ISL-negative control 65-79*0402 did not trigger any cytokine production.
- Other cytokines IL-4, IL-10, IL-12 IL-1 ⁇ , TGF ⁇
- did not show any increased production, attesting to the specificity of the ISL effect (ISLE FIG. 7 ).
- the ISL inhibited IDO activity ISLE FIG. 6
- its IL-6 production effect was restricted to the CD8 ⁇ DCs subset (ISLE FIG. 7 ).
- CD11c+ CD8 ⁇ DCs ISL-activated IL-6 production was observed CD11c+ CD8 ⁇ DCs only when they were separated from the CD11c+CD8+ subset, but not when unfractionated CD11c+ DCs were assayed (ISLE FIG. 7 ).
- CD11c+CD8+ DCs are a small subset ( ⁇ 5-15% of splenic CD11c+ cells), once activated by the ISL, they could exert potent inhibitory effect on the activation of CD11c+CD8 ⁇ DCs, consistent with previously reported DCs suppressive effects (Ardavin et al.
- IL-23 levels in DCs did not increase following stimulation with the ISL ligand (ISLE FIG. 8 ).
- the ISL had a prolonged synergistic effect in CD11c+DCs.
- the ISL had no effect when applied alone, but in the presence of LPS it had a synergistic effect, which lasted for up to 72 hours after stimulation, long after LPS effect had subsided (ISLE FIG. 8 ).
- the effect was specific for IL-23, since no synergism was found in the production of another LPS-inducible cytokine, IL-6 (ISLE FIG. 8 , bottom).
- IDO inhibition and/or increased IL-6 levels inhibit Treg cells (Sharma et al. 2007 J Clin Invest 117:2570-2582.; Korn et al. 2007 Nature 448:484-487.; herein incorporated by reference in their entireties).
- DBA/1 CD11c+DCs were first incubated overnight with the ISL ligand 65-79*0401, or ISL-negative control 65-79*0402, or with medium.
- DCs were then co-cultured with purified syngeneic CD4+ T cells (ISLE FIG. 9A ) or CD4+CD25 ⁇ CD62L+CD44 ⁇ na ⁇ ve T cells (ISLE FIG. 9B ) in the presence of TGF- ⁇ (2.5 ng/ml) and anti-CD3 antibodies (5.0 ⁇ g/ml). After 5 days, CD4+CD25+Foxp3+ Treg abundance was determined by flow cytometry.
- the ISL ligand 65-79*0401 significantly inhibited Treg expansion and differentiation, respectively (ISLE FIG. 9 ).
- the inhibitory effect of 65-79*040 on Treg differentiation was statistically significant, yet modest.
- Treg differentiation experiments were performed using ISL-positive HLA-DR tetramer (designated T-DRB1*0401), or control, ISL-negative HLA-DR tetramers (T-DRB1*1501 or T-DRB1*0301) instead of soluble peptides.
- the HLA-DR molecule in tetramers is folded in its natural tri-dimensional conformation and therefore better preserves the physiologic function of the protein.
- the ISL-positive tetramer T-DRB1*0401 indeed had a specific and much more potent inhibitory effect on Treg differentiation (ISLE FIG. 9C ).
- the ISL ligand 65-79*0401 triggered a robust production of IL-6, an obligatory cytokine for Th17 differentiation.
- IL-23 production by LPS-treated DCs was also augmented by 65-79*0401.
- CD11c+DCs were stimulated overnight with either peptidic or tetrameric ligands.
- CD4+CD25 ⁇ CD62L+CD44 ⁇ na ⁇ ve T cells were added and cultured in the presence of a Th17-polarizing cocktail of cytokines and antibodies. After 6 days, cells were collected and analyzed by flow cytometry.
- the ISL ligand 65-79*0401 induced a significant increase in the differentiation of CD4+IL17A+ T cells (ISLE FIG. 10A ).
- a more robust ISL-induced Th17 polarization effect was observed when DCs were stimulated with ISL-positive HLA-DR tetramers (ISLE FIG. 10B ).
- ISL-activated DCs were incubated overnight with ISL ligands or control reagents. Cells were then co-cultured with total CD4+ T cells. ISL-activated DCs induced higher intracellular (ISLE FIG. 11A ) and extracellular (ISLE FIG. 11B ) IL-17 expression in co-cultured CD4+ T cells, compared to cells cultured with DCs pre-incubated with a control reagents or medium. The effect was seen both with a soluble ISL peptidic ligand, as well as with conformationally preserved ligand in the form of an HBc particle (ISLE FIG. 11B ).
- the ISL affects the proliferation of Th17 and Tregs in a reciprocal manner. Enhanced expansion through increased proliferative activity of Th17 cells and decreased proliferative activity of Tregs was observed in both TCR-independent and TCR-mediated T cell activation conditions.
- mice were immunized with chicken collagen type II (CII)+ M. tuberculosis H37Ra in the form of Complete Freund's Adjuvant (CFA) in the presence of ISL (peptide 65-79*0401), or a control peptide (65-79*0402).
- CFA Complete Freund's Adjuvant
- mice were injected intraperitoneally with 100 ⁇ g of ISL (peptide 65-79*0401), or control peptide (65-79*0402) in 50 ⁇ A of PBS.
- lymph-nodes were isolated, single-cell suspensions were made, and Th17 cells were quantified by flow cytometry (See FIG. 14A and discussion below).
- Lymph-node cells (1 ⁇ 10 6 cells/ml) were re-stimulated in vitro in 96 well plates with 100 ⁇ g/ml of denaturated CII, 10 ⁇ g/ml of Mycobacterium bovis purified protein derivative (PPD) of mycobacteria, or PBS (NIL).
- PPD Mycobacterium bovis purified protein derivative
- lymph node cells were re-stimulated for 6 days in the presence of a purified derivative protein (PPD) of M. tuberculosis , CII, or PBS.
- PPD purified derivative protein
- CII M. tuberculosis
- PBS purified derivative protein
- the invention provides that ISL facilitates antibacterial immune responses (e.g., polarization of bacterial antigen-specific Th17 cells).
- AGBU Alloc glycine building units
- Alloc allyloxycarbonyl
- BTC bis(trichloromethyl)carbonate
- CD Circular dichroism
- DCM dichloromethane
- DIPEA diisopropylethylamine
- Fmoc 9-fluorenylmethyloxycarbonyl
- HATU (2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
- HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate)
- HLA human leukocyte antigen
- MBHA methylbenzhydrylamine
- NMP 1-methyl-2-pyrrolidinone
- NO nitric oxide
- RA Rheumatoid arthritis
- RP-HPLC reverse phase high pressure liquid
- Preparative HPLC were recorded at 220 nm on a RP-18 column (10 ⁇ 250 ⁇ 10 mm, 110 ⁇ ), Eluents A (0.05% TFA in TDW) and B (0.05% TFA in ACN) were used in a linear gradient (95% A ⁇ 75% A in 30 min) at a flow of 5 ml/min.
- HATU coupling Fmoc protected amino acids (1.5 equiv) were dissolved in NMP, DIPEA (1.5 equiv) and HATU (1.5 equiv) were added and the mixture was preactivated by mixing for 1 min, added to the resin, and shaken for 2 h. The resin was washed with NMP (3 ⁇ 2 min). Alloc removal: The resin was washed with DCM (2 ⁇ 2 min) and dried under vacuum. A solution of PhSiH 3 (10 equiv) in DCM was added under a stream of argon and Pd(PPh 3 ) 4 (0) (0.5 equiv) was added.
- Nitric Oxide Assay Human fibroblast M1 cells were plated at a density of 1 ⁇ 10 5 cells per well in 96-well plates the day prior to the Nitric Oxide assay. To determine the rate of NO production in fibroblast, cells were first loaded with 20 ⁇ M of the fluorescent NO probe 4,5-diaminofluorescein diacetate (DAF-2DA), incubated in the dark at 37° C. for 1 hour and washed in 100 ⁇ L of DMEM/phenol red-free medium. The fluorescence level was recorded every 5 minutes over a period of 500 minutes, using a Fusion ⁇ HT system (PerkinElmer Life Sciences) at an excitation wavelength of 488 nm and emission wavelength of 515 nm. The NO production rate is expressedas the mean ⁇ SEM fluorescence units per minute.
- DAF-2DA fluorescent NO probe 4,5-diaminofluorescein diacetate
- Trypsin/chymotrypsin stability assay was conducted as previously described (See, e.g., Pakkala et al., Journal of Peptide Science 2007, 13, 348; Tal-Gan et al., Bioorganic & Medicinal Chemistry 2010, 18, 2976. 400 ⁇ L of each peptide (1 mM) dissolved in 200 mM NH 4 HCO 3 buffer solution (pH 8) were mixed with 1 ⁇ L of trypsin and chymotrypsin (porcine pancreas, Biological Industries Israel, Beit Haemek LTD) solution (2.5 mg/1 ml). The peptides were incubated at 37° C., 30 ⁇ L samples were taken every 30 min and mixed with 30 ⁇ L of 2% TFA and 30% ACN in water. Samples were analyzed by HPLC and by MALDI-TOF MS.
- Helix mimetic cyclic analogs usually have bridges at positions i, i+4 or i, i+7 (See, e.g., Moellering et al., Nature 2009, 462, 182; Walensky et al., Science 2004, 305, 1466).
- the consensus SE motif Gln-Lys-X-X-Ala (SEQ ID NO. 15) was incorporated into an i, i+4 backbone cyclic scaffold.
- a Trp residue was added to the amino terminus to aid in determining the concentrations of the cyclic analogs using UV spectroscopy (See, e.g., Gill and von Hippel, Anal Biochem 1989, 182, 319).
- the synthesis and general structure of the backbone cyclic peptides are described in FIG. 15 .
- the two linear 15-mer peptides had no defined structure and the CD spectra resembled a random coil (See FIG. 16 a ).
- CD spectra of the three cyclic analogs indicated a putative Type III ⁇ -turn conformation (See FIG. 16 b ; see also Crisma et al., Int J Pept Protein Res 1984, 23, 411; Johnson, Annu Rev Biophys Biophys Chem 1988, 17, 145).
- the cyclic, bioactive pharmacophors of the peptide acquire an active conformation (e.g., helix conformation) upon binding to their binding site.
- the cyclic (e.g., short) peptides display enhanced activity compared to the linear (e.g., longer) peptides due to a restricted conformation of the cyclic peptides (e.g., a more biologically active confirmation).
- the 15-mer peptides 65-79*0401 H-Lys-Asp-Leu-Leu-Glu-Gln-Lys-Arg-Ala-Ala-Val-Asp-Thr-Tyr-Cys-NH 2 ) (SEQ ID NO. 7) and 65-79*0402 (H-Lys-Asp-Ile-Leu-Glu-Asp-Glu-Arg-Ala-Ala-Val-Asp-Thr-Tyr-Cys-NH 2 ) (SEQ ID NO. 9) were used as positive and negative controls, respectively.
- FIGS. 17A and 17B show that cyclic analogs activated NO production significantly above the negative control levels. Furthermore, as shown in FIG. 17B , c(HS6-4) maintained elevated NO production levels at concentrations five times lower than the positive control. Both c(HS4-4) (SEQ ID NO: 2), and c(HS6-2) (SEQ ID NO. 3) were observed to be potent analogs.
- both of these cyclic peptides maintained high NO production levels even in concentrations 50,000 times lower than 65-79*0401, and activated NO production even in the low nM concentrations. Accordingly, in some embodiments, the invention provides that subtle changes in the conformation of bioactive SE pharmacophors alter the biological activity of the peptides.
- the invention provides a variety peptides encompassing a broad range of activity (e.g., biological activity (e.g., ability to activate shared epitope (SE) type signaling events).
- the invention provides cyclic peptides (e.g., selected from SEQ ID NOS. 1-6, 13 and 14) for use as agonists of SE triggered signaling (e.g., to induce nitric oxide (NO) production and/or NO signaling cascades (e.g., to induce an immune response)).
- the invention provides QKRAA (SEQ ID NO.:2) or QRRAA (SEQ ID NO.:3) as potent agonists of biological signalling cascades (e.g., to induce nitric oxide (NO) production and/or NO signaling cascades and/or to induce an immune response (e.g., increase T helper 17 (Th17) cell expansion, increase production of IL-17 and/or IL-6, or to inhibit T regulatory cell activity and/or expansion (e.g., to block or decrease T cell tolerance))).
- one or more peptides described herein are used as antagonists of SE triggered signaling.
- cyclic analog, c(HS4-4) was completely stable towards trypsin/chymotrypsin degradation even after 4 hours of incubation with the proteases whereas the linear analogs, 65-79*0401 and 65-79*0404 were degraded completely after 30 minutes (See FIG. 18 ).
- the specific cleavage sites were determined using MS analysis to extract further information about the degradation of the peptides.
- Several cleavage sites were identified from the analyzed fragments of the linear 15-mer peptides, 65-79*0401 and 65-79*0404, containing the SE motif (residues 70-74) (See Table 3). These cleavage sites were between Tyr78 and Cys79 (chymotrypsin), Arg72 and Ala73 (trypsin), and Arg71/Lys71 and Arg72 (trypsin). As two of the identified cleavage sites (after residue 71 and 72) are found within the SE segment and are conserved in the cyclic analog, the 15-mer peptides serve as good controls for comparison.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a divisional of co-pending U.S. patent application Ser. No. 13/331,354 filed Dec. 20, 2011, which is a continuation-in-part of U.S. patent application Ser. No. 13/162,382 filed Jun. 16, 2011, now abandoned, which claims priority to U.S. Provisional Patent Application Ser. No. 61/355,413 filed Jun. 16, 2010, each of which is hereby incorporated by reference in its entirety.
- This invention was made with government support under AI047331, AR055170 and AR056786 awarded by the National Institutes of Health. The government has certain rights in the invention.
- The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
- Recent evidence indicates that two newly identified subsets of T lymphocytes, regulatory T (Treg) cells and IL-17-producing T helper (Th17), are playing reciprocal roles in immune responses. Treg cells act as suppressors of the immune response against tumors and infectious pathogens (Wilczynski et al. Front Biosci. 2008 Jan. 1; 13:2275-89.; Rouse & Suvas. J. Immunol. 2004 Aug. 15; 173(4):2211-5.; herein incorporated by reference in their entireties). Among various molecular mechanisms involved in Treg expansion, is the
tolerogenic enzyme indoleamine - Attempts have been made in the past to inhibit Treg cells to improve immune response. Because Treg cells express high affinity IL-2 receptors (CD25), experiments using anti-CD25 antibodies, or IL-2 conjugated with toxins have been carried out in various experimental tumor models and in human trials with mixed results (Schabowsky et al. Curr Opin Investig Drugs. 2007 December; 8(12):1002-8.; herein incorporated by reference in its entirety). Similarly, depleting Treg cells by anti-CD25 antibodies failed to improve protective immunity against BCG in mice (Quinn et al. Eur J. Immunol. 2008 March; 38(3):695-705.; herein incorporated by reference in its entirety). Other immune stimulating approaches, using antibodies against CTLA-4 or GITR have been unsuccessful (Schabowsky et al. Curr Opin Investig Drugs. 2007 December; 8(12):1002-8.; herein incorporated by reference in its entirety). Thus, taken together, current strategies to inhibit Treg suffer from significant pitfalls.
- Immunotherapy is an appealing anti-cancer treatment strategy. However, despite the fact that tumor cells express many immunogenic antigens, the immune system often fails to recognize or respond to them. This occurs because cancer cells utilize mechanisms that render the immune system tolerant, thereby evading immune recognition and/or eradication (Zou. Nat. Rev Cancer. 2005 April; 5(4):263-74; herein incorporated by reference in its entirety). Similarly, many pathogens have evolved sophisticated strategies to manipulate and evade their host immune system (Rouse. J Immunol. 2004 Aug. 15; 173(4):2211-5; herein incorporated by reference in its entirety). Consequently, attempts to establish preventive or therapeutic immunity using conventional immunization protocols have often met with disappointing results (Orme. J Leukoc Biol. 2001 July; 70(1):1-10.; Guinn et al. Mol. Ther. 2007 June; 15(6):1065-71; herein incorporated by reference in their entireties).
- There have been no meaningful attempts to investigate the therapeutic utility of Th17 stimulation against tumors. In infectious diseases, on the other hand, there has been progress. The growing realization that the IL-23/Th17 axis is critical in both primary protective response and vaccination (Khader & Cooper. Cytokine 2008 February; 41(2):79-83.; herein incorporated by reference in its entirety), has prompted IL-23 gene transfer experiments in mice (Happel et al. Infect Immun. 2005 September; 73(9):5782-8.; Wozniak et al. Infect Immun. 2006 January; 74(1):557-65.; herein incorporated by reference in their entireties). The results have indeed confirmed that the IL-23 gene product can act as an adjuvant during BCG vaccination; however, while these findings are encouraging, the feasibility of mass administration of genes or their recombinant products is questionable, given the cost involved, the possibility of triggering neutralizing antibodies or allergic responses and lingering concerns about the safety of gene delivery.
- The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
- Accordingly, in some embodiments, the invention provides a composition (e.g., immunogenic composition) comprising one or more immunostimulatory ligands (ISLs) alone or in the context of another molecule (e.g., a peptide, protein, polysaccharide, oligosaccharide, carbohydrate, and/or carbohydrate-containing molecule). In preferred embodiments, an ISL comprises the motif Q/K-K/R-R-A-A (SEQ ID NO.: 1) (e.g., QKRAA (SEQ ID NO.:2), QRRAA (SEQ ID NO.:3), KKRAA (SEQ ID NO.:4) or KRRAA (SEQ ID NO.:5)) or Q/R-K/R-R-A-A (SEQ ID NO.:6) (e.g., RKRAA (SEQ ID NO.: 13) and RRRAA (SEQ ID NO.: 14)). The present invention is not limited by a particular formulation of a composition (e.g., immunogenic composition) comprising an ISL or by a specific type of ISL. In some embodiments, ISL and/or protein or peptide comprising an ISL is a soluble ISL and/or soluble protein or peptide comprising an ISL.
- In some embodiments, ISL and/or protein or peptide comprising an ISL is in the form of a human leukocyte antigen (HLA) tetramer. In some embodiments, ISL and/or protein or peptide comprising an ISL is in the form of a cell bound surface protein and/or peptide (e.g., a cell surface marker protein and/or peptide). In some embodiments, ISL and/or protein or peptide comprising an ISL is in the form of a cell surface antigen. In a preferred embodiment, the ISL is a recombinant peptide and/or protein. In a further preferred embodiment, the ISL is a cyclic peptide or protein comprising a sequence selected from SEQ ID NOS. 1-6, 13 and 14. The invention is not limited by the method or procedure utilized to generate a cyclic ISL peptide and/or protein. Indeed, a variety of methods may be utilized including, but not limited to, a urea backbone cyclic protocol (See, e.g., Hurevich et al., Journal of Peptide Science 2010, 16, 178), an amide backbone-to-side chain cyclic peptides synthesis scheme (e.g., using microwave heating synthesis (See, e.g., Hayouka et al. 2011)), other known cyclization methods (e.g., disclosed in Gilon et al. Biopolymers 1991, 31: 745-50), or a combination thereof.
- In some embodiments, the ISL is present in a biologically active protein or peptide (e.g., a protein or peptide displaying antigenic or immunogenic properties (e.g., capable of inducing an immune response in a subject administered the peptide)). The peptide or protein may have antigenic or immunogenic characteristics in the absence of the ISL, or, may have no antigenic or immunogenic properties in the absence of the ISL but when the ISL is introduced into the protein or peptide the protein or peptide displays antigenic or immunogenic properties. The invention is not limited by the type of peptide. Indeed, a peptide containing an ISL of the invention may be any peptide described herein. In some embodiments, the peptide or protein is derived from a tumor or cancer protein. In some embodiment, a peptide or protein (e.g., recombinantly produced peptide or protein) containing an ISL of the invention is generated using a backbone cyclization (BC) strategy and/or method (See, Example 5). Thus, in some embodiments, the cyclic peptide is a conformationally intact peptidomimetic ISL. The invention is not limited by the length of a peptide, protein, polysaccharide, oligosaccharide, carbohydrate, and/or carbohydrate-containing molecule sequence which harbours an ISL. In some embodiments, a recombinant peptide and/or protein is engineered to contain an ISL. The peptide or protein may be from any microbe such as a bacterium, virus, fungi, yeast or the like. In some embodiments, the protein or peptide is from Staphylococcus aureus; Staphylococcus epidermidis; Enterococcus faecalis; Mycobacterium tuberculsis; Streptococcus group B; Streptoccocus pneumoniae; Helicobacter pylori; Neisseria gonorrhea; Streptococcus group A; Borrelia burgdorferi; Coccidiodes immitis; Histoplasma sapsulatum; Neisseria meningitidis type B; Shigella flexneri; Escherichia coli; Haemophilus influenzae, bacteria of the strain or genus Klebsiella, Mycoplasma, E. coli, and/or Mycobacterium.
- In some embodiments, the invention provides a method of inducing an immune response (e.g., innate and/or acquired immune response) in a subject comprising: administering to the subject a composition comprising an ISL (e.g., linear or cyclic peptide/ISL). In some embodiments, the composition comprises a peptide, polypeptide, or protein comprising an immunostimulatory ligand. In some embodiments, the immune response comprises expansion of Th17 cells. In some embodiments, the Th17 cells are pathogen-specific. In some embodiments, the immune response comprises inhibition of T regulatory cell differentiation or activity. In some embodiments, the immune response comprises enhanced nitric oxide signalling and/or enhanced production of IL-6. In some embodiments, the immune response is cancer and/or tumor specific (e.g., specific for a cancer epitope or a tumor epitope). In some embodiments, the subject suffers from cancer, is suspected of having cancer, or is at risk of developing cancer. In some embodiments, the subject suffers from an infectious disease, is suspected of having an infectious disease, or is at risk of contracting an infectious disease.
- In other embodiments, an ISL of the invention comprising a linear or cyclic peptide and/or protein comprising a sequence selected from SEQ ID NOS. 1-6, 13 and 14 is used in the manufacture of a medicament (e.g., to act as an agonist or antagonist of share epitope-triggered signaling events (e.g., due to a particular conformation (e.g., α-helix conformation) of the peptide and/or protein) for the treatment and/or prevention of disease (e.g., autoimmune disease (e.g., rheumatoid arthritis)).
- In some embodiments, ISL is an effective adjuvant during vaccination and/or booster immunization against pathogens and/or tumors. In some embodiments, ISL shifts the immune balance from tolerance toward a Th17-polarized response. In some embodiments, ISL is provided as an immune adjuvant during anti-infection or anti-tumor chemotherapy. In some embodiments, ISL is administered to a subject to treat or prevent infection by bacteria, protozoa and/or viruses. In some embodiments, ISL is administered to a subject to treat or prevent infection by bacteria, protozoa and/or viruses capable of escaping immune eradication by Treg-mediated immune dysregulation. In some embodiments, the present invention provides a simultaneous effect on Treg and Th17. In some embodiments, ISL does not trigger neutralizing antibodies or allergic reactions.
- The invention also provides a method of inhibiting T cell tolerance in a subject comprising administering to the subject an effective dose of a composition comprising an isolated, recombinant immunostimulatory ligand (ISL), selected from the group consisting of SEQ ID NOS.: 1-6, 13 and 14 under conditions such that T cell tolerance is reduced in the subject. In some embodiments, the subject is selected from the group consisting of a subject suffering from cancer, suspected of having cancer, at risk of developing cancer, suffering from an infectious disease, suspected of having an infectious disease, or at risk of contracting an infectious disease.
- In some embodiments, the invention provides a method of treating cancer in a subject comprising administering to the subject a composition comprising an ISL (e.g., to induce an innate or acquired (e.g., cancer specific) immune response in the subject). In some embodiments, ISL is administered to a subject therapeutically to treat known cancer within a subject. In some embodiments, ISL is administered to a subject prophylactically to prevent cancer developing in a subject (e.g. a subject at risk for cancer). In some embodiments, the present invention finds use (e.g. therapeutically or prophylactically) with any type of cancer (e.g. bladder, melanoma, breast, non-Hodgkin lymphoma, colon, rectal, pancreatic, endometrial, prostate, kidney, skin (e.g. nonmelanoma), leukemia, thyroid, lung, etc.).
- In some embodiments, the present invention provides a method of treating and/or preventing infection within a subject. In some embodiments, a subject is known or suspected of having an infection (e.g. bacterial, viral, etc.). In some embodiments, a subject is thought to be at risk for developing an infection (e.g. bacterial, viral, eukaryotic, etc.). In some embodiments, ISL is administered to a subject to heighten immune response when a subject is expected to become at risk for infection (e.g. during chemotherapy, travel, when immunocompromised by another disease).
- In some embodiments, the present invention provides methods of administering ISL to a subject to treat or prevent a disease (e.g. cancer), infection, condition, etc. followed by testing the subject for the presence of the disease (e.g. cancer), infection, condition, etc. In some embodiments, the present invention provides methods of administering ISL to a subject to treat or prevent a disease (e.g. cancer), infection, condition, etc. followed by testing the subject for a change in the status of the disease (e.g. cancer), infection, condition, etc. In some embodiments, the present invention provides methods comprising testing a subject for the presence of a disease (e.g. cancer), infection, condition, etc. followed by administering ISL to a subject to treat or prevent the disease (e.g. cancer), infection, condition, etc. In some embodiments, the present invention provides a method comprising testing a subject for the presence of a disease (e.g. cancer), infection, condition, etc. followed by administering ISL to a subject to treat or prevent the disease (e.g. cancer), infection, condition, etc. followed by testing the subject for the presence of, or a change in the status of, the disease (e.g. cancer), infection, condition, etc.
- The specification may be better understood when read in conjunction with the accompanying drawings which are included by way of example and not by way of limitation.
-
FIG. 1 shows a plot demonstrating synergism between IPP and IFN-γ. Human fibroblasts were preincubated overnight with various doses of IPP, followed by 48 h stimulation with various doses of rhIFN-γ. IDO activity was determined by quantifying kynurenine production. -
FIG. 2 shows a plot demonstrating NO inhibits IFN-γ-inducedindoleamine 2,3-dioxygenase (IDO) activation. Human fibroblasts were preincubated overnight with or without 100 μM of the nitric oxide (NO) donor, S-nitroso-N-acetyl-1,1-penicillamine (SNAP), followed by stimulation with or without 1000 U/ml rhIFN-γ, and IDO activity was measured by quantifying kynurenine production. -
FIG. 3 shows that ISL activates nitric oxide (NO) signaling in dendritic cells (DCs). Bone marrow cells from Balb/c (A and B) or DBA/1 (C and D) mice were differentiated into DCs in culture with GM-CSF (10 μg/ml) and IL-4 (10 μg/ml). CD11c+ DCs were purified using magnetic beads with >95% purity. DCs were then incubated with SE-positive (65-79*0401 or 65-79*0404), or with SE-negative (65-79*0402 or 65-79*0403) 15mer peptides and NO production was measured as described below. The results are expressed as mean±SEM fluorescence units (FU), or FU per minute. *p<0.01 compared to all ligand controls. -
FIG. 4 shows Inhibition of IDO activity by ISL. (A) Human fibroblasts were incubated overnight with either medium, the NO donor, SNAP, or different 15mer peptides (100 U/ml). Cells were subsequently cultured for 48 h with or without rhIFNγ (1000 U/ml) and cellular IDO activity was determined. (B) Murine L cells expressing either ISL-positive (L-0401, L-0404) or ISL-negative (L-0402, L-0402) DRβ chains on their surface through cDNA transfection were incubated for 48 h with rmIFNγ (1000 U/ml) and cellular IDO activity was determined. (C) CD11+ CD8+ DC were purified from DBA/1 spleens and incubated for 24 h with LPS to induce maturation. Stimulation with IFNγ and IDO activity determination were as above. (D) Immature CD11+ CD8+ DC were purified from DBA/1 spleens and pre-incubated for 1 h with or without HBc particles engineered to express the 65-79 region of DRβ chains, encoded by either ISL-positive (HBc*0401) or ISL-negative (HBc*0402) DRB1 alleles. DCs were subsequently stimulated with IFNγ and IDO activity was determined. -
FIG. 5 shows ISL-stimulated cytokine production by DC. Splenic CD8+ and CD8− DC were isolated from DBA/1 mice as above and cultured in 96-well plates over time in the presence or absence of ISL-positive (65-79*0401) or ISL-negative (65-79*0402) peptides (50 μg/ml). At various time points thereafter, supernatants were collected and assayed for cytokine content, using the Luminex platform. -
FIG. 6 shows inhibition of IDO activity by the ISL. (A) Murine L cells expressing either ISL-positive (L-565.5, or L-300.8) or ISL-negative (L-514.3, or L-259.3) functional HLA-DR molecules on their surface through cDNA transfection were incubated for 48 hrs with rhIFNγ (1000 U/ml) and cellular IDO activity was determined. (B) M1 fibroblasts were incubated overnight with medium, NO donor SNAP, or 100 μg/ml of ISL ligands (65-79*0401, 65-79*0404), or with ISL-negative controls (65-79*0402, or 65-79*0403). Cells were cultured for 48 hrs with rhIFNγ and cellular IDO activity was determined. (C) The CD11c+CD8+ and CD11c+ CD8− DCs subsets were purified from DBA/1 spleens and their IDO activity in response to IFNγ was determined. (D) CD11c+CD8+ DCs were purified from DBA/1 spleens, maturated or not with LPS, and their IDO activity in response to IFNγ was determined. (E) DBA/1 splenic CD11c+CD8+ DCs were activated with or without IFNγ, in the presence of absence of the NO donor SNAP. IDO activity was determined at 48 h as above. (F) DBA/1 splenic CD11c+CD8+ DCs were pre-incubated for 1 hr with or without HBc particles engineered to express the 65-79 region of DRβ chains, encoded by either ISL-positive (HBc*0401) or ISL-negative (HBc*0402) HLA-DRB1 alleles. DCs were subsequently stimulated with IFNγ and IDO activity was determined as above. -
FIG. 7 shows The ISL activates IL-6 production in CD8-DCs. DBA/1 splenic unfractionated CD11c+ DCs (CD11c+), or their purified CD11c+CD8+ DCs (CD8+) or CD11c+CD8− DCs (CD8−) subsets were cultured with the ISL 65-79*0401 or ISL-negative control 65-79*0402 or medium. Supernatants were collected at different time points and assayed for cytokine content using a Luminex platform. -
FIG. 8 shows the ISL augments IL-23 production in LPS-stimulated CD11c+DCs. DBA/1 bone marrow-derived CD11c+DCs were cultured with or without 100 ng/ml LPS in the presence or absence of ISL-positive or ISL-negative 15mer peptides (50 μg/ml). Supernatants were collected at different time points and assayed for IL-23 and IL-6 content by ELISA. -
FIG. 9 shows ISL inhibits Treg generation. (A) DBA/1 bone marrow-derived CD11c+DCs were cultured overnight with 50 μg/ml SL ligand 65-79*0401 or ISL-negative control 65-79*0402, or medium. Syngeneic splenic CD4+ T cells were then added to the culture, and incubated with anti-CD3 and TGF-β for 5 days. On the left, flow cytometry dot plots showing percentages of CD25+Foxp3+ cells obtained from gated CD4+ T cells in each treatment. Each plot is representative of three experiments. On the right, bar graphs present results as mean percentage±SD of replicate samples. (B) Cultures were performed as in (A), with the exception that CD4+CD25−CD62L+CD44− naïve T cells, instead of CD4+ T cells were added to the CD11c+DCs. (C) DBA/1 bone marrow-derived CD11c+DCs were incubated overnight with 2 μg/ml tetramers (ISL-positive T-DRB1*0401, versus ISL-negative T-DRB1*0301, or T-DRB1*1501). Syngeneic CD4+CD25−CD62L+CD44− naïve T cells, anti-CD3 and TGF-β were then added to the culture and incubated for 5 days and analyzed as above. -
FIG. 10 shows ISL facilitates Th17 differentiation. DBA/1 bone marrow-derived CD11c+DCs were cultured overnight in the presence or absence of (A) ISL 65-79*0401 or ISL-negative control 65-79*0402, or (B) ISL-positive T-DRB1*0401 tetramers, versus ISL-negative T-DRB1*0301, or T-DRB1*1501 tetramers. Syngeneic splenic CD4+CD25−CD62L+CD44− naïve T cells plus a Th17-differentiation cytokine/antibody cocktail were then added to the culture and incubated for 6 days. Intracellular IL17A was determined by flow cytometry. On the left: a representative experiment, one of three repetitions, showing percentages of CD4+IL17A+ cells as dot plots. On the right: bar graphs show results presented as mean percentage±SD of replicate samples. -
FIG. 11 shows activation of IL-17 production in CD4+ T cells by ISL. (A) DBA/1 bone marrow-derived CD11c+ DCs were cultured overnight with different peptidic ligands as above. Syngeneic splenic CD4+ T cells plus a Th17-polarizing cocktail were added to the culture and incubated for 6 days. IL-17A-positive cells were quantified by flow cytometry. On the left: dot plots showing percentage of CD4+IL17A+ T cells. On the right: bar graphs (mean±SD) of replicate samples (B) To measure IL-17 secretion, DBA/1 bone marrow-derived CD11c+DCs were treated overnight with peptidic or particular ligands or medium and then co-cultured with CD4+ T cells as above. Supernatants were assayed for IL-17 content by ELISA. -
FIG. 12 shows ISL facilitates Th17 polarization in vivo. (A) DBA/1 mice were immunized with CII in CFA in the presence of PBS, 65-79*0401 or 65-79*0402. Onday 7, cells from draining lymph nodes were isolated, cultured for 6 hours with PMA, Ionomycin and Brefeldin A and then stained with anti-mouse CD4, IL17A and IFN-γ as above. On the left: Representative dot plots showing percentages of IL17A+ and IFN-γ+ cells obtained from gated CD4+ cells. On the right, bar graphs showing results as mean±SD of duplicate experiments. (B) DBA/1 and CII-TCR Tg mice were immunized as in (A). Onday 7, splenic cells were isolated and cultured with the synthetic peptide CII260-267 (5 μg/ml). Supernatants were collected every 24 hours and assayed for IL-17 levels by ELISA. -
FIG. 13 shows ISL function in autoimmunity; although the present invention is not limited to any particular mechanism of action and an understanding of the mechanism of action is not necessary to practice the present invention. -
FIG. 14 shows that ISL facilitates polarization of bacterial antigen-specific Th17 cells. -
FIG. 15 shows a synthesis scheme of c(HSn-4) compounds. Conditions: a) 20% piperidine, DMF; b) HBTU, DIPEA; c) HATU, DIPEA; d) Pd(PPh3)4 (0), PhSiH3; e) BTC, DIPEA; f) TFA, TIPS, TDW. -
FIG. 16 shows CD spectra of cyclic and 15-mer linear peptides. a) Random coil CD spectra were observed for the two linear 15-mer peptides. b) Type III β-turn CD spectra were observed for the three cyclic analogs. -
FIGS. 17A and 17B show dose-response experiments of NO production rate induced by cyclic analogs. Human M1 fibroblasts were incubated with different concentrations of the listed cyclic peptides, or with 50 μM of positive (65-79*0401) or negative (65−79*0402) control peptides. NO production rates were determined using thefluorescent probe 4,5-diaminofluorescein diacetate (DAF-2DA) (See Ling et al.,Arthritis Res Ther 2007, 9, R5; Ling et al., J. J Immunol 2007, 179, 6359; Ling et al., Arthritis Rheum 2006, 54, 3423). -
FIG. 18 shows a comparison of the degradation rates of c(HS4-4), 65-79*0401 and 65-79*0404 towards trypsin and chymotrypsin enzymatic cleavage. - To facilitate an understanding of the present invention, a number of terms and phrases are defined below:
- As used herein, the term “microorganism” refers to any species or type of microorganism, including but not limited to, bacteria, viruses, archaea, fungi, protozoans, mycoplasma, prions, and parasitic organisms. The term microorganism encompasses both those organisms that are in and of themselves pathogenic to another organism (e.g., animals, including humans, and plants) and those organisms that produce agents that are pathogenic to another organism, while the organism itself is not directly pathogenic or infective to the other organism.
- As used herein the term “pathogen,” and grammatical equivalents, refers to an organism (e.g., biological agent), including microorganisms, that causes a disease state (e.g., infection, pathologic condition, disease, etc.) in another organism (e.g., animals and plants) by directly infecting the other organism, or by producing agents that causes disease in another organism (e.g., bacteria that produce pathogenic toxins and the like). “Pathogens” include, but are not limited to, viruses, bacteria, archaea, fungi, protozoans, mycoplasma, prions, and parasitic organisms.
- The terms “bacteria” and “bacterium” refer to all prokaryotic organisms, including those within all of the phyla in the Kingdom Procaryotae. It is intended that the term encompass all microorganisms considered to be bacteria including Mycoplasma, Chlamydia, Actinomyces, Streptomyces, and Rickettsia. All forms of bacteria are included within this definition including cocci, bacilli, spirochetes, spheroplasts, protoplasts, etc.
- As used herein, the term “fungi” is used in reference to eukaryotic organisms such as molds and yeasts, including dimorphic fungi.
- As used herein the terms “disease” and “pathologic condition” are used interchangeably, unless indicated otherwise herein, to describe a deviation from the condition regarded as normal or average for members of a species or group (e.g., humans), and which is detrimental to an affected individual under conditions that are not inimical to the majority of individuals of that species or group. Such a deviation can manifest as a state, signs, and/or symptoms (e.g., diarrhea, nausea, fever, pain, blisters, boils, rash, immune suppression, inflammation, etc.) that are associated with any impairment of the normal state of a subject or of any of its organs or tissues that interrupts or modifies the performance of normal functions. A disease or pathological condition may be caused by or result from contact with a microorganism (e.g., a pathogen or other infective agent (e.g., a virus or bacteria)), may be responsive to environmental factors (e.g., malnutrition, industrial hazards, and/or climate), may be responsive to an inherent defect of the organism (e.g., genetic anomalies) or to combinations of these and other factors.
- The terms “host” or “subject,” as used herein, refer to an individual to be treated by (e.g., administered) the compositions and methods of the present invention. Subjects include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and most preferably includes humans. In the context of the invention, the term “subject” generally refers to an individual who will be administered or who has been administered one or more compositions of the present invention (e.g., a composition for inducing an immune response (e.g., comprising ISL).
- As used herein, the terms “a composition for inducing an immune response”, “immunogenic composition” and grammatical equivalents refer to a composition that, once administered to a subject (e.g., once, twice, three times or more (e.g., separated by weeks, months or years)), stimulates, generates and/or elicits an immune response in the subject (e.g., resulting in total or partial immunity to a microorganism (e.g., pathogen) capable of causing disease). In preferred embodiments of the invention, the composition comprises ISL (e.g., purified (e.g., synthetic, recombinant, or otherwise isolated)) or derivatives or analogues thereof (e.g., cyclic mimetic ISL fragments). In further preferred embodiments, the composition comprising ISL comprises one or more other compounds or agents including, but not limited to, therapeutic agents, physiologically tolerable liquids, gels, carriers, diluents, adjuvants, excipients, salicylates, steroids, immunosuppressants, immunostimulants, antibodies, cytokines, antibiotics, binders, fillers, preservatives, stabilizing agents, emulsifiers, and/or buffers. An immune response may be an innate (e.g., a non-specific) immune response or a learned (e.g., acquired (e.g., cellular or humoral) immune response (e.g. that decreases the infectivity, morbidity, or onset of mortality in a subject (e.g., caused by exposure to a pathogenic microorganism), that prevents infectivity, pathology, morbidity, or onset of mortality in a subject (e.g., caused by exposure to a pathogenic microorganism), or that decreases tolerance (e.g., to a tumor antigen) in a subject). Thus, in some preferred embodiments, an immunogenic composition comprising ISL is administered to a subject to induce an immune response (e.g., as a vaccine (e.g., to prevent or attenuate a disease (e.g., by providing to the subject total or partial immunity against the disease or the total or partial attenuation (e.g., suppression) of a sign, symptom or condition of the disease))).
- As used herein, the term “adjuvant” refers to any substance that can stimulate an immune response. Some adjuvants can cause activation of a cell of the immune system (e.g., an adjuvant can cause an immune cell to produce and secrete a cytokine).
- As used herein, the terms “an amount effective to induce an immune response” and “effective amount” (e.g., of a composition for inducing an immune response), refers to the dosage level required (e.g., when administered to a subject) to stimulate, generate and/or elicit an immune response in the subject. An effective amount can be administered in one or more administrations (e.g., via the same or different route), applications or dosages and is not intended to be limited to a particular formulation or administration route.
- As used herein, the term “under conditions such that said subject generates an immune response” refers to any condition that leads to a qualitative or quantitative induction, generation, and/or stimulation of an immune response (e.g., innate or acquired).
- A used herein, the term “immune response” refers to any detectable response by the immune system of a subject. For example, immune responses include, but are not limited to, an alteration (e.g., increase) in Toll receptor activation, lymphokine (e.g., cytokine (e.g., Th1, Th2 or Th17 type cytokines) or chemokine) expression and/or secretion, macrophage activation, dendritic cell activation, T cell (e.g., CD4+ or CD8+ T cell) activation, NK cell activation, and/or B cell activation (e.g., antibody generation and/or secretion). Additional examples of immune responses include binding of an immunogen (e.g., antigen (e.g., immunogenic polypeptide)) to an MHC molecule and induction of a cytotoxic T lymphocyte (“CTL”) response, induction of a B cell response (e.g., antibody production), and/or T-helper lymphocyte response, and/or a delayed type hypersensitivity (DTH) response (e.g., against the antigen from which an immunogenic polypeptide is derived), expansion (e.g., growth of a population of cells) of cells of the immune system (e.g., T cells, B cells (e.g., of any stage of development (e.g., plasma cells), and increased processing and presentation of antigen by antigen presenting cells. An immune response may be to immunogens that the subject's immune system recognizes as foreign (e.g., non-self antigens from microorganisms (e.g., pathogens), or self-antigens recognized as foreign). Thus, it is to be understood that, as used herein, “immune response” refers to any type of immune response, including, but not limited to, innate immune responses (e.g., activation of Toll receptor signaling cascade) cell-mediated immune responses (e.g., responses mediated by T cells (e.g., antigen-specific T cells) and non-specific cells of the immune system) and humoral immune responses (e.g., responses mediated by B cells (e.g., via generation and secretion of antibodies into the plasma, lymph, and/or tissue fluids). The term “immune response” is meant to encompass all aspects of the capability of a subject's immune system to respond to an antigen and/or immunogen (e.g., both the initial response to an immunogen (e.g., a pathogen) as well as acquired (e.g., memory) responses that are a result of an adaptive immune response).
- As used herein, the term “immunity” refers to protection from disease (e.g., preventing or attenuating (e.g., suppression of) a sign, symptom or condition of the disease) upon exposure to a microorganism (e.g., pathogen) capable of causing the disease. Immunity can be innate (e.g., non-adaptive (e.g., non-acquired) immune responses that exist in the absence of a previous exposure to an antigen) and/or acquired (e.g., immune responses that are mediated by B and T cells following a previous exposure to antigen (e.g., that exhibit increased specificity and reactivity to the antigen)).
- As used herein, the term “immunogen” refers to an agent (e.g., a microorganism (e.g., bacterium, virus or fungus) or portion thereof)) that is capable of eliciting an immune response in a subject. In preferred embodiments, immunogens elicit immunity against the immunogen (e.g., microorganism (e.g., pathogen) or portion thereof (e.g., an antigen)) when administered in combination with ISL of the present invention.
- As used herein, the term “pathogen product” refers to any component or product derived from a pathogen including, but not limited to, polypeptides, peptides, proteins, nucleic acids, membrane fractions, and polysaccharides. Pathogen product include recombinant and synthetic agents.
- As used herein, the term “enhanced immunity” refers to an increase in the level of adaptive and/or acquired immunity in a subject to a given immunogen and/or antigen (e.g., microorganism (e.g., pathogen)) following administration of a composition (e.g., composition for inducing an immune response of the present invention) relative to the level of adaptive and/or acquired immunity in a subject that has not been administered the composition (e.g., composition for inducing an immune response of the present invention).
- As used herein, the term “cytokine” refers to immune system proteins that are biological response modifiers. They coordinate antibody and T-cell immune system interactions, and amplify immune reactivity. Cytokines include monokines synthesised by macrophages and lymphokines produced by activated T lymphocytes and natural killer cells. Monokines include interleukin (IL)-1, tumor necrosis factor (TNF), α- and β-interferon (IFN), and colony-stimulating factors. Lymphokines include IL's, γ-IFN, granulocyte-macrophage colony-stimulating factor (GM-CSF), and lymphotoxin. Endothelial cells and fibroblasts and selected other cell types may also synthesise cytokines Examples of cytokines include IL-2, IL-4, IL-13, IL-17, GM-CSF, IFN-γ, Flt-31, SCF, TNF-α.
- As used herein, the terms “host,” “subject” and “patient” refer to any animal, including but not limited to, human and non-human animals (e.g. rodents, arthropods, insects (e.g., Diptera), fish (e.g., zebrafish), non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, ayes, etc.), that is studied, analyzed, tested, diagnosed or treated. As used herein, the terms “host,” “subject” and “patient” are used interchangeably.
- The term “isolated” when used in relation to a protein as in “isolated protein” refers to a protein or protein sequence (e.g., a polypeptide sequence) that is identified and separated from at least one contaminant protein with which it is ordinarily associated in its natural source. Isolated protein is present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated proteins and/or polypeptides are found in the state they exist in nature.
- The term “recombinant” when made in reference to a protein or a polypeptide refers to a protein molecule which is expressed using a recombinant nucleic acid molecule. A recombinant nucleic acid molecule refers to a nucleic acid molecule which is comprised of segments of nucleic acid joined together by means of molecular biological techniques.
- As used herein, the term “non-human animals” refers to all non-human animals including, but are not limited to, vertebrates such as rodents, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, ayes, etc.
- As used herein, the term “effective amount” refers to the amount of a composition (e.g., comprising ISL and/or peptide or protein comprising ISL) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “a therapeutically effective amount” of a composition comprising ISL and/or peptide or protein comprising ISL is herein defined as the dosage level/amount required to achieve a therapeutically beneficial result in a subject (e.g., that induces an immune response in the subject).
- As used herein, the terms “administration” and “administering” refer to the act of giving a drug, prodrug, or other agent, or therapeutic treatment (e.g., compositions of the present invention) to a subject (e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs). Exemplary routes of administration to the human body can be through the eyes (ophthalmic), mouth (oral), skin (transdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, rectal, by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.) and the like.
- As used herein, the term “autologous cells” refers to cells that are a subject's own cells.
- As used herein, the term “allogeneic cells” refers cells which are genetically different, but of the same species.
- The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative) medicine.
- Accordingly, the invention provides a composition (e.g., immunogenic composition) comprising one or more immunostimulatory ligands (herein referred to as “ISLs”) alone or in the context of another molecule (e.g., a peptide, protein, polysaccharide, oligosaccharide, carbohydrate, and/or carbohydrate-containing molecule). As used herein, the terms “immunostimulatory ligand,” “ISL,” “immunostimulatory ligands” or “ISLs”) refer to a peptide comprising an amino acid sequence comprising the motif Q/K-K/R-R-A-A (SEQ ID NO.: 1) (e.g., QKRAA (SEQ ID NO.:2), QRRAA (SEQ ID NO.:3), KKRAA (SEQ ID NO.:4) or KRRAA (SEQ ID NO.:5)) or Q/R-K/R-R-A-A (SEQ ID NO.:6) (e.g., RKRAA (SEQ ID NO.: 13) and RRRAA (SEQ ID NO.: 14)). The present invention is not limited by a particular formulation of a composition (e.g., immunogenic composition) comprising an ISL or by a specific type of ISL (See, e.g., Examples 1-5). In some embodiments, ISL and/or protein or peptide comprising an ISL is a soluble ISL and/or soluble protein or peptide comprising an ISL. In some embodiments, ISL and/or protein or peptide comprising an ISL is in the form of a human leukocyte antigen (HLA) tetramer. In some embodiments, ISL and/or protein or peptide comprising an ISL is in the form of a cell bound surface protein and/or peptide (e.g., a cell surface marker protein and/or peptide). In some embodiments, ISL and/or protein or peptide comprising an ISL is in the form of a cell surface antigen.
- In some embodiments, the ISL is present in a biologically active protein or peptide (e.g., a protein or peptide displaying antigenic or immunogenic properties (e.g., capable of inducing an immune response in a subject administered the peptide)). The peptide or protein may have antigenic or immunogenic characteristics in the absence of the ISL, or, may have no antigenic or immunogenic properties in the absence of the ISL but when the ISL is introduced into the protein or peptide the protein or peptide displays antigenic or immunogenic properties. The invention is not limited by the type of peptide. Indeed, a peptide containing an ISL of the invention may be any peptide described herein. In some embodiment, a peptide or protein (e.g., recombinantly produced peptide or protein) containing an ISL of the invention is generated using a backbone cyclization (BC) strategy (See, Example 5). The invention is not limited by the method or procedure utilized to generate a cyclic ISL peptide and/or protein. Indeed, a variety of methods may be utilized including, but not limited to, a urea backbone cyclic protocol (See, e.g., Hurevich et al., Journal of Peptide Science 2010, 16, 178), an amide backbone-to-side chain cyclic peptides synthesis scheme (e.g., using microwave heating synthesis (See, e.g., Hayouka et al. 2011)), peptide stapling methods (See, e.g., Walensky et al., Science 2004, 305, 1466; Stewart et al.,
Nature Chemical Biology 2010, 6, 595) other known methods (See, e.g., Gilon et al. Biopolymers 1991, 31: 745-50), or a combination thereof. In a preferred embodiment, the ISL is a recombinant peptide and/or protein. In a further preferred embodiment, the ISL is a cyclic peptide or protein comprising a sequence selected from SEQ ID NOS. 1-6, 13 and 14. - The invention provides multiple examples of cyclic peptides that are metabolically stable, selective (e.g., due to peptide conformation), and/or that are bioavailable. In some embodiments, the cyclic peptides are in fast equilibrium among many conformations in solution with no single restricted conformation. In a preferred embodiment, the invention provides cyclic peptides, that retain the biological activity of their parent linear peptides, that also possess desirable pharmacological properties (See, e.g., Example 5). For example, the invention provides cyclic peptides that activate nitric oxide (NO) production in the low nM range. Although an understanding of the mechanism is not needed to practice the invention, and the invention is not limited to any particular mechanism of action, in some embodiments, a biologically active cyclic peptide of the invention possesses a stable α-helix conformation that contains the SE consensus motif. As described herein, in some embodiments, the activity of the cyclic peptide can be modified (e.g., the ability of the peptide to induce NO production and/or signaling events can be altered) based upon the conformation of the peptide generated (e.g., based upon the ring size generated using a cyclization method described herein). For example, in some embodiments, the invention provides methods of generating and characterizing cyclic peptides encompassing all types of peptides including linear peptides as well as peptides that possess secondary, tertiary and/or quaternary structures (e.g., that possess α-helix conformation and/or β-turn conformations). In some embodiments, peptides and/or proteins of the invention are utilized as agonists (e.g., to induce NO production and/or signaling events (e.g., utilizing a peptide and/or protein of the invention that possesses a desired conformation (e.g., a secondary or higher structure conformation important for biologic activity (e.g. for dimerization or coupling to target protein). In other embodiments, peptides and/or proteins of the invention are utilized as antagonists (e.g., to block immune system activity (e.g. NO production and/or signaling events (e.g., utilizing a peptide and/or protein of the invention that possesses a desired conformation (e.g., a conformation that impedes the activity of normal biologic activity (e.g. that blocks dimerization or coupling to target protein(s))))).
- Thus, in some embodiments, the cyclic peptide is a conformationally intact peptidomimetic ISL. The invention is not limited by the length of a peptide, protein, polysaccharide, oligosaccharide, carbohydrate, and/or carbohydrate-containing molecule sequence which harbours an ISL. In some embodiments, a recombinant peptide and/or protein is engineered to contain an ISL. The peptide or protein may be from any microbe such as a bacteria, virus, fungi, yeast or the like. In some embodiments, the protein or peptide is from Staphylococcus aureus; Staphylococcus epidermidis; Enterococcus faecalis; Mycobacterium tuberculsis; Streptococcus group B; Streptoccocus pneumoniae; Helicobacter pylori; Neisseria gonorrhea; Streptococcus group A; Borrelia burgdorferi; Coccidiodes immitis; Histoplasma sapsulatum; Neisseria meningitidis type B; Shigella flexneri; Escherichia coli; Haemophilus influenzae, bacteria of the strain or genus Klebsiella, Mycoplasma, E. coli, and/or Mycobacterium.
- In a preferred embodiment, the protein or peptide containing an ISL is from a pathogen (e.g., bacteria or virus) to which a Th17 type immune response is beneficial in the clearance of the pathogen from a host. For example, in some embodiments the protein or peptide is from a bacteria of the strain or genus Klebsiella, Mycoplasma, E. coli, and/or Mycobacterium. In another preferred embodiment, the protein or peptide containing an ISL is a tumor antigen or a cancer antigen. The invention is not limited to any particular tumor or cancer antigen. Indeed, an ISL may be utilized with any tumor or cancer antigen known in the art (e.g., to make the tumor or cancer antigen antigenic and/or immunogenic (e.g., in order to overcome immune evasion characteristics of the tumor and/or cancer)). In some embodiments, an immunogenic composition of the invention comprises an ISL in the context of a recombinant or isolated protein or peptide which comprises an amino acid sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of a sequence found in its native state in a host organism (e.g., a cancer or tumor antigen and/or a protein or polypeptide of a microorganism). Peptides or proteins may be native or recombinant, full-length protein or optionally a mature protein in which any signal sequence has been removed. The protein may be isolated directly from a sample (e.g., a microorganism or tumor) or produced by recombinant DNA techniques. Immunogenic fragments of a protein or peptide containing an ISL may be incorporated into an immunogenic composition of the invention. The invention is not limited by the length of polypeptide or protein containing an ISL. For example, in some embodiments a protein or polypeptide containing ISL comprises at least 5 amino acids, 10 amino acids, preferably 20 amino acids, more preferably 30 amino acids, more preferably 40 amino acids or 50 amino acids, more preferably 100 or more amino acids, taken contiguously from the amino acid sequence of a protein. A protein or polypeptide containing ISL include proteins or polypeptides that when administered at an effective dose, (e.g., either alone or together with a pharmaceutically acceptable carrier and/or adjuvant), elicit a protective immune response against the host microorganism and/or tumor from which the protein and/or polypeptide is derived, and more preferably, such immune response is protective (e.g., prophylactically and/or therapeutically) against infection caused by the microorganism and/or disease caused by the tumor and/or cancer. In some embodiments, a protein or polypeptide containing ISL is immunologically reactive with antibodies generated against the microorganism and/or tumor or cancer or with antibodies generated by infection of a mammalian host with the microorganism. In some embodiments, a protein or polypeptide containing ISL contains one or more T cell epitopes.
- In an embodiment, immunogenic compositions of the invention may contain fusion proteins of a protein or polypeptide containing ISL proteins. Such fusion proteins may be made recombinantly and may comprise one portion of at least 2, 3, 4, 5, 6 or more proteins or polypeptides (e.g., from a microorganism and/or tumor/cancer). Alternatively, a fusion protein may comprise multiple portions of at least 2, 3, 4, or 5 proteins/peptides. These may combine different proteins or fragments thereof in the same protein. Alternatively, the invention also includes individual fusion proteins of proteins or fragments thereof, as a fusion protein with heterologous sequences such as a provider of T-cell epitopes or purification tags, for example: β-galactosidase, glutathione-S-transferase, green fluorescent proteins (GFP), epitope tags such as FLAG, myc tag, poly histidine, or viral surface proteins such as influenza virus haemagglutinin, or bacterial proteins such as tetanus toxoid, diphtheria toxoid, and/or CRM197.
- The invention is not limited by a particular formulation of a composition (e.g., immunogenic composition) comprising an ISL or by a specific type of ISL. In some embodiments, a protein or peptide comprises an amino acid sequence comprising the motif Q/K-K/R-R-A-A (SEQ ID NO.: 1). In some embodiments, an ISL comprises the sequence QKRAA (SEQ ID NO.:2). In some embodiments, an ISL comprises the sequence QRRAA (SEQ ID NO.:3). In some embodiments, an ISL comprises the sequence KKRAA (SEQ ID NO.:4). In some embodiments, an ISL comprises the sequence KRRAA (SEQ ID NO.:5). In some embodiments, an ISL comprises the sequence Q/R-K/R-R-A-A (SEQ ID NO.:6) (e.g., RKRAA (SEQ ID NO.: 13) and RRRAA (SEQ ID NO.: 14)). In some embodiments, a protein or peptide comprises a cyclic peptide (e.g., generated using a backbone cyclization (BC) strategy) comprising the sequence Q/K-K/R-R-A-A (SEQ ID NO.: 1) (e.g., QKRAA (SEQ ID NO.:2), QRRAA (SEQ ID NO.:3), KKRAA (SEQ ID NO.:4) or KRRAA (SEQ ID NO.:5)) or Q/R-K/R-R-A-A (SEQ ID NO.:6) (e.g., RKRAA (SEQ ID NO.: 13) and RRRAA (SEQ ID NO.: 14)).
- In some embodiments, the invention provides one or more ISLs and methods of inducing an immune response (e.g., innate and/or adaptive immune responses) in a subject therewith. In some embodiments, administration of a composition comprising ISL and/or a peptide or protein containing an ISL of the invention generates an innate immune response (e.g., activates Toll-like receptor signaling and/or activation of NF-kB) in a subject.
- Although an understanding of a mechanism of action is not necessary to practice the invention, and the invention is not limited to any particular mechanism of action, in some embodiments, compositions (e.g. comprising an ISL) inhibit
indoleamine - A preferred embodiment of the invention is a method of preventing or treating cancer and/or tumor growth or spread comprising the step of administering an immunogenic composition or vaccine of the invention to a patient in need thereof. In one embodiment, the patient is awaiting elective surgery. Another embodiment of the invention is a use of the immunogenic composition of the invention in the manufacture of a vaccine for treatment or prevention of cancer and/or tumor metastasis (e.g., post-surgical treatment).
- A composition (e.g., immunogenic composition) comprising one or more ISLs and/or a composition (e.g., immunogenic composition) comprising a protein or peptide comprising an ISL of the invention may comprise one or more different agents in addition to the one or more ISLs and/or protein or peptide comprising an ISL. These agents or cofactors include, but are not limited to, adjuvants, surfactants, additives, buffers, solubilizers, chelators, oils, salts, therapeutic agents, drugs, bioactive agents, antibacterials, and antimicrobial agents (e.g., antibiotics, antivirals, etc.). In some embodiments, a composition comprising one or more ISLs and/or protein or peptide comprising an ISL of the invention comprises an agent and/or co-factor that enhance the ability of the one or more ISLs and/or protein or peptide comprising an ISL to induce an immune response (e.g., an adjuvant). In some preferred embodiments, the presence of one or more co-factors or agents reduces the amount of ISL and/or protein or peptide comprising an ISL required for induction of an immune response (e.g., a protective immune respone (e.g., protective immunization)). In some embodiments, the presence of one or more co-factors or agents can be used to skew the immune response towards a cellular (e.g., T cell mediated) or humoral (e.g., antibody mediated) immune response. The present invention is not limited by the type of co-factor or agent used in a therapeutic agent of the present invention. In some embodiments, the co-factor or agent is a drug or therapeutic used for cancer treatment and/or therapy known in the art. In a preferred embodiment, a therapeutically effective amount of a composition comprising ISL and/or peptide or protein comprising an ISL is administered to a subject.
- Adjuvants are described in general in Vaccine Design—the Subunit and Adjuvant Approach, edited by Powell and Newman, Plenum Press, New York, 1995. The present invention is not limited by the type of adjuvant utilized (e.g., for use in a composition (e.g., pharmaceutical composition) comprising ISL and/or protein or peptide comprising an ISL). For example, in some embodiments, suitable adjuvants include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate. In some embodiments, an adjuvant may be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.
- In some embodiments, it is preferred that a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention comprises one or more adjuvants that induce a Th1-type response. However, in other embodiments, it will be preferred that a composition comprising a NE and immunogen of the present invention comprises one or more adjuvants that induce a Th2-type response. In another preferred embodiment, a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention comprises one or more adjuvants that induce a Th17-type response
- In general, an immune response is generated to an antigen through the interaction of the antigen with the cells of the immune system. Immune responses may be broadly categorized into two categories: humoral and cell mediated immune responses (e.g., traditionally characterized by antibody and cellular effector mechanisms of protection, respectively). These categories of response have been termed Th1-type responses (cell-mediated response), and Th2-type immune responses (humoral response).
- Stimulation of an immune response can result from a direct or indirect response of a cell or component of the immune system to an intervention (e.g., exposure to an immunogen). Immune responses can be measured in many ways including activation, proliferation or differentiation of cells of the immune system (e.g., B cells, T cells, dendritic cells, APCs, macrophages, NK cells, NKT cells etc.); up-regulated or down-regulated expression of markers and cytokines; stimulation of IgA, IgM, or IgG titer; splenomegaly (including increased spleen cellularity); hyperplasia and mixed cellular infiltrates in various organs. Other responses, cells, and components of the immune system that can be assessed with respect to immune stimulation are known in the art.
- Although an understanding of the mechanism is not necessary to practice the present invention and the present invention is not limited to any particular mechanism of action, in some embodiments, compositions and methods of the present invention induce expression and secretion of cytokines (e.g., by macrophages, dendritic cells and/or CD4+ T cells). Modulation of expression of a particular cytokine can occur locally or systemically. It is known that cytokine profiles can determine T cell regulatory and effector functions in immune responses. In some embodiments, Th1-type cytokines can be induced, and thus, the immunostimulatory compositions of the present invention can promote a Th1 type antigen-specific immune response including cytotoxic T-cells. However in other embodiments, Th2-type cytokines can be induced thereby promoting a Th2 type antigen-specific immune response. In a preferred embodiment, Th17-type cytokines are induced, and thus, the immunostimulatory compositions of the present invention promotes a Th17 type antigen-specific immune response including inhibition of T regulatory cell activity.
- Cytokines play a role in directing the T cell response. Helper (CD4+) T cells orchestrate the immune response of mammals through production of soluble factors that act on other immune system cells, including B and other T cells. Most mature CD4+T helper cells express one of two cytokine profiles: Th1 or Th2. Th1-type CD4+ T cells secrete IL-2, IL-3, IFN-γ, GM-CSF and high levels of TNF-α. Th2 cells express IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, GM-CSF and low levels of TNF-α. Th1 type cytokines promote both cell-mediated immunity, and humoral immunity that is characterized by immunoglobulin class switching to IgG2a in mice and IgG1 in humans. Th1 responses may also be associated with delayed-type hypersensitivity and autoimmune disease. Th2 type cytokines induce primarily humoral immunity and induce class switching to IgG1 and IgE. The antibody isotypes associated with Th1 responses generally have neutralizing and opsonizing capabilities whereas those associated with Th2 responses are associated more with allergic responses.
- Several factors have been shown to influence skewing of an immune response towards either a Th1 or Th2 type response. The best characterized regulators are cytokines IL-12 and IFN-γ are positive Th1 and negative Th2 regulators. IL-12 promotes IFN-γ production, and IFN-γ provides positive feedback for IL-12. IL-4 and IL-10 appear important for the establishment of the Th2 cytokine profile and to down-regulate Th1 cytokine production.
- Thus, in some preferred embodiments, the present invention provides a method of stimulating a Th1-type immune response in a subject comprising administering to a subject a composition comprising ISL and/or protein or peptide comprising an ISL. However, in other preferred embodiments, the present invention provides a method of stimulating a Th2-type immune response in a subject comprising administering to a subject a composition comprising a ISL and/or protein or peptide comprising an ISL. In further preferred embodiments, adjuvants can be used (e.g., can be co-administered with a composition of the present invention) to skew an immune response toward either a Th1 or Th2 type immune response. For example, adjuvants that induce Th2 or weak Th1 responses include, but are not limited to, alum, saponins, and SB-As4. Adjuvants that induce Th1 responses include but are not limited to MPL, MDP, ISCOMS, IL-12, IFN-γ, and SB-AS2.
- Several other types of Th1-type immunogens can be used (e.g., as an adjuvant) in compositions and methods of the present invention. These include, but are not limited to, the following. In some embodiments, monophosphoryl lipid A (e.g., in particular 3-de-O-acylated monophosphoryl lipid A (3D-MPL)), is used. 3D-MPL is a well known adjuvant manufactured by Ribi Immunochem, Montana. Chemically it is often supplied as a mixture of 3-de-O-acylated monophosphoryl lipid A with either 4, 5, or 6 acylated chains. In some embodiments, diphosphoryl lipid A, and 3-O-deacylated variants thereof are used. Each of these immunogens can be purified and prepared by methods described in GB 2122204B, hereby incorporated by reference in its entirety. Other purified and synthetic lipopolysaccharides have been described (See, e.g., U.S. Pat. No. 6,005,099 and
EP 0 729 473; Hilgers et al., 1986, Int. Arch. Allergy. Immunol., 79(4):392-6; Hilgers et al., 1987, Immunology, 60(1):141-6; andEP 0 549 074, each of which is hereby incorporated by reference in its entirety). In some embodiments, 3D-MPL is used in the form of a particulate formulation (e.g., having a small particle size less than 0.2 μm in diameter, described inEP 0 689 454, hereby incorporated by reference in its entirety). - In some embodiments, saponins are used as an immunogen (e.g., Th1-type adjuvant) in a composition of the present invention. Saponins are well known adjuvants (See, e.g., Lacaille-Dubois and Wagner (1996)
Phytomedicine vol 2 pp 363-386). Examples of saponins include Quil A (derived from the bark of the South American tree Quillaja Saponaria Molina), and fractions thereof (See, e.g., U.S. Pat. No. 5,057,540; Kensil, Crit. Rev Ther Drug Carrier Syst, 1996, 12 (1-2):1-55; andEP 0 362 279, each of which is hereby incorporated by reference in its entirety). Also contemplated to be useful in the present invention are the haemolytic saponins QS7,QS 17, and QS21 (HPLC purified fractions of Quil A; See, e.g., Kensil et al. (1991). J. Immunology 146, 431-437, U.S. Pat. No. 5,057,540; WO 96/33739; WO 96/11711 andEP 0 362 279, each of which is hereby incorporated by reference in its entirety). Also contemplated to be useful are combinations of QS21 and polysorbate or cyclodextrin (See, e.g., WO 99/10008, hereby incorporated by reference in its entirety. - In some embodiments, an immunogenic oligonucleotide containing unmethylated CpG dinucleotides (“CpG”) is used as an adjuvant in the present invention. CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. CpG is known in the art as being an adjuvant when administered by both systemic and mucosal routes (See, e.g., WO 96/02555, EP 468520, Davis et al., J. Immunol, 1998, 160(2):870-876; McCluskie and Davis, J. Immunol., 1998, 161(9):4463-6; and U.S. Pat. App. No. 20050238660, each of which is hereby incorporated by reference in its entirety). For example, in some embodiments, the immunostimulatory sequence is Purine-Purine-C-G-pyrimidine-pyrimidine; wherein the CG motif is not methylated.
- Although an understanding of the mechanism is not necessary to practice the present invention and the present invention is not limited to any particular mechanism of action, in some embodiments, the presence of one or more CpG oligonucleotides activate various immune subsets including natural killer cells (which produce IFN-γ) and macrophages. In some embodiments, CpG oligonucleotides are formulated into a composition of the present invention for inducing an immune response. In some embodiments, a free solution of CpG is co-administered together with an antigen (e.g., present within a NE solution (See, e.g., WO 96/02555; hereby incorporated by reference). In some embodiments, a CpG oligonucleotide is covalently conjugated to an antigen (See, e.g., WO 98/16247, hereby incorporated by reference), or formulated with a carrier such as aluminium hydroxide (See, e.g., Brazolot-Millan et al., Proc. Natl. Acad Sci., USA, 1998, 95(26), 15553-8 (e.g., ISL and/or protein or peptide comprising an ISL).
- In some embodiments, adjuvants such as Complete Freunds Adjuvant and Incomplete Freunds Adjuvant, cytokines (e.g., interleukins (e.g., IL-2, IFN-γ, IL-4, IL-6, IL-17, IL-23, etc.), macrophage colony stimulating factor, tumor necrosis factor, etc.), detoxified mutants of a bacterial ADP-ribosylating toxin such as a cholera toxin (CT), a pertussis toxin (PT), or an E. Coli heat-labile toxin (LT), particularly LT-K63 (where lysine is substituted for the wild-type amino acid at position 63) LT-R72 (where arginine is substituted for the wild-type amino acid at position 72), CT-S 109 (where serine is substituted for the wild-type amino acid at position 109), and PT-K9/G129 (where lysine is substituted for the wild-type amino acid at position 9 and glycine substituted at position 129) (See, e.g., WO93/13202 and WO92/19265, each of which is hereby incorporated by reference), and other immunogenic substances (e.g., that enhance the effectiveness of a composition of the present invention) are used with a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention.
- Additional examples of adjuvants that find use in the present invention include poly(di(carboxylatophenoxy)phosphazene (PCPP polymer; Virus Research Institute, USA); derivatives of lipopolysaccharides such as monophosphoryl lipid A (MPL; Ribi ImmunoChem Research, Inc., Hamilton, Mont.), muramyl dipeptide (MDP; Ribi) and threonyl-muramyl dipeptide (t-MDP; Ribi); OM-174 (a glucosamine disaccharide related to lipid A; OM Pharma SA, Meyrin, Switzerland); and Leishmania elongation factor (a purified Leishmania protein; Corixa Corporation, Seattle, Wash.).
- Adjuvants may be added to a composition comprising ISL and/or protein or peptide comprising an ISL, or, the adjuvant may be formulated with carriers, for example liposomes, or metallic salts (e.g., aluminium salts (e.g., aluminium hydroxide)) prior to combining with or co-administration with a composition comprising ISL and/or protein or peptide comprising an ISL.
- In some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL comprises a single adjuvant. In other embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL comprises two or more adjuvants (See, e.g., WO 94/00153; WO 95/17210; WO 96/33739; WO 98/56414; WO 99/12565; WO 99/11241; and WO 94/00153, each of which is hereby incorporated by reference in its entirety). In some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention comprises one or more mucoadhesives (See, e.g., U.S. Pat. App. No. 20050281843, hereby incorporated by reference in its entirety). The present invention is not limited by the type of mucoadhesive utilized. Indeed, a variety of mucoadhesives are contemplated to be useful in the present invention including, but not limited to, cross-linked derivatives of poly(acrylic acid) (e.g., carbopol and polycarbophil), polyvinyl alcohol, polyvinyl pyrollidone, polysaccharides (e.g., alginate and chitosan), hydroxypropyl methylcellulose, lectins, fimbrial proteins, and carboxymethylcellulose. Although an understanding of the mechanism is not necessary to practice the present invention and the present invention is not limited to any particular mechanism of action, in some embodiments, use of a mucoadhesive (e.g., in a composition comprising ISL and/or protein or peptide comprising an ISL) enhances induction of an immune response in a subject (e.g., administered a composition of the present invention) due to an increase in duration and/or amount of exposure to an immunogen that a subject experiences when a mucoadhesive is used compared to the duration and/or amount of exposure to an immunogen in the absence of using the mucoadhesive.
- In some embodiments, a composition of the present invention may comprise sterile aqueous preparations. Acceptable vehicles and solvents include, but are not limited to, water, Ringer's solution, phosphate buffered saline and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed mineral or non-mineral oil may be employed including synthetic mono-ordi-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Carrier formulations suitable for mucosal, subcutaneous, intramuscular, intraperitoneal, intravenous, or administration via other routes may be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa.
- The invention provides compositions comprising ISL and/or protein or peptide comprising an ISL that possess a range of biologic activity (e.g., based upon the structure of the peptide and/or protein (e.g., linear, possessing secondary, tertiary and/or quaternary structure (e.g., α-helix and/or β-turn conformation that mimics a parent molecule or that blocks activity of a parent molecule))), as well as methods of generating and characterizing the same. Accordingly, in some embodiments, compositions and methods of the invention are utilized for the treatment and/or prevention of disease. The invention is not limited by the type of disease that may be treated and/or prevented utilizing a composition or method disclosed herein. In a preferred embodiment, the disease is an autoimmune disease. The invention is not limited by the type of autoimmune disease. Indeed, compositions and methods of the invention find use in a variety of autoimmune diseases including, but not limited to, rheumatoid arthritis, systemic lupus erythematosus (SLE), Cogan's syndrome, unclassified systemic autoimmune disease, Raynaud's syndrome, Wegener's granulomatosis, autoimmune uveoretinitis, autoimmune vasculitis, bullous pemphigus, myasthenia gravis, autoimmune thyroiditis or Hashimoto's disease, Sjogren's syndrome, granulomatous orchitis, autoimmune oophoritis, Crohn's disease, sarcoidosis, rheumatic carditis, ankylosing spondylitis, Grave's disease, or autoimmune thrombocytopenic purpura.
- A composition comprising ISL and/or protein or peptide comprising an ISL (e.g., a cyclic peptide and/or protein generated using an ISL (e.g., cyclic or linear) of the invention) can be used therapeutically (e.g., to enhance an immune response (e.g., against a pathogen and/or a tumor or cancer) or to inhibit an immune response (e.g., using a non-biologically active peptide mimetic) or as a prophylactic (e.g., for immunization (e.g., to prevent signs or symptoms of disease)). A composition comprising ISL and/or protein or peptide comprising an ISL of the present invention can be administered to a subject via a number of different delivery routes and methods.
- In some embodiments, compositions of the present invention are administered mucosally (e.g., using standard techniques; See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Company, Easton, Pa., 19th edition, 1995 (e.g., for mucosal delivery techniques, including intranasal, pulmonary, vaginal and rectal techniques), as well as European Publication No. 517,565 and Illum et al., J. Controlled Rel., 1994, 29:133-141 (e.g., for techniques of intranasal administration), each of which is hereby incorporated by reference in its entirety). Alternatively, the compositions of the present invention may be administered dermally or transdermally, using standard techniques (See, e.g., Remington: The Science arid Practice of Pharmacy, Mack Publishing Company, Easton, Pa., 19th edition, 1995). The present invention is not limited by the route of administration.
- For example, the compositions of the present invention can be administered to a subject (e.g., mucosally (e.g., nasal mucosa, vaginal mucosa, etc.)) by multiple methods, including, but not limited to: being suspended in a solution and applied to a surface; being suspended in a solution and sprayed onto a surface using a spray applicator; being mixed with a mucoadhesive and applied (e.g., sprayed or wiped) onto a surface (e.g., mucosal surface); being placed on or impregnated onto a nasal and/or vaginal applicator and applied; being applied by a controlled-release mechanism; being applied as a liposome; or being applied on a polymer.
- In some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention may be used to protect or treat a subject susceptible to, or suffering from, disease by means of administering a composition of the present invention via a mucosal route (e.g., an oral/alimentary or nasal route). Alternative mucosal routes include intravaginal and intra-rectal routes. Methods of intranasal vaccination are well known in the art, including the administration of a droplet or spray form of the vaccine into the nasopharynx of a subject to be immunized. In some embodiments, a nebulized or aerosolized composition comprising ISL and/or protein or peptide comprising an ISL is provided. Enteric formulations such as gastro resistant capsules for oral administration, suppositories for rectal or vaginal administration also form part of this invention. Compositions of the present invention may also be administered via the oral route. Under these circumstances, a composition comprising ISL and/or protein or peptide comprising an ISL may comprise a pharmaceutically acceptable excipient and/or include alkaline buffers, or enteric capsules. Formulations for nasal delivery may include those with dextran or cyclodextran and saponin as an adjuvant.
- Compositions of the present invention may also be administered via a vaginal route. In such cases, a composition comprising ISL and/or protein or peptide comprising an ISL may comprise pharmaceutically acceptable excipients and/or emulsifiers, polymers (e.g., CARBOPOL), and other known stabilizers of vaginal creams and suppositories. In some embodiments, compositions of the present invention are administered via a rectal route. In such cases, a composition comprising ISL and/or protein or peptide comprising an ISL may comprise excipients and/or waxes and polymers known in the art for forming rectal suppositories.
- In some embodiments, the same route of administration (e.g., mucosal administration) is chosen for both a priming and boosting vaccination. In some embodiments, multiple routes of administration are utilized (e.g., at the same time, or, alternatively, sequentially) in order to stimulate an immune response (e.g., using a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention).
- For example, in some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL is administered to a mucosal surface of a subject in either a priming or boosting vaccination regime. Alternatively, in some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL is administered systemically in either a priming or boosting vaccination regime. In some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL is administered to a subject in a priming vaccination regimen via mucosal administration and a boosting regimen via systemic administration. In some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL is administered to a subject in a priming vaccination regimen via systemic administration and a boosting regimen via mucosal administration. Examples of systemic routes of administration include, but are not limited to, a parenteral, intramuscular, intradermal, transdermal, subcutaneous, intraperitoneal or intravenous administration. A composition comprising ISL and/or protein or peptide comprising an ISL may be used for both prophylactic and therapeutic purposes.
- In some embodiments, compositions of the present invention are administered by pulmonary delivery. For example, a composition of the present invention can be delivered to the lungs of a subject (e.g., a human) via inhalation (e.g., thereby traversing across the lung epithelial lining to the blood stream (See, e.g., Adjei, et al. Pharmaceutical Research 1990; 7:565-569; Adjei, et al. Int. J. Pharmaceutics 1990; 63:135-144; Braquet, et al. J. Cardiovascular Pharmacology 1989 143-146; Hubbard, et al. (1989) Annals of Internal Medicine, Vol. III, pp. 206-212; Smith, et al. J. Clin. Invest. 1989; 84:1145-1146; Oswein, et al. “Aerosolization of Proteins”, 1990; Proceedings of Symposium on Respiratory Drug Delivery II Keystone, Colorado; Debs, et al. J. Immunol. 1988; 140:3482-3488; and U.S. Pat. No. 5,284,656 to Platz, et al, each of which are hereby incorporated by reference in its entirety). A method and composition for pulmonary delivery of drugs for systemic effect is described in U.S. Pat. No. 5,451,569 to Wong, et al., hereby incorporated by reference; See also U.S. Pat. No. 6,651,655 to Licalsi et al., hereby incorporated by reference in its entirety.
- Further contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary and/or nasal mucosal delivery of pharmaceutical agents including, but not limited to, nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art. Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer (Mallinckrodt Inc., St. Louis, Mo.); the Acorn II nebulizer (Marquest Medical Products, Englewood, Colo.); the Ventolin metered dose inhaler (Glaxo Inc., Research Triangle Park, N.C.); and the Spinhaler powder inhaler (Fisons Corp., Bedford, Mass.). All such devices require the use of formulations suitable for dispensing of the therapeutic agent. Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvants, surfactants, carriers and/or other agents useful in therapy. Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.
- Thus, in some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention may be used to protect and/or treat a subject susceptible to, or suffering from, a disease by means of administering a compositions comprising ISL and/or protein or peptide comprising an ISL by mucosal, intramuscular, intraperitoneal, intradermal, transdermal, pulmonary, intravenous, subcutaneous or other route of administration described herein. Methods of systemic administration of an immunogenic composition comprising ISL and/or protein or peptide comprising an ISL may include conventional syringes and needles, or devices designed for ballistic delivery of solid vaccines (See, e.g., WO 99/27961, hereby incorporated by reference), or needleless pressure liquid jet device (See, e.g., U.S. Pat. No. 4,596,556; U.S. Pat. No. 5,993,412, each of which are hereby incorporated by reference), or transdermal patches (See, e.g., WO 97/48440; WO 98/28037, each of which are hereby incorporated by reference). The present invention may also be used to enhance the immunogenicity of antigens applied to the skin (transdermal or transcutaneous delivery, See, e.g., WO 98/20734; WO 98/28037, each of which are hereby incorporated by reference). Thus, in some embodiments, the present invention provides a delivery device for systemic administration, pre-filled with an immunogenic composition of the present invention.
- The present invention is not limited by the type of subject administered (e.g., in order to stimulate an immune response (e.g., in order to generate protective immunity (e.g., mucosal and/or systemic immunity))) a composition of the present invention. Indeed, a wide variety of subjects are contemplated to be benefited from administration of a composition of the present invention. In preferred embodiments, the subject is a human. In another preferred embodiment, the subject is a subject displaying signs, symptoms or other characteristics of cancer (e.g., a subject diagnosed as having cancer). In some embodiments, human subjects are of any age (e.g., adults, children, infants, etc.) that have been or are likely to become exposed to a microorganism. In some embodiments, the general public is administered (e.g., vaccinated with) a composition of the present invention (e.g., to prevent the occurrence or spread of disease). For example, in some embodiments, compositions and methods of the present invention are utilized to vaccinate a group of people (e.g., a population of a region, city, state and/or country) for their own health (e.g., to prevent or treat disease) and/or to prevent or reduce the risk of disease spread from animals (e.g., birds, cattle, sheep, pigs, etc.) to humans. In some embodiments, the subjects are non-human mammals (e.g., pigs, cattle, goats, horses, sheep, or other livestock; or mice, rats, rabbits or other animal). In some embodiments, compositions and methods of the present invention are utilized in research settings (e.g., with research animals).
- A composition of the present invention may be formulated for administration by any route, such as mucosal, oral, topical, parenteral or other route described herein. The compositions may be in any one or more different forms including, but not limited to, tablets, capsules, powders, granules, lozenges, foams, creams or liquid preparations.
- Topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, foams, and aerosols, and may contain appropriate conventional additives such as preservatives, solvents (e.g., to assist penetration), and emollients in ointments and creams.
- Topical formulations may also include agents that enhance penetration of the active ingredients through the skin. Exemplary agents include a binary combination of N-(hydroxyethyl) pyrrolidone and a cell-envelope disordering compound, a sugar ester in combination with a sulfoxide or phosphine oxide, and sucrose monooleate, decyl methyl sulfoxide, and alcohol.
- Other exemplary materials that increase skin penetration include surfactants or wetting agents including, but not limited to, polyoxyethylene sorbitan mono-oleoate (Polysorbate 80); sorbitan mono-oleate (Span 80); p-isooctyl polyoxyethylene-phenol polymer (Triton WR-1330); polyoxyethylene sorbitan tri-oleate (Tween 85); dioctyl sodium sulfosuccinate; and sodium sarcosinate (Sarcosyl NL-97); and other pharmaceutically acceptable surfactants.
- In certain embodiments of the invention, compositions may further comprise one or more alcohols, zinc-containing compounds, emollients, humectants, thickening and/or gelling agents, neutralizing agents, and surfactants. Water used in the formulations is preferably deionized water having a neutral pH. Additional additives in the topical formulations include, but are not limited to, silicone fluids, dyes, fragrances, pH adjusters, and vitamins.
- Topical formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. The ointment base can comprise one or more of petrolatum, mineral oil, ceresin, lanolin alcohol, panthenol, glycerin, bisabolol, cocoa butter and the like.
- In some embodiments, pharmaceutical compositions of the present invention may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product.
- The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, preferably do not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents (e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like) that do not deleteriously interact with the ISL and/or protein or peptide comprising an ISL of the formulation. In some embodiments, immunostimulatory compositions of the present invention are administered in the form of a pharmaceutically acceptable salt. When used the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.
- Suitable buffering agents include, but are not limited to, acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives may include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v). Vaccine preparation is generally described in Vaccine Design (“The subunit and adjuvant approach” (eds Powell M. F. & Newman M. J.) (1995) Plenum Press New York). Encapsulation within liposomes is described by Fullerton, U.S. Pat. No. 4,235,877.
- In some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL is co-administered with one or more antibiotics. For example, one or more antibiotics may be administered with, before and/or after administration of a composition comprising ISL and/or protein or peptide comprising an ISL. The present invention is not limited by the type of antibiotic co-administered. Indeed, a variety of antibiotics may be co-administered including, but not limited to, β-lactam antibiotics, penicillins (such as natural penicillins, aminopenicillins, penicillinase-resistant penicillins, carboxy penicillins, ureido penicillins), cephalosporins (first generation, second generation, and third generation cephalosporins), and other β-lactams (such as imipenem, monobactams,), β-lactamase inhibitors, vancomycin, aminoglycosides and spectinomycin, tetracyclines, chloramphenicol, erythromycin, lincomycin, clindamycin, rifampin, metronidazole, polymyxins, doxycycline, quinolones (e.g., ciprofloxacin), sulfonamides, trimethoprim, and quinolines.
- A wide variety of antimicrobial agents are currently available for use in treating bacterial, fungal and viral infections. For a comprehensive treatise on the general classes of such drugs and their mechanisms of action, the skilled artisan is referred to Goodman & Gilman's “The Pharmacological Basis of Therapeutics” Eds. Hardman et al., 9th Edition, Pub. McGraw Hill,
chapters 43 through 50, 1996, (herein incorporated by reference in its entirety). Generally, these agents include agents that inhibit cell wall synthesis (e.g., penicillins, cephalosporins, cycloserine, vancomycin, bacitracin); and the imidazole antifungal agents (e.g., miconazole, ketoconazole and clotrimazole); agents that act directly to disrupt the cell membrane of the microorganism (e.g., detergents such as polmyxin and colistimethate and the antifungals nystatin and amphotericin B); agents that affect the ribosomal subunits to inhibit protein synthesis (e.g., chloramphenicol, the tetracyclines, erthromycin and clindamycin); agents that alter protein synthesis and lead to cell death (e.g., aminoglycosides); agents that affect nucleic acid metabolism (e.g., the rifamycins and the quinolones); the antimetabolites (e.g., trimethoprim and sulfonamides); and the nucleic acid analogues such as zidovudine, gangcyclovir, vidarabine, and acyclovir which act to inhibit viral enzymes essential for DNA synthesis. Various combinations of antimicrobials may be employed. - The present invention also includes methods involving co-administration of a composition comprising ISL and/or protein or peptide comprising an ISL with one or more additional active and/or immunostimulatory agents (e.g., a composition comprising ISL and/or protein or peptide comprising an ISL, an antibiotic, anti-oxidant, etc.). Indeed, it is a further aspect of this invention to provide methods for enhancing conventional immunostimulatory methods (e.g., immunization methods) and/or pharmaceutical compositions by co-administering a composition of the present invention. In co-administration procedures, the agents may be administered concurrently or sequentially. In one embodiment, the compositions described herein are administered prior to the other active agent(s). The pharmaceutical formulations and modes of administration may be any of those described herein. In addition, the two or more co-administered agents may each be administered using different modes (e.g., routes) or different formulations. The additional agents to be co-administered (e.g., antibiotics, adjuvants, etc.) can be any of the well-known agents in the art, including, but not limited to, those that are currently in clinical use.
- Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compositions, increasing convenience to the subject and a physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer based systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Pat. No. 5,075,109, hereby incorporated by reference. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Pat. Nos. 4,452,775, 4,675,189, and 5,736,152, each of which is hereby incorporated by reference and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Pat. Nos. 3,854,480, 5,133,974 and 5,407,686, each of which is hereby incorporated by reference. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.
- In preferred embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention comprises a suitable amount of ISL and/or protein or peptide comprising an ISL to induce an immune response in a subject when administered to the subject. In preferred embodiments, the immune response is sufficient to provide the subject protection (e.g., immune protection) against a subsequent exposure to an immunogen (e.g., a pathogen) or the microorganism (e.g., bacteria or virus) from which the protein or peptide comprising an ISL was derived. The present invention is not limited by the amount of ISL and/or protein or peptide comprising an ISL used. In some preferred embodiments, the amount of ISL and/or protein or peptide comprising an ISL in a composition comprising a ISL and/or protein or peptide comprising an ISL (e.g., for use as an immunization dose) is selected as that amount which induces an immunoprotective response without significant, adverse side effects. The amount will vary depending upon which specific ISL and/or protein or peptide comprising an ISL or combination thereof is/are employed, and can vary from subject to subject, depending on a number of factors including, but not limited to, the species, age and general condition (e.g., health) of the subject, and the mode of administration. Procedures for determining the appropriate amount of ISL and/or protein or peptide comprising an ISL administered to a subject to elicit an immune response (e.g., a protective immune response (e.g., protective immunity)) in a subject are well known to those skilled in the art.
- In some embodiments, it is expected that each dose (e.g., of a composition comprising ISL and/or protein or peptide comprising an ISL (e.g., administered to a subject to induce an immune response (e.g., a protective immune response (e.g., protective immunity))) comprises 0.05-5000 μg of each ISL and/or protein or peptide comprising an ISL (e.g., recombinant and/or purified peptide or protein), in some embodiments, each dose will comprise 1-500 μg, in some embodiments, each dose will comprise 350-750 μg, in some embodiments, each dose will comprise 50-200 μg, in some embodiments, each dose will comprise 25-75 μg of ISL and/or protein or peptide comprising an ISL (e.g., recombinant and/or purified peptide or protein). In some embodiments, each dose comprises an amount of the ISL and/or protein or peptide comprising an ISL sufficient to generate an immune response. An effective amount of the immunogen in a dose need not be quantified, as long as the amount of ISL and/or protein or peptide comprising an ISL generates an immune response in a subject when administered to the subject. An optimal amount for a particular administration (e.g., to induce an immune response (e.g., a protective immune response (e.g., protective immunity))) can be ascertained by one of skill in the art using standard studies involving observation of antibody titers and other responses in subjects.
- In some embodiments, it is expected that each dose (e.g., of a composition comprising a ISL and/or protein or peptide comprising an ISL (e.g., administered to a subject to induce and immune response)) is from 0.001 to 15% or more (e.g., 0.001-10%, 0.5-5%, 1-3%, 2%, 6%, 10%, 15% or more) by weight ISL and/or protein or peptide comprising an ISL. In some embodiments, an initial or prime administration dose contains more ISL and/or protein or peptide comprising an ISL than a subsequent boost dose
- In some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention is formulated in a concentrated dose that can be diluted prior to administration to a subject. For example, dilutions of a concentrated composition may be administered to a subject such that the subject receives any one or more of the specific dosages provided herein. In some embodiments, dilution of a concentrated composition may be made such that a subject is administered (e.g., in a single dose) a composition comprising 0.5-50% of the ISL and/or protein or peptide comprising an ISL present in the concentrated composition. In some preferred embodiments, a subject is administered in a single dose a composition comprising 1% of the ISL and/or protein or peptide comprising an ISL present in the concentrated composition. Concentrated compositions are contemplated to be useful in a setting in which large numbers of subjects may be administered a composition of the present invention (e.g., an immunization clinic, hospital, school, etc.). In some embodiments, a composition comprising ISL and/or protein or peptide comprising an ISL of the present invention (e.g., a concentrated composition) is stable at room temperature for more than 1 week, in some embodiments for more than 2 weeks, in some embodiments for more than 3 weeks, in some embodiments for more than 4 weeks, in some embodiments for more than 5 weeks, and in some embodiments for more than 6 weeks.
- In some embodiments, following an initial administration of a composition of the present invention (e.g., an initial vaccination), a subject may receive one or more boost administrations (e.g., around 2 weeks, around 3 weeks, around 4 weeks, around 5 weeks, around 6 weeks, around 7 weeks, around 8 weeks, around 10 weeks, around 3 months, around 4 months, around 6 months, around 9 months, around 1 year, around 2 years, around 3 years, around 5 years, around 10 years) subsequent to a first, second, third, fourth, fifth, sixth, seventh, eights, ninth, tenth, and/or more than tenth administration. Although an understanding of the mechanism is not necessary to practice the present invention and the present invention is not limited to any particular mechanism of action, in some embodiments, reintroduction of ISL and/or protein or peptide comprising an ISL in a boost dose enables vigorous systemic immunity in a subject. The boost can be with the same formulation given for the primary immune response, or can be with a different formulation that contains a different ISL and/or protein or peptide comprising an ISL. The dosage regimen will also, at least in part, be determined by the need of the subject and be dependent on the judgment of a practitioner.
- Dosage units may be proportionately increased or decreased based on several factors including, but not limited to, the weight, age, and health status of the subject. In addition, dosage units may be increased or decreased for subsequent administrations (e.g., boost administrations).
- A composition comprising ISL and/or protein or peptide comprising an ISL of the present invention finds use where the nature of the infectious and/or disease causing agent (e.g., for which protective immunity is sought to be elicited) is known, as well as where the nature of the infectious and/or disease causing agent is unknown (e.g., in emerging disease (e.g., of pandemic proportion (e.g., influenza or other outbreaks of disease))).
- It is contemplated that the compositions and methods of the present invention will find use in various settings, including research settings. For example, compositions and methods of the present invention also find use in studies of the immune system (e.g., characterization of adaptive immune responses (e.g., protective immune responses (e.g., mucosal or systemic immunity))). Uses of the compositions and methods provided by the present invention encompass human and non-human subjects and samples from those subjects, and also encompass research applications using these subjects. Compositions and methods of the present invention are also useful in studying and optimizing ISL and/or protein or peptide comprising an ISL, and other components and for screening for new components. Thus, it is not intended that the present invention be limited to any particular subject and/or application setting.
- The compositions of the present invention are useful for preventing and/or treating a wide variety of diseases and infections caused by viruses, bacteria, parasites, and fungi, as well as for eliciting an immune response against a variety of antigens. Not only can the compositions be used prophylactically or therapeutically, as described above, the compositions can also be used in order to prepare antibodies, both polyclonal and monoclonal (e.g., for diagnostic purposes), as well as for immunopurification of an antigen of interest. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) can be immunized with the compositions of the present invention. The animal is usually boosted 2-6 weeks later with one or more—administrations of the antigen. Polyclonal antisera can then be obtained from the immunized animal and used according to known procedures (See, e.g., Jurgens et al., J. Chrom. 1985, 348:363-370).
- In some embodiments, the present invention provides a kit comprising a composition comprising ISL and/or protein or peptide comprising an ISL. In some embodiments, the kit further provides a device for administering the composition. The present invention is not limited by the type of device included in the kit. In some embodiments, all kit components are present within a single container (e.g., vial or tube). In some embodiments, each kit component is located in a single container (e.g., vial or tube). In some embodiments, one or more kit component are located in a single container (e.g., vial or tube) with other components of the same kit being located in a separate container (e.g., vial or tube). In some embodiments, a kit comprises a buffer. In some embodiments, the kit further comprises instructions for use.
- The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
- Studies have been conducted involving anti- and pro-oxidative signal transduction pathways (Wu et al. Mutat. Res. 546: 93-102, 2004.; Ling et al. Muat. Res. 554: 33-43, 2004.; US Patent Application No. 20050215529, filed: Sep. 29, 2005.; Ling et al. Arthritis Rheum, 54, 3423-3432, 2006.; Ling et al. Arthritis Res. Therapy. 9, R5, 2007.; Holoshitz & Ling. Ann New York Acad Sci, 1110:73-83, 2007.; Ling & Holoshitz. J. Immunol. 179:6359-6367, 2007.; herein incorporated by reference in their entireties). Isopentenyl diphosphate (IPP), a product of several pathogens (Puan et al. Int Immunol. 2007 May; 19(5):657-73.; herein incorporated by reference in its entirety), was found to be a very potent activator of antioxidative signaling pathway with an IC50 of 1.7×10-11 M. Anti-oxidative signaling could be blocked by nitric oxide (NO).
- Experiments were conducted during development of embodiments of the present invention to determine the effect of IPP on the activity of IDO, a key immune regulatory enzyme. IPP had a very strong synergistic effect with IFN-γ on IDO activation (ISLE
FIG. 1 ). For example, at 10 μM, IPP more than doubled IDO activation in cells treated with 500 U/ml IFN-γ and more than tripled IDO activation in cells treated with 100 U/ml IFN-γ. - In contrast to the anti-oxidative effect of IPP, NO has a pro-oxidative effect. NO has also been shown to inhibit IDO activation (Alberati-Giani et al. J. Immunol. 159, 419-426, 1997.; Hucke et al. Infect Immun. 72, 2723-2730, 2004.; herein incorporated by reference in their entireties). Consistent with published reports in other cell systems, the NO donor S-nitroso-Nacetylpenicillamine (SNAP) had an inhibitory effect on IFN-γ-induced activation of IDO in fibroblasts (ISLE
FIG. 2 ). Thus, IPP is not only a highly potent antioxidant, it also operate synergistically with IFNγ to increase the activity of IDO, a key enzyme in immune tolerance. - There appears to be a functional role for the sequence motif Q/R-K/R-R-A-A in the HLA-DRβ chain. This motif is shared by over 90% of all patients with rheumatoid arthritis. Q/R-K/R-R-A-A was found to act as a ligand capable of triggering NO-mediated pro-oxidative signaling in many cell types via cell surface calreticulin (Ling et al. Arthritis Rheum, 54, 3423-3432, 2006.; Ling et al. Arthritis Res. Therapy. 9, R5, 2007.; Holoshitz & Ling. Ann New York Acad Sci, 1110:73-83, 2007.; Ling & Holoshitz. J. Immunol. 179:6359-6367, 2007.; herein incorporated by reference in their entireties). Table 1 summarize different ligands tested in the studies described herein, and their source sequence.
-
TABLE 1 Ligands used in this study Core Name: Origin and composition sequence* SEQ ID NO ISL 65-79′0401 Region 65-79 of DRβ chain QKRAA SEQ ID NO. + encoded by DRB1*0401 2 65-79′0402 Region 65-79 of DRβ chain DERAA SEQ ID NO. − encoded by DRB1*0402 11 65-79′0403 Region 65-79 of DRβ chain QRRAE SEQ ID NO. − encoded by DRB1*0403 12 65-79′0404 Region 65-79 of DRβ chain QRRAA SEQ ID NO. + encoded by DRB1*0404 3 L-0401 L cell transfectants QKRAA SEQ ID NO. + expressing human DRB1*0401 2 L-0402 L cell transfectants DERAA SEQ ID NO. − expressing human DRB1*0402 11 L-0403 L cell transfectants QRRAE SEQ ID NO. − expressing human DRB1*0403 12 L-0404 L cell transfectants QRRAA SEQ ID NO. + expressing human DRB1*0404 3 HBc*0401 Hepatitis B core particles QRAA SEQ ID NO. + expressing region 65-79 2 of DRβ chain encoded by DRB1*0401 HBc*0402 Hepatitis B core particles DERAA SEQ ID NO. − expressing region 65-79 11 of DRβ chain encoded by DRB1*0401 *Sequence of the polymorphic residues 70-74 of the DRβ chain - DCs play a key role in immune regulation. Studies were conducted during development of embodiments of the present invention to examine whether the ISL can activate innate signaling in murine DC. Bone marrow cells were isolated from three mouse strains and cultured for 7 days in the presence of 20 ng/ml GM-CSF. Then, DC were isolated by CD11c magnetic beads with >95% purity. DC cells were incubated over time with 100 μg/ml of ISL-positive or -negative 15mer peptides, and NO production was measured. The ISL-positive peptides 65-79*0401 triggered a much more robust NO production, compared to ISL-negative peptides 65-79*0402 and 65-79*0403 in Balb/c DC (ISLE
FIG. 3A-B ). Similar trends were seen in DC from C57BL/6 (ISLEFIG. 3C ) and CBA/J mice. These data indicate that ISL can activate NO signaling in DC. - IDO plays an important role in T cell regulation, and NO has been previously found to inhibit IDO activity (Alberati-Giani et al. J. Immunol. 159, 419-426, 1997.; Hucke et al. Infect Immun. 72, 2723-2730, 2004.; herein incorporated by reference in their entireties). Experiments were conducted during development of embodiments of the present invention to examine whether ISL affects IDO activity. First, the effect of ISL-positive and ISL-negative 15mer peptides on IFNγ-induced IDO activity in human fibroblasts was examined. Cells were incubated overnight with 100 μg/ml of ISL-positive or ISL-negative 15mer peptides, cultured for additional 48 h with IFNγ, and IDO activity was measured.
- The ISL-positive peptides 65-79*0401 and 65-79*0404 effectively blocked conversion of tryptophan to kynurenine, while ISL-negative peptides 65-79*0402 and 65-79*0403 did not have such effect (ISLE
FIG. 4A ). Murine L cells expressing ISL-positive DRβ chains on their surface through cDNA transfection (lines L-0401 and L-0404, expressing the ISL-positive DRβ 0401 andDRβ 0404 molecules, respectively), produced significantly less kynurenine in response to IFNγ, when compared to transfectants expressing ISL-negative DRβ chains (lines L-0402 and L-0403, expressing ISL-negative molecules DRβ0402 andDRβ 0403, respectively) (ISLEFIG. 4B ). These results demonstrate ISL effectively inhibits the activity of the tolerogenic enzyme IDO in both human and murine cells. - IFNγ-induced IDO activity was found in DCs expressing the CD8a surface marker (CD8+ DC), but not in CD8α-negative DC(CD8− DC). Experiments were conducted to examine the effect of maturation on IDO activity. CD11c+ CD8+ DC were incubated for 24 h with or without LPS and IFNγ-induced IDO activity was determined. Activation of IDO in immature DC was significantly higher than in mature cells (ISLE
FIG. 4C ). To determine the effect of ISL on IDO activity in DC, immature CD11c+ CD8+ DC were purified from DBA/1 spleens and pre-exposed to ISL in the form of HBc particles engineered to express the 65-79 region of DRβ chains, encoded by the ISL-positive allele DRB1*0401 (particle HBc*0401). ISL-negative particles (HBc*0402), expressing the DRβ 65-79 region encoded by the ISL-negative DRB1*0402 allele were used as control (these 2 particles differ by only 2 amino acid residues in the 70-74 region of the insert). DCs were subsequently stimulated with IFNγ and IDO activity was determined. ISL-positive, but not ISL-negative particles inhibited IDO activity in DC (ISLEFIG. 4D ). - In addition to IDO-mediated T cell regulation, DC can also regulate immune responses by production of various cytokines that can activate or expand particular subsets of T cells, thereby polarizing the immune response. Experiments were conducted during development of embodiments of the present invention to determine whether ISL-mediated signaling in DC could induce particular cytokines Supernatants of ISL-stimulated DC were examined using the Luminex platform. While CD8+ DC showed no production of any cytokines, in the CD8−subset, the ISL-positive peptide 65-79*0401 triggered a robust production of IL-6 (ISLE
FIG. 5 ). The ISL-negative peptide 65-79*0402 did not trigger any increased production, similar to cultures incubated with PBS. Other cytokines (IL-4, IL-10 and IL-12) did not show any increased production, indicating the specificity of ISL effect. - Experiments were performed during development of embodiments of the present invention to elucidate the role of the ISL in the immune system. The effect of ISL on T cell polarization in mice was examined. In CD11c+ CD8+ DCs, the ISL inhibited the enzymatic activity of IDO, a key enzyme in immune tolerance and T cell regulation, while in CD11c+CD8− DCs the ligand activated robust production of IL-6. When ISL-activated DCs were co-cultured with CD4+ T cells, the differentiation of Foxp3+ T regulatory (Treg) cells was suppressed, while Th17 cells were expanded. The polarizing effects were observed with ISL-positive synthetic peptides, but even more so, when the ISL was in its natural tri-dimensional conformation as part of HLA-DR tetrameric proteins. In vivo administration of the ISL resulted in higher abundance of Th17 cells in the draining lymph nodes and increased IL-17 production by splenocytes, demonstrating that the ISL acts as a potent immune-stimulatory ligand that can polarize T cell differentiation toward Th17 cells, a T cell subset that has been recently implicated in the pathogenesis of autoimmune diseases, including RA.
- All mice were from Jackson Laboratory. Experiments were carried out in 5-10 week-old male DBA/1, Balb/c, C57BL/6, or a DBA/1 mouse line carrying transgenic (Tg) collagen type II (CII)-specific TCR (D1Lac.Cg-Tg(TCRa,TCRb)24Efro/J); the latter mouse line is designated herein as “CII-TCR Tg mice.” The animals were housed in the University of Michigan Unit for Laboratory Animal Medicine facility. All experiments were performed in accordance with protocols approved by University of Michigan Committee on Use and Care of Animals.
- Monoclonal antibodies against mouse CD3 (clone 2C11), IL-4 (clone 11B11), IFNγ (clone R46A2), and IL-2 (clone S4B6) were purified from the supernatants of hybridomas obtained from the University of Michigan Hybridoma Core Facility. Purified anti-mouse CD28 (clone 37.51) and murine rIL-23 were purchased from e-Bioscience (San Diego, Calif.). Human rTGFβ and rIFNγ, as well as murine rIL-4, rIFNγ, rGM-CSF and rIL-6 were purchased from Peprotech (Rocky Hill, N.J.).
- Peptides were synthesized and HPLC-purified to >90% by the University of Michigan Protein Structure Facility as previously described (9, 12). ISL-expressing 15mer peptides, designated as 65-79*0401 (aa sequence 65-KDLLEQKRAAVDTYC-79 SEQ ID NO.: 7), or 65-79*0404 (aa sequence 65-KDLLEQRRAAVDTYC-79 SEQ ID NO.: 8), corresponded to the third allelic hypervariable region (HVR3) of the DRβ chain encoded by of ISL-positive HLA-DRB1*0401 or HLA-DRB1*0404 alleles, respectively. Control 15mer peptides 65-79*0402 (65-KDILEDERAAVDTYC-79 SEQ ID NO.: 9) and 65-79*0403 (65-KDLLEQRRAEVDTYC-79 SEQ ID NO.: 10) corresponded to the HVR3 of the DRβ chain encoded by of ISL-negative HLA-DRB1*0402 or HLA-DRB1*0403 alleles, respectively. The CII259-273 peptide, which corresponds to residues 259-273 of chicken CII.
- Chimeric hepatitis B core (HBc) particles engineered to express the HVR3 of the HLA-DRβ chain were prepared at the Latvian Biomedical Research and Study Center, (Riga, Latvia)(Holoshitz & Ling. 2007 Ann N Y Acad Sci 1110:73-83.; herein incorporated by reference in its entirety). HBc particles expressing a ISL-positive HVR3, encoded by HLA-DRB1*0401 (designated here as HBc*0401) or a ISL-negative HVR3, encoded by HLA-DRB1*0402 (designated here as HBc*0402) were used in experiments conducted herein. ISL-positive HLA-DR tetramers DRB1*0401/DRA1*0101 (designated here as T-DRB1*0401), ISL-negative DRB1*1501/DRA1*0101 (T-DRB1*1501), and ISL-negative DRB1*0301/DRA1*0101 (T-DRB1*0301), all containing identical class II-associated invariant chain peptide (CLIP) in the peptide-binding groove, were generated by the National Institutes of Health Tetramer Core Facility as previously described (Day et al. 2003. J Clin Invest 112:831-842.; herein incorporated by reference in its entirety. Unless stated otherwise, all chemicals were from Sigma-Aldrich (St. Louis, Mo.).
- Murine L cell transfectants expressing human HLA-DRα/β heterodimers (Olson et al. Hum Immunol 41:193-200.; herein incorporated by reference in its entirety) and human fibroblast line M1 (Holoshitz & Ling. 2007 Ann N Y Acad Sci 1110:73-83.; herein incorporated by reference in its entirety) were maintained as we previously described. For generation of CD11c+DCs, mouse bone barrow cells were plated in culture flasks (2×106 cells/ml per T150, Costar, Corning, N.Y.) in RPMI 1640 medium containing 2 mM L-glutamine, 10% FBS, 1% Penicillin-Streptomycin, 10 mM HEPES buffer solution, 10 mM Sodium Pyruvate, 50 mM 2-mercaptoethanol, GM-CSF (10 ng/ml) and IL-4 (10 ng/ml). On
day 3, half of the medium was removed and fresh medium containing GM-CSF (10 ng/ml) and IL-4 (10 ng/ml) were added. After 5-7 days, DCs were purified using positive selection columns with CD11c microbeads (Miltenyi Biotec Inc, CA, USA) as previously described (Grohmann et al. 1998 Immunity 9:315-323.; herein incorporated by reference in its entirety). For preparation of CD11c+CD8+ and CD11c+CD8− DCs, freshly isolated splenic DCs were subjected to positive selection with CD11c and CD8α microbeads. Purified DC subsets were then cultured in RPMI 1640 medium containing 2 mM L-glutamine, 10% FBS, 1% Penicillin-Streptomycin, 10 mM HEPES buffer solution, 10 mM Sodium Pyruvate and 50 mM 2-mercaptoethanol. CD4+ T cells were isolated from the spleen, using a negative selection immunomagnetic isolation kit (EasySep®, Stem Cell technology, Vancouver, Canada) according to the manufacturer's instructions. To purify CD4+CD25−CD62L+CD44− naïve T cells, CD4+T cells were incubated with FITC anti-mouse CD4 and a mixture of PE-labeled anti-CD25, APC-labeled anti-CD62L and Pe-Cy7-labeled anti-CD44 antibodies (all from Biolegend, San Diego, Calif.). CD4+CD25−CD62L+CD44− naïve T cells were sorted using a FACSDiva™ instrument (Becton Dickinson, Franklin Lakes, N.J.) with a purity >98%. - To determine the rate of NO production, cells were loaded with 20 μM of the
fluorescent NO probe 4,5-diaminofluorescein diacetate (DAF-2DA) and the fluorescence level was recorded every 5 minutes over a period of 500 minutes using a Fusion aHT system (PerkinElmer Life Sciences) at an excitation wavelength of 488 nm and emission wavelength of 515 nm. To determine IDO enzymatic activity, the generation of its product, kynurenine was measured (Takikawa et al. 1988. J Biol Chem 263:2041-2048.; herein incorporated by reference in its entirety). Cytokine concentrations were measured in cell culture supernatants using a Luminex platform (Millipore Corporation, Danvers, Mass.). In some experiments, cytokines were determined using ELISA (Quantikine®, R&D Systems, Minneapolis, Minn.) following the manufacture's instruction. - Splenic cells from DBA/1 mice were isolated followed by purification of DC subtypes using positive selection columns with CD11c and CD8α microbeads. Purified cells were stained for flow cytometry analysis using PE anti-mouse CD8 (clone 53-6.7, BD Pharmigen, San Jose, Calif.), FITC anti-rabbit CRT (ABR—Affinity Bioreagents, Rockford, Ill.) and isotype controls (Biolegend, San Diego, Calif.).
- DBA/1 bone marrow-derived CD11c+DCs were placed in 24-well plates (BD Biosciences, San Jose, Calif.) at a density of 2.5×105 cells per well and cultured overnight with or without 50 μg/ml of peptidic (65-79*0401 or 65-79*0402), or 2 μg/ml of tetrameric (T-DR1*0401, T-DR1*0301, or T-DR1*1501) ligands at 37° C. On the following day, 5.0×105 CD4+ T cells or CD4+CD25−CD62L+CD44− naïve T cells, isolated as described above, were added to each well in addition to anti-CD3 antibodies (5 μg/ml) and rhTGFβ (2.5 ng/ml).
- After 5 days in culture, cells were harvested and stained for flow cytometric analysis using FITC anti-mouse CD4 (clone XMG1.2), PE anti-mouse CD25 (clone PC61) and isotype controls (Biolegend, San Diego, Calif.). Next, cells were permeabilized and fixed using a Cytofix/Cytoperm kit (BD Biosciences, San Jose, Calif.) as recommended by the manufacturer. After permeabilization, cells were stained using an APC-conjugated anti-mouse Foxp3 antibody (clone FLK-16S from e-Bioscience, San Diego, Calif.) and analyzed by FACScalibur flow cytometer using the CELLQuest™ software (Becton Dickinson, Franklin Lakes, N.J.).
- Bone marrow-derived CD11c+DCs (2.5×105 cells per well) were cultured overnight in 24-well plates with or without ISL ligands or controls as above. Then, 5×105 CD4+ T cells or CD4+CD25−CD62L+CD44− naïve T cells were added at the ratio of 2:1 in the presence of Th17-polarazing cytokine/antibodies cocktail containing: anti-IL4 (2 μg/ml), anti-IFNγ (2 μg/ml), anti-IL2 (3 μg/ml), rhTGFI3 (5 ng/ml), rmIL-6 (20 ng/ml), rmIL-23 (10 ng/ml), anti-CD3 (5 μg/ml) and anti-CD28 (1 μg/ml) as previously described (32).
- After 6 days, cells were stimulated with PMA (5 ng/ml) and ionomycin (500 ng/ml) for the last 6 hrs of culture. Brefeldin A (10 μg/ml) was added to the culture for the last 5 hrs. Cells were then harvested and stained for surface marker using PercP anti-mouse CD4 or isotype control (Biolegend, San Diego, Calif.) followed by fixation and permeabilization using a Cytofix/Cytoperm™ kit. Intracellular staining was performed using PE-conjugated anti-mouse IL-17A mAb (clone TC11-18H 10.1 from Biolegend, San Diego, Calif.). Mean florescence intensity and percentages of stained cells were determined by flow cytometry.
- Cells were labeled with 1 μM of CFISL (Molecular Probes™, Invitrogen Corporation, Carlsbad, Calif.), stained with CD4-PercP, CD25-Pe, and Foxp3-APC or IL-17A-APC antibodies (Biolegend, San Diego, Calif.) and proliferation was determined by measuring the percentages of CFISL-labeled cycling CD4+ T, CD4+CD25+Foxp3+ Treg or CD4+IL17A+Th17 cells, using a FACS analysis.
- Mice were injected subcutaneously in the footpad with 100 μg of chicken collagen type II (CII) (Chondrex, Inc, Redmond, Wash.) emulsified in CFA (4 mg/ml). The inoculums contained 10 μg of either ISL-positive 65-79*0401 or ISL-negative 65-79*0402 ligands in PBS, or an equal volum of PBS alone. Animals were sacrificed 7 days after immunization. For Th17 quantification studies, inguinal and popliteal lymph nodes were collected and single cell suspensions were prepared. Unfractionated lymph node cells were cultured with PMA, Ionomycin and Brefeldin A for 6 hours as above. Cells were stained with FITC anti-mouse CD4 or isotype controls, followed by fixation and permeabilization using a Cytofix-Cytoperm™ kit. After permeabilization, intracellular staining was performed using PE-conjugated anti-mouse IL17A and APC-conjugated anti-mouse IFN-γ and cells were analyzed by flow cytometry as above. To measure IL-17 production, splenocytes from mice immunized as above were stimulated in vitro with 5 μg of CII259-273 peptide. At different time points thereafter, supernatants were collected and assayed for IL-17 by ELISA as above.
- The ISL activates NO signaling in different cell lineages from several species (Holoshitz & Ling. 2007 Ann N Y Acad Sci 1110:73-83.; Ling et al. 2006 Arthritis Rheum 54:3423-3432.; Ling et al. 2007 Arthritis Res Ther 9:R5.; Ling et al. 2007 J Immunol 179:6359-6367.; herein incorporated by reference in their entireties). The ISL activated robust NO production in CD11c+DCs from several mouse strains in a strictly allele-specific manner. Thus, similar to its effect in many other cell lineages, the ISL activates NO signaling in mouse DCs as well.
- Given the known inhibitory effect of NO on IDO activity (Alberati-Giani et al. 1997 J Immunol 159:419-426.; herein incorporated by reference in its entirety), experiments were conducted during development of embodiments of the present invention to determine the effect IDO enzymatic activity. In addition to a small subset of DCs (Fallarino et al. 2002. Int Immunol 14:65-68.; herein incorporated by reference in its entirety), IDO is expressed in several other cell lineages, including fibroblasts. Given the much greater abundance of fibroblasts over IDO-producing DCs, the effect of the ISL on IDO activity in murine fibroblast L-cells transfectants expressing functionally and structurally intact HLA-DRα/β heterodimeric molecules on their surface through cDNA transfection was determined. Transfectants expressing ISL-positive HLA-DR molecules on their surface (lines L-565.5 and L-300.8, expressing the ISL-
positive DRβ 0401 orDRβ 0404 molecules, respectively) produced significantly less kynurenine in response to IFNγ, compared to transfectants expressing ISL-negative HLA-DR molecules (lines L-514.3 and L-259.3 expressing ISL-negative DRβ 0402 orDRβ 0403 molecules, respectively) (ISLEFIG. 6 ). An identical pattern was observed when M1 fibroblasts were stimulated with ISL peptidic ligands 65-79*0401 or 65-79*0404. The ISL ligands strongly inhibited IFNγ-induced IDO activity (ISLEFIG. 6B ). ISL-negative controls 65-79*0402 and 65-79*0403 did not inhibit IDO activity. Consistent with previous studies (Alberati-Giani et al. 1997 J Immunol 159:419-426.; Thomas et al. 1994. J Biol Chem 269:14457-14464.; herein incorporated by reference in their entireties) the NO-donor S-nitroso-N-acetylpenicillamine (SNAP) inhibited IDO activity too. Thus, these results demonstrate that the ISL, whether physiologically expressed on the cell surface (e.g., in the form of HLA-DR), or added as a cell-free ligand, effectively and specifically inhibits the activity of the tolerogenic enzyme IDO in human and murine cells. - IFNγ-induced IDO activity in DBA/1 mice was observed in CD11c+CD8+ DCs, but not in CD11c+CD8− DCs (ISLE
FIG. 6C ), similar to published reports in other strains (Fallarino et al. 2002. Int Immunol 14:65-68.; herein incorporated by reference in its entirety). To examine the effect of maturation on IDO activity in DBA/1 mice, CD11c+CD8+ DCs were incubated for 24 hrs with or without LPS (1 μg/ml) and IFNγ-induced IDO activity was determined. Activation of IDO in immature DCs was significantly more potent than in mature cells (ISLEFIG. 6D ). Similar to other mouse strains, IDO activation in DBA/1 mice was inhibited by NO by demonstrating that IFNγ-induced IDO activity in DBA/1 immature CD11c+CD8+ DCs is potently inhibited by the NO-donor SNAP (ISLEFIG. 6E ). To determine the effect of the ISL on IDO activity in DCs, DBA/1 immature CD11c+CD8+ DCs were pre-incubated with HBc particles engineered to express the HVR3 (residues 65-79) encoded by the ISL-positive allele DRB1*0401 (designated HBc*0401), or the HVR3 encoded by the ISL-negative allele DRB1*0402 (HBc*0402). Cells were then stimulated with IFNγ and IDO activity was determined as above. ISL-positive HBc*0401 but not ISL-negative HBc*0402 particles significantly inhibited IDO activity in DCs (ISLEFIG. 6F ). Thus, experiments conducted during development of embodiments of the present invention indicate that the ISL ligand inhibits IDO activity in CD11c+CD8+ DCs. - In addition to IDO-mediated T cell regulation, DCs can affect immune responses by producing cytokines capable of activating or expanding particular subsets of T cells, thereby polarizing the immune response. For example, in mice, the combination of IL-6 and TGFβ facilitates differentiation of Th17 cells, while IL-23 is involved in the expansion of this subset (Ivanov et al. 2007 Semin Immunol 19:409-417.; herein incorporated by reference in its entirety). In order to determine whether ISL-activated signaling in DCs induces cytokine production, supernatants of ISL-stimulated DCs were examined. The ISL ligand 65-79*0401 activated a robust production of IL-6 in CD11c+CD8− DCs, but not in the CD11c+CD8+ subset (ISLE
FIG. 7 ). IL-6 levels peaked at a relatively early time point (24 h) and later declined. This pattern is likely a result of short half life of the peptidic ligand due to rapid degradation in tissue culture conditions. The ISL-negative control 65-79*0402 did not trigger any cytokine production. Other cytokines (IL-4, IL-10, IL-12 IL-1β, TGFβ) did not show any increased production, attesting to the specificity of the ISL effect (ISLEFIG. 7 ). Thus, while in CD8+ DCs the ISL inhibited IDO activity (ISLEFIG. 6 )) its IL-6 production effect was restricted to the CD8−DCs subset (ISLEFIG. 7 ). - ISL-activated IL-6 production was observed CD11c+ CD8− DCs only when they were separated from the CD11c+CD8+ subset, but not when unfractionated CD11c+ DCs were assayed (ISLE
FIG. 7 ). Although CD11c+CD8+ DCs are a small subset (˜5-15% of splenic CD11c+ cells), once activated by the ISL, they could exert potent inhibitory effect on the activation of CD11c+CD8− DCs, consistent with previously reported DCs suppressive effects (Ardavin et al. 2004 Immunity 20:17-23.; herein incorporated by reference in its entirety); although the present invention is not limited to any particular mechanism of action and an understanding of the mechanism of action is not necessary to practice the present invention. Recent studies have indeed shown that IDO produced by a small subset of DCs can dominantly suppress production of IL-6 in other DCs (Sharma, et al. 2009 Blood 113:6102-6111.; Baban et al. 2009 J Immunol 183:2475-2483.; herein incorporated by reference in their entireties). - IL-23 levels in DCs did not increase following stimulation with the ISL ligand (ISLE
FIG. 8 ). However, in the presence of LPS (100 ng/ml), the ISL had a prolonged synergistic effect in CD11c+DCs. The ISL had no effect when applied alone, but in the presence of LPS it had a synergistic effect, which lasted for up to 72 hours after stimulation, long after LPS effect had subsided (ISLEFIG. 8 ). The effect was specific for IL-23, since no synergism was found in the production of another LPS-inducible cytokine, IL-6 (ISLEFIG. 8 , bottom). - IDO inhibition and/or increased IL-6 levels inhibit Treg cells (Sharma et al. 2007 J Clin Invest 117:2570-2582.; Korn et al. 2007 Nature 448:484-487.; herein incorporated by reference in their entireties). The ISL inhibited IDO activity in CD11c+CD8+ DCs and increased IL-6 production in CD11c+CD8− DCs. Experiments were conducted during development of embodiments of the present invention to determine whether the ISL interferes with Treg differentiation or expansion. Accordingly, DBA/1 CD11c+DCs were first incubated overnight with the ISL ligand 65-79*0401, or ISL-negative control 65-79*0402, or with medium. DCs were then co-cultured with purified syngeneic CD4+ T cells (ISLE
FIG. 9A ) or CD4+CD25−CD62L+CD44− naïve T cells (ISLEFIG. 9B ) in the presence of TGF-β (2.5 ng/ml) and anti-CD3 antibodies (5.0 μg/ml). After 5 days, CD4+CD25+Foxp3+ Treg abundance was determined by flow cytometry. The ISL ligand 65-79*0401 significantly inhibited Treg expansion and differentiation, respectively (ISLEFIG. 9 ). The inhibitory effect of 65-79*040 on Treg differentiation was statistically significant, yet modest. Peptidic ISL ligands have been observed to exert weaker signaling effects due to their flexible conformation in solution (Holoshitz & Ling. Ann N Y Acad Sci 1110:73-83.; Ling et al. 2006. Arthritis Rheum 54:3423-3432.; Ling et al. 2007 J Immunol 179:6359-6367.; herein incorporated by reference in their entireties). Treg differentiation experiments were performed using ISL-positive HLA-DR tetramer (designated T-DRB1*0401), or control, ISL-negative HLA-DR tetramers (T-DRB1*1501 or T-DRB1*0301) instead of soluble peptides. The HLA-DR molecule in tetramers is folded in its natural tri-dimensional conformation and therefore better preserves the physiologic function of the protein. The ISL-positive tetramer T-DRB1*0401 indeed had a specific and much more potent inhibitory effect on Treg differentiation (ISLEFIG. 9C ). - In the CD11c+CD8− DC subset, the ISL ligand 65-79*0401 triggered a robust production of IL-6, an obligatory cytokine for Th17 differentiation. IL-23 production by LPS-treated DCs was also augmented by 65-79*0401. Experiments were conducted during development of embodiments of the present invention to determine whether the ISL ligand can facilitate Th17 differentiation or activation. CD11c+DCs were stimulated overnight with either peptidic or tetrameric ligands. CD4+CD25−CD62L+CD44− naïve T cells were added and cultured in the presence of a Th17-polarizing cocktail of cytokines and antibodies. After 6 days, cells were collected and analyzed by flow cytometry. The ISL ligand 65-79*0401 induced a significant increase in the differentiation of CD4+IL17A+ T cells (ISLE
FIG. 10A ). A more robust ISL-induced Th17 polarization effect was observed when DCs were stimulated with ISL-positive HLA-DR tetramers (ISLEFIG. 10B ). - To determine whether ISL-activated DCs can increase IL-17 production in CD4+ T cells, CD11c+DCs were incubated overnight with ISL ligands or control reagents. Cells were then co-cultured with total CD4+ T cells. ISL-activated DCs induced higher intracellular (ISLE
FIG. 11A ) and extracellular (ISLEFIG. 11B ) IL-17 expression in co-cultured CD4+ T cells, compared to cells cultured with DCs pre-incubated with a control reagents or medium. The effect was seen both with a soluble ISL peptidic ligand, as well as with conformationally preserved ligand in the form of an HBc particle (ISLEFIG. 11B ). - The ISL affects the proliferation of Th17 and Tregs in a reciprocal manner. Enhanced expansion through increased proliferative activity of Th17 cells and decreased proliferative activity of Tregs was observed in both TCR-independent and TCR-mediated T cell activation conditions.
- Experiments were conducted during development of embodiments of the present invention to characterize the ISL polarizing effect in vivo (ISLE
FIG. 12 ). Draining lymph nodes of control DBA/1 mice immunized with CII had a 0.65% abundance of Th17 cells, consistent with published data showing frequencies of less than 1% of Th17 in draining lymph nodes (Iwanami et al. 2009 Arthritis Res Ther 11:R167.; Notley et al. 2008. J Exp Med 205:2491-2497.; herein incorporated by reference in their entireties). Co-administration of the ISL-negative 65-79*0402 had no effect on Th17 abundance. However, co-administration of the ISL ligand 65-79*0401 dramatically increased the frequency of these cells (ISLEFIG. 12A ). The ISL-induced expansion was specific for Th17 cells since there was no change in the frequency of Th1 (IFNγ-positive) cells (ISLEFIG. 12A ). Additionally, splenocytes from DBA/1 mice immunized with CII in the presence of the ISL ligand 65-79*0401 showed significantly more robust CII-stimulated IL-17 production, compared to splenocytes obtained from mice co-immunized with the ISL-negative control 65-79*0402 (ISLEFIG. 12B ). Experiments conducted deuring development of embodiments of the present invention demonstrate that the ISL facilitates Th17 polarization both in vitro and in vivo. - In order to examine the utility of ISLs described herein, experiments were performed to determine whether the ISLs could expand anti-pathogen-specific Th17 cells. To this end mice were immunized with chicken collagen type II (CII)+M. tuberculosis H37Ra in the form of Complete Freund's Adjuvant (CFA) in the presence of ISL (peptide 65-79*0401), or a control peptide (65-79*0402). The draining lymph nodes were harvested and single cell suspensions were generated.
- Six to 10 weeks old DBA/1 mouse carrying transgenic collagen type II-specific TCR (D1Lac.Cg-Tg(TCRa,TCRb)24Efro/J) were immunized with chicken collagen type II (CII) in Complete Freund's Adjuvant (CFA) containing Mycobacterium tuberculosis H37Ra. 50 μl of an emulsion containing 100 μg of CII in 25 μl of 0.05 M acetic acid and 25 μl of CFA was injected intradermally at the base of the tail. At
days FIG. 14A and discussion below). Lymph-node cells (1×106 cells/ml) were re-stimulated in vitro in 96 well plates with 100 μg/ml of denaturated CII, 10 μg/ml of Mycobacterium bovis purified protein derivative (PPD) of mycobacteria, or PBS (NIL). After 6 days, cells were harvested, stained and analyzed by flow cytometry (SeeFIG. 14B and discussion below). All samples were acquired on a FACScalibur, and data were analyzed with CellQuest Pro software (BD biosciences). An appropriate isotype-matched control antibody was used in all FACS analysis. Bar graphs show results as the percentage (mean±SEM). *p<0.03, compared to PBS and 65-79*0402. - Flow cytometry analysis revealed a significant increase of total antigen non-stimulated Th17 cells in draining lymph nodes (See
FIG. 14 ). In order to determine the impact of ISL on antigen-specific Th17 cells, lymph node cells were re-stimulated for 6 days in the presence of a purified derivative protein (PPD) of M. tuberculosis, CII, or PBS. In mice administered ISL, antigen-specific re-stimulation resulted in major expansion of Th17 cells (SeeFIG. 14B ). Specifically, without any antigen stimulation the percentage of Th17 cells after 6 days in culture was 5.4±0.4%; while cultures stimulated with CII produced 8.4±0.5% Th17 cells. Cultures re-stimulated with the bacterial antigen PPD gave a robust expansion of anti-PPD-specific Th17 cells (13.1±0.5%). Thus, in some embodiments, the invention provides that ISL facilitates antibacterial immune responses (e.g., polarization of bacterial antigen-specific Th17 cells). - Experiments were conducted during development of embodiments of the invention to generate conformationally intact peptidomimetic ISL reagents. The utility of cyclic peptides was examined with an interest in determining whether the cyclization of the peptides improved chemical stability and/or extended the biological half-life compared to their linear counterparts. In order to avoid usage of essential side chains, and/or amino and carboxyl ends, a backbone cyclization (BC) strategy can be utilized to impose a conformational constraint on peptides where nitrogen atoms in the backbone are covalently connected by an intramolecular bridge to form a ring. An advantage of backbone cyclization is that cyclization is achieved mainly by using backbone atoms and not side chains that are important for biological activity.
- Materials and Methods.
- Abbreviations used herein are as follows: AGBU, Alloc glycine building units; Alloc, allyloxycarbonyl; BTC, bis(trichloromethyl)carbonate; CD, Circular dichroism; DCM, dichloromethane; DIPEA, diisopropylethylamine; Fmoc, 9-fluorenylmethyloxycarbonyl; HATU, (2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate); HBTU, (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate); HLA, human leukocyte antigen; MBHA, methylbenzhydrylamine; NMP, 1-methyl-2-pyrrolidinone; NO, nitric oxide; RA, Rheumatoid arthritis; RP-HPLC, reverse phase high pressure liquid chromatography; SAR, structure activity relationship; SE, shared epitope; SPPS, solid phase peptide synthesis; TDW, tri-distilled water; TFA, trifluoroacetic acid.
- All starting materials were purchased from commercial sources and were used without further purification. Exact mass spectra were recorded on an AGILENT TECHNOLOGIES 6520B ACCURATE MASS Q-TOF LC\MS. MALDI-TOF spectra were recorded on a PERSEPTIVE BIOSYSTEMS MALDI-TOF MS, using α-cyano-4-hydroxycinnamic acid as the matrix. All analytical HPLC were recorded at 220 nm at a flow of 1 ml/min on a RP-18 column (5
μm 250×4.6 mm, 110 Å), eluents A (0.05% TFA in TDW) and B (0.05% TFA in ACN) were used in a linear gradient (95% A→>5% A in 35 min). Preparative HPLC were recorded at 220 nm on a RP-18 column (10μ 250×10 mm, 110 Å), Eluents A (0.05% TFA in TDW) and B (0.05% TFA in ACN) were used in a linear gradient (95% A→75% A in 30 min) at a flow of 5 ml/min. - Peptide design. All the peptides were synthesized using standard Fmoc SPPS procedures (See, e.g., Chan and White, Fmoc Solid Phase Peptide Synthesis; Oxford: Oxford University Press, 2000) on Rink amide MBHA resin as the solid support. The urea backbone cyclic peptides, designated c(HSn-4), were synthesized according to the procedures described by Hurevich et al. (See, e.g., Hurevich et al., Journal of Peptide Science 2010, 16, 178) using various AGBU, where n stands for the number of atoms in the N-alkyl chain on the glycine at
position 2. The sequences of the linear 15 mer peptides are as follows: -
65-79*0401: (SEQ ID NO. 7) H-Lys-Asp-Leu-Leu-Glu-Gln-Lys-Arg-Ala-Ala-Val-Asp- Thr-Tyr-Cys-NH2 65-79*0402: (SEQ ID NO. 9) H-Lys-Asp-Ile-Leu-Glu-Asp-Glu-Arg-Ala-Ala-Val-Asp- Thr-Tyr-Cys-NH2 65-79*0404: (SEQ ID NO. 8) H-Lys-Asp-Leu-Leu-Glu-Gln-Arg-Arg-Ala-Ala-Val-Asp- Thr-Tyr-Cys-NH2 - General methods for SPPS. Swelling: The resin was swelled for at least 2 h in DCM. Fmoc removal: The resin was treated with a solution of 20% piperidine in NMP (2×20 min) and then washed with NMP (5×2 min). HBTU coupling: Fmoc protected amino acids (1.5 equiv) were dissolved in NMP. DIPEA (1.5 equiv) and HBTU (1.5 equiv) were added and the mixture was pre-activated by mixing for 1 min, added to the resin, and shaken for 1 h. The resin was washed with NMP (3×2 min). HATU coupling: Fmoc protected amino acids (1.5 equiv) were dissolved in NMP, DIPEA (1.5 equiv) and HATU (1.5 equiv) were added and the mixture was preactivated by mixing for 1 min, added to the resin, and shaken for 2 h. The resin was washed with NMP (3×2 min). Alloc removal: The resin was washed with DCM (2×2 min) and dried under vacuum. A solution of PhSiH3 (10 equiv) in DCM was added under a stream of argon and Pd(PPh3)4(0) (0.5 equiv) was added. The reaction was stirred in the dark for 1 h and then washed with 0.5% DIPEA in NMP (3×5 min), 0.5% sodium diethyldithiocarbamate trihydrate in NMP (5×2 min), NMP (2×2 min) and DCM (2×2 min). Urea cyclization: A solution of BTC (0.33 equiv) in DCM was added to the resin and stirred. After 2 h, DIPEA (2 equiv) was added and the reaction was stirred overnight at room temperature. The resin was washed with DCM (2×2 min). Cleavage: The resin was washed with DCM (2×2 min) and dried under vacuum. A solution of 2.5% TDW and 2.5% triisopropylsilane in TFA was added and the reaction proceeded for 3 h at room temperature. The solution was separated by filtration and the resin was rinsed with neat TFA. The TFA mixture was treated with a cooled solution of ether:hexane 1:1 and the peptides were precipitated by centrifugation. The crude peptides were dissolved in ACN:TDW 1:1 solution and lyophilized.
- Nitric Oxide Assay. Human fibroblast M1 cells were plated at a density of 1×105 cells per well in 96-well plates the day prior to the Nitric Oxide assay. To determine the rate of NO production in fibroblast, cells were first loaded with 20 μM of the
fluorescent NO probe 4,5-diaminofluorescein diacetate (DAF-2DA), incubated in the dark at 37° C. for 1 hour and washed in 100 μL of DMEM/phenol red-free medium. The fluorescence level was recorded every 5 minutes over a period of 500 minutes, using a Fusion αHT system (PerkinElmer Life Sciences) at an excitation wavelength of 488 nm and emission wavelength of 515 nm. The NO production rate is expressedas the mean±SEM fluorescence units per minute. - CD Measurements. Samples of each peptide were prepared by dissolving a lyophilized peptide in TDW. Far-UV CD spectra were collected over 190-260 nm at room temperature using a J-810 spectropolarimeter (Jasco) in a 0.1 cm quartz cuvette for far-UV CD spectroscopy.
- Trypsin/chymotrypsin stability assay. The trypsin stability assay was conducted as previously described (See, e.g., Pakkala et al., Journal of Peptide Science 2007, 13, 348; Tal-Gan et al., Bioorganic & Medicinal Chemistry 2010, 18, 2976. 400 μL of each peptide (1 mM) dissolved in 200 mM NH4HCO3 buffer solution (pH 8) were mixed with 1 μL of trypsin and chymotrypsin (porcine pancreas, Biological Industries Israel, Beit Haemek LTD) solution (2.5 mg/1 ml). The peptides were incubated at 37° C., 30 μL samples were taken every 30 min and mixed with 30 μL of 2% TFA and 30% ACN in water. Samples were analyzed by HPLC and by MALDI-TOF MS.
- Peptide design and synthesis. Helix mimetic cyclic analogs usually have bridges at positions i, i+4 or i, i+7 (See, e.g., Moellering et al., Nature 2009, 462, 182; Walensky et al., Science 2004, 305, 1466). The consensus SE motif Gln-Lys-X-X-Ala (SEQ ID NO. 15) was incorporated into an i, i+4 backbone cyclic scaffold. A Trp residue was added to the amino terminus to aid in determining the concentrations of the cyclic analogs using UV spectroscopy (See, e.g., Gill and von Hippel, Anal Biochem 1989, 182, 319). The synthesis and general structure of the backbone cyclic peptides are described in
FIG. 15 . - The characterization of the cyclic peptides is summarized in Table 2, below.
-
TABLE 2 Characterization of peptides generated utilizing backbone cyclization. Peptide Bridge Calcd Observed Purity TR HPLC* Name n Size Ring Size MH+ MH+ (HRMS) HPLC (%) (min) c(HS2-4) 2 9 22 941.5428 941.5446 >95 18.65 c(HS4-4) 4 11 24 969.5741 969.5744 >95 18.68 c(HS6-4) 6 13 26 997.6054 997.6062 >95 18.83 - β-turn conformation observed for the cyclic analogs using CD. The conformational changes induced by cyclization and the variety of ring sizes were studied by CD of the cyclic peptides and two positive control 15-mers (65-79*0401, H-Lys-Asp-Leu-Leu-Glu-Gln-Lys-Arg-Ala-Ala-Val-Asp-Thr-Tyr-Cys-NH2(SEQ ID NO. 7), and 65-79*0404, H-Lys-Asp-Leu-Leu-Glu-Gln-Arg-Arg-Ala-Ala-Val-Asp-Thr-Tyr-Cys-NH2 (SEQ ID NO. 8)). The two linear 15-mer peptides had no defined structure and the CD spectra resembled a random coil (See
FIG. 16 a). CD spectra of the three cyclic analogs indicated a putative Type III β-turn conformation (SeeFIG. 16 b; see also Crisma et al., Int JPept Protein Res 1984, 23, 411; Johnson, Annu RevBiophys Biophys Chem 1988, 17, 145). Thus, in some embodiments, the cyclic, bioactive pharmacophors of the peptide acquire an active conformation (e.g., helix conformation) upon binding to their binding site. Although an understanding of a mechanism is not necessary to practice the invention, and the invention is not limited to any particular mechanism, in some embodiments, the cyclic (e.g., short) peptides display enhanced activity compared to the linear (e.g., longer) peptides due to a restricted conformation of the cyclic peptides (e.g., a more biologically active confirmation). - NO production induced by the cyclic analogs. The ability of the cyclic analogs to activate NO production in fibroblasts was examined. The 15-mer peptides 65-79*0401 (H-Lys-Asp-Leu-Leu-Glu-Gln-Lys-Arg-Ala-Ala-Val-Asp-Thr-Tyr-Cys-NH2) (SEQ ID NO. 7) and 65-79*0402 (H-Lys-Asp-Ile-Leu-Glu-Asp-Glu-Arg-Ala-Ala-Val-Asp-Thr-Tyr-Cys-NH2) (SEQ ID NO. 9) were used as positive and negative controls, respectively. An optimal concentration for the positive control, 65-79*0401, was previously determined to be 50 μM (See, e.g., Ling et al.,
Arthritis Res Ther 2007, 9, R5; Ling et al., J. J Immunol 2007, 179, 6359; Ling et al., Arthritis Rheum 2006, 54, 3423).FIGS. 17A and 17B show that cyclic analogs activated NO production significantly above the negative control levels. Furthermore, as shown inFIG. 17B , c(HS6-4) maintained elevated NO production levels at concentrations five times lower than the positive control. Both c(HS4-4) (SEQ ID NO: 2), and c(HS6-2) (SEQ ID NO. 3) were observed to be potent analogs. - Both of these cyclic peptides maintained high NO production levels even in concentrations 50,000 times lower than 65-79*0401, and activated NO production even in the low nM concentrations. Accordingly, in some embodiments, the invention provides that subtle changes in the conformation of bioactive SE pharmacophors alter the biological activity of the peptides.
- Thus, the invention provides a variety peptides encompassing a broad range of activity (e.g., biological activity (e.g., ability to activate shared epitope (SE) type signaling events). In some embodiments, the invention provides cyclic peptides (e.g., selected from SEQ ID NOS. 1-6, 13 and 14) for use as agonists of SE triggered signaling (e.g., to induce nitric oxide (NO) production and/or NO signaling cascades (e.g., to induce an immune response)). In a preferred embodiment, the invention provides QKRAA (SEQ ID NO.:2) or QRRAA (SEQ ID NO.:3) as potent agonists of biological signalling cascades (e.g., to induce nitric oxide (NO) production and/or NO signaling cascades and/or to induce an immune response (e.g., increase T helper 17 (Th17) cell expansion, increase production of IL-17 and/or IL-6, or to inhibit T regulatory cell activity and/or expansion (e.g., to block or decrease T cell tolerance))). In other embodiments, one or more peptides described herein are used as antagonists of SE triggered signaling.
- Stability towards enzymatic degradation. In order to assess the stability of one of the potent cyclic analogs, c(HS4-4) (SEQ ID NO:2), towards enzymatic degradation as compared to the linear 15-mers, 65-79*0401 and 65-79*0404, a trypsin/chymotrypsin stability assay was conducted. HPLC analysis was used to determine the percent of degradation (See
FIG. 18 ), whereas MS analysis was used to identify the specific cleavage sites (See Table 3). The cyclic analog, c(HS4-4) was completely stable towards trypsin/chymotrypsin degradation even after 4 hours of incubation with the proteases whereas the linear analogs, 65-79*0401 and 65-79*0404 were degraded completely after 30 minutes (SeeFIG. 18 ). -
TABLE 3 Fragmentation of c(HS4-4), 65-79*0401 and 65-79*0404 after degradation by trypsin/chymotrypsin# Name Deduced sequence of fragment Observed MH+ c(HS4-4) 969.53 65-79*0401 K-D-L-L-E-Q-K-R-A-A-V-D-T-Y-C 1752.98 Fragment 1K-D-L-L-E-Q-K-R-A-A-V-D-T-Y 1649.93 Fragment 2 C ## Fragment 3 K-D-L-L-E-Q-K-R 1029.64 Fragment 4A-A-V-D-T-Y 638.51 Fragment 5K-D-L-L-E-Q-K 872.53 Fragment 6R-A-A-V-D-T-Y 795.43 65-79*0404 K-D-L-L-E-Q-R-R-A-A-V-D-T-Y-C 1778.84 Fragment 1K-D-L-L-E-Q-R-R-A-A-V-D-T-Y 1676.84 Fragment 2 C ## Fragment 3 K-D-L-L-E-Q-R-R- 1057.23 Fragment 4A-A-V-D-T-Y 638.59 Fragment 5K-D-L-L-E-Q-R 901.71 Fragment 6R-A-A-V-D-T-Y 795.40 #Fragments were identified by MS ## Complementary fragment - The specific cleavage sites were determined using MS analysis to extract further information about the degradation of the peptides. Several cleavage sites were identified from the analyzed fragments of the linear 15-mer peptides, 65-79*0401 and 65-79*0404, containing the SE motif (residues 70-74) (See Table 3). These cleavage sites were between Tyr78 and Cys79 (chymotrypsin), Arg72 and Ala73 (trypsin), and Arg71/Lys71 and Arg72 (trypsin). As two of the identified cleavage sites (after residue 71 and 72) are found within the SE segment and are conserved in the cyclic analog, the 15-mer peptides serve as good controls for comparison. Regarding the cyclic peptide, c(HS4-4), in accordance with the HPLC results, no fragments were observed in the MS analysis, indicating that the restricted conformation induced by cyclization was not recognized by trypsin and chymotrypsin. The fact that cleavage was not observed at either of the cleavage sites within the conserved SE segment (after residue 71 and 72) in the cyclic analog indicates that the use of backbone cyclization confers enzymatic stability to the peptides.
- All publications and patents mentioned in the present application and/or listed below are herein incorporated by reference. Various modification and variation of the described methods and compositions of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the relevant fields are intended to be within the scope of the following claims.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/164,732 US9555086B2 (en) | 2010-06-16 | 2014-01-27 | Compositions and methods for inducing an immune response |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35541310P | 2010-06-16 | 2010-06-16 | |
US13/162,382 US20120034252A1 (en) | 2010-06-16 | 2011-06-16 | Compositions and methods for inducing an immune response |
US13/331,354 US8658603B2 (en) | 2010-06-16 | 2011-12-20 | Compositions and methods for inducing an immune response |
US14/164,732 US9555086B2 (en) | 2010-06-16 | 2014-01-27 | Compositions and methods for inducing an immune response |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/331,354 Division US8658603B2 (en) | 2010-06-16 | 2011-12-20 | Compositions and methods for inducing an immune response |
Publications (2)
Publication Number | Publication Date |
---|---|
US20140212444A1 true US20140212444A1 (en) | 2014-07-31 |
US9555086B2 US9555086B2 (en) | 2017-01-31 |
Family
ID=46162457
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/331,354 Active 2031-08-25 US8658603B2 (en) | 2010-06-16 | 2011-12-20 | Compositions and methods for inducing an immune response |
US14/164,732 Active 2031-11-25 US9555086B2 (en) | 2010-06-16 | 2014-01-27 | Compositions and methods for inducing an immune response |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/331,354 Active 2031-08-25 US8658603B2 (en) | 2010-06-16 | 2011-12-20 | Compositions and methods for inducing an immune response |
Country Status (1)
Country | Link |
---|---|
US (2) | US8658603B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104151402A (en) * | 2014-08-06 | 2014-11-19 | 苏州大学 | Viral myocarditis cyclic peptide vaccine and preparation method thereof |
WO2016073738A3 (en) * | 2014-11-05 | 2016-07-07 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9598422B2 (en) | 2014-11-05 | 2017-03-21 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9643972B2 (en) | 2014-11-05 | 2017-05-09 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10987322B2 (en) | 2014-06-06 | 2021-04-27 | Flexus Biosciences, Inc. | Immunoregulatory agents |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201312133D0 (en) * | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
US10293044B2 (en) | 2014-04-18 | 2019-05-21 | Auburn University | Particulate formulations for improving feed conversion rate in a subject |
KR20210089270A (en) | 2015-07-16 | 2021-07-15 | 바이오카인 테라퓨틱스 리미티드 | Compositions and methods for treating cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014835A1 (en) * | 1989-05-31 | 1990-12-13 | Scripps Clinic And Research Foundation | Method to treat rheumatoid arthritis |
US20090081156A1 (en) * | 2006-08-03 | 2009-03-26 | William Soo Hoo | Bioactive molecular matrix and methods of use in the treatment of disease |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
CA2082951C (en) | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
IT1247472B (en) | 1991-05-31 | 1994-12-17 | Fidia Spa | PROCESS FOR THE PREPARATION OF MICROSPHERES CONTAINING BIOLOGICALLY ACTIVE COMPONENTS. |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
JP3723231B2 (en) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | Adjuvant |
IT1253009B (en) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES |
JP3755890B2 (en) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | Adjuvant-containing vaccine composition |
CN1087176C (en) | 1993-03-23 | 2002-07-10 | 史密斯克莱·比奇曼生物公司 | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
WO1995014026A1 (en) | 1993-11-17 | 1995-05-26 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
ES2267100T5 (en) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | IMMUNOMODULATING OLIGONUCLEOTIDES. |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
WO1997048440A1 (en) | 1996-06-18 | 1997-12-24 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
JP4111403B2 (en) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Immunostimulatory polynucleotide / immunomodulatory molecule complex |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
ES2195190T3 (en) | 1996-12-20 | 2003-12-01 | Alza Corp | DEVICE AND METHOD FOR IMPROVING THE TRANSDERMAL AGENT FLOW. |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
AU734180B2 (en) | 1997-08-29 | 2001-06-07 | Antigenics Llc | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
ES2298316T3 (en) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | WATER OIL EMULSIONS CONTAINING SAPONINS. |
WO1999027961A1 (en) | 1997-12-02 | 1999-06-10 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
DE69942774D1 (en) | 1999-02-26 | 2010-10-28 | Novartis Vaccines & Diagnostic | USE OF BIOADHAESIVES AND ADJUVANTIES FOR THE MUCOSAL APPLICATION OF ANTIGENES |
US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
AU2002347062B2 (en) | 2001-10-06 | 2008-06-26 | Merial Ltd | CpG formulations and related methods |
US20050215529A1 (en) | 2004-03-24 | 2005-09-29 | The Regents Of The University Of Michigan | Method of treating oxidative stress-associated conditions with isopentenyl diphosphate |
-
2011
- 2011-12-20 US US13/331,354 patent/US8658603B2/en active Active
-
2014
- 2014-01-27 US US14/164,732 patent/US9555086B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014835A1 (en) * | 1989-05-31 | 1990-12-13 | Scripps Clinic And Research Foundation | Method to treat rheumatoid arthritis |
US20090081156A1 (en) * | 2006-08-03 | 2009-03-26 | William Soo Hoo | Bioactive molecular matrix and methods of use in the treatment of disease |
Non-Patent Citations (1)
Title |
---|
Rink et al, To protect peptide pharmaceuticals against peptidases (Journal of Pharmacological and Toxicological Methods 61 (2010) 210-218) * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10987322B2 (en) | 2014-06-06 | 2021-04-27 | Flexus Biosciences, Inc. | Immunoregulatory agents |
CN104151402A (en) * | 2014-08-06 | 2014-11-19 | 苏州大学 | Viral myocarditis cyclic peptide vaccine and preparation method thereof |
WO2016073738A3 (en) * | 2014-11-05 | 2016-07-07 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9598422B2 (en) | 2014-11-05 | 2017-03-21 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9643972B2 (en) | 2014-11-05 | 2017-05-09 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10106546B2 (en) | 2014-11-05 | 2018-10-23 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10206893B2 (en) | 2014-11-05 | 2019-02-19 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10533014B2 (en) | 2014-11-05 | 2020-01-14 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11932601B2 (en) | 2014-11-05 | 2024-03-19 | Flexus Biosciences, Inc. | Immunoregulatory agents |
Also Published As
Publication number | Publication date |
---|---|
US9555086B2 (en) | 2017-01-31 |
US20120141516A1 (en) | 2012-06-07 |
US8658603B2 (en) | 2014-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9555086B2 (en) | Compositions and methods for inducing an immune response | |
JP2021107443A (en) | Regulatory t cell epitope, composition, and use thereof | |
KR102556485B1 (en) | Novel immunogenic peptides | |
US10350284B1 (en) | Antigen specific multi epitope-based anti-infective vaccines | |
Schülke et al. | Fusion protein of TLR5-ligand and allergen potentiates activation and IL-10 secretion in murine myeloid DC | |
JP7102430B2 (en) | Peptides and methods for the treatment of diabetes | |
KR20160131998A (en) | Oncology vaccine | |
WO2007103048A2 (en) | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity | |
US20210283242A1 (en) | Immune-mediated coronavirus treatments | |
KR20180134935A (en) | New immunogenic CD1d binding peptides | |
Wells et al. | Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity | |
Schülke et al. | Critical role of mammalian target of rapamycin for IL-10 dendritic cell induction by a flagellin A conjugate in preventing allergic sensitization | |
CN102027003A (en) | Chlamydia antigens | |
JP2005528373A (en) | Method using Flt3 ligand in immunization protocol | |
WO2014176604A1 (en) | Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis | |
US20230054958A1 (en) | Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof | |
AU2016271857B2 (en) | IL-23-P19 vaccines | |
US20120034252A1 (en) | Compositions and methods for inducing an immune response | |
RU2005141524A (en) | PHL P 5A DERIVATIVES WITH REDUCED ALLERGENCY AND PRESERVED T-CELL REACTIVITY | |
US20160158330A1 (en) | Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis | |
Andersson | Novel allergen preparations for use in allergen-specific immunotherapy | |
Neimert Andersson | Novel allergen preparations for use in allergen-specific immunotherapy | |
JPWO2022036193A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF MICHIGAN;REEL/FRAME:032323/0643 Effective date: 20140203 |
|
AS | Assignment |
Owner name: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, MICHIGA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HOLOSHITZ, JOSEPH;LING, SONG;PI, XIUJUN;AND OTHERS;SIGNING DATES FROM 20140303 TO 20140325;REEL/FRAME:032872/0137 |
|
AS | Assignment |
Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GILON, CHAIM;HOFFMAN, AMNON;REEL/FRAME:032998/0584 Effective date: 20140422 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |